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1.  Zusammenfassung 
 
   Telomestatin (Abb. 1.1) ist ein von Streptomyces anulatus 3533-SV4 isolierter 
Naturstoff. Es ist einer der stärksten Inhibitoren für das Enzym Telomerase und weist 
auch sonst ein breites Spektrum biologischer Wirkungen auf. 
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Abb. 1.1: Der Naturstoff Telomestatin 
 
   Man vermutet, dass Telomestatin über eine selektive Bindung an die G-Quadruplex 
Struktur wirk. Diese ist u.a. im 3'-Überhang der Telomerenenden menschlicher 
Chromosomen zu finden. Die hohe Affinität und Spezifität für diese G-Quadruplex 
DNS erklärt man sich mit der zum G-Quartet der G-Quadruplex DNS gut passenden 
Grösse und Form des Moleküls. Die Form von Telomestatin ist jedoch auf Grund der 
einen Thiazolin-Einheit nicht ideal, da diese die Planarität von Telomestatin aufhebt. 
Trotz aller Versuche ist es bisher niemandem gelungen, einen Makrozyklus 
herzustellen, der acht Azol-Einheiten enthält und vollständig planar ist. Der Grund 
dafür liegt vermutlich an einer erhöhten makrozyklischen Ringspannung. Diese sollte 
durch Substitution von vier Oxazol- durch vier Thiazol-Einheiten im makrozyklischen 
System reduziert werden können. Daher arbeiteten wir an der Synthese von drei 
neuen, vollständig planaren Telomestatin Analoga, die jeweils vier Thiazole und 
entweder vier Oxazole, Imidazole oder Thiazole enthalten (Schema 1.1). Die 
folgende Arbeit berichtet von der Konzipierung und der synthetischen Arbeit  hin zu 
diesen Molekülen, wobei die drei Aminosäuren Serin, Asparagin und Cystein als 
Startmaterialien dienten (Schema 1.1). 
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Schema 1.1. Synthese neuer Telomestatin Analoga 
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   Im Prinzip wurden zwei Aminosäuren miteinander gekoppelt, worauf der Sauerstoff 
der neu gebildeten Amidbindung und die Seitenkette der einen Aminosäure unter 
Wasserabspaltung zum Azol zyklisiert wurden. Die synthetisierte, Azol enthaltende 
neue Aminosäure wurde tetramerisiert und makrolaktamisiert, wobei Standard 
Peptidchemie angewendet werden konnte. Die dabei übrig bleibenden Aminosäuren 
Seitenketten wurden anschliessend wiederum unter Dehydratatisierung für 
Ringschlüsse verwendet. So konnte in 18 Synthesestufen das C4-symmetrische 
4TOP hergestellt werden. Dieses ist die erste, acht Azole enthaltende, 
makrozyklische Verbindung, die je hergestellt worden ist.  
   Auf dem Weg zu diesem anspruchsvollen Ziel, konnten neue synthetische 
Methoden entwickelt werden. Es ist dies zum einen die Verwendung von Silyl-
geschützten Verbindungen für Zyklodehydratatisierungen, sowie eine sehr effiziente 
und milde Methode, geschützte Aminosäuren mit 18O zu markieren.  
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2.  Summary 
 
   Telomestatin (Figure 2.1) is a natural product isolated from Streptomyces anulatus 
3533-SV4. It is one of the most potent telomerase inhibitors reported to date, and it 
exhibits a broad range of biological activities.  
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Figure 2.1: Natural product telomestatin  
 
   The proposed mode of action of telomestatin involves selective binding of G-
quadruplex structures present in the 3' telomeric overhang of human chromosomes. 
The high affinity and specificity of telomestatin for G-quadruplex DNA is rationalized 
by its size and shape complementarity with the G-tetrads of G-qadruplex DNA. In 
reality, the shape of telomestatin is not perfect for G-tetrad stacking due to the 
presence of a single thiazoline unit. This makes telomestatin a non-planar molecule. 
Due to high macrocyclic ring-strain, all attempts to synthesise a macrocycle 
containing eight azole-units have thus far proven fruitless. Ring-stain is reduced by 
replacing four oxazole units with thiazole in the macrocyclic system. We therefore 
pursued the synthesis of three new, fully planar telomestatin analogs, each 
containing four thiazoles and the remaining units comprising oxazoles, imidazoles or 
thiazoles (Scheme 2.1). The following work presents the design and the synthetic 
efforts towards these target molecules starting with three different amino acids: 
serine, asparagine and cysteine (Scheme 2.1).  
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Scheme 2.1. Synthesis of new telomestatin analogs 
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   Our synthetic strategy involves the coupling of amino acids followed by 
cyclodehydration reactions. The resulting azole-containing amino acids are 
tetramerized and macrolactamized using standard peptide chemistry. The remaining 
amino acid side chains are then used for four cyclodehydration reactions in a single 
step. In 18 synthetic steps total, the C4-symmetric 4TOP could be synthesised. This 
is the first macrocyclic compound containing eight azole units ever reported. 
   Along the way towards this challenging goal, new synthetic methodologies were 
developed including the use of silyl-protected alcohols for cyclodehydration reactions, 
as well as a highly efficient and mild method for 18O labelling of protected amino 
acids.  
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3.  Introduction  
 
3.1  G-Quadruplex DNA 
 
3.1.1  Structure  
   In 1910, Bang and coworkers observed that guanosine monophosphate (GMP) 
behaves differently than other known nucleotides, due to self-assembly of GMP that 
results in a gel[1]. More than 50 years later, Gellert, Lipsett and Davis[2] proposed an 
explanation for this phenomenon, where four guanines arrange themselves in a 
square planar array with two hydrogen bonds on the face of each guanine residue. 
This type of "Hoogsteen" basepairing was predicted by Karst Hoogsteen in 1963. 
Such G-tetrads are further stabilized by monovalent cations such as K+ between two 
stacks of G-tetrads (Figure 3.1). Multiple stacks G-tetrads are contained within four-
stranded G-quadruplex structures. The thermodynamic stability of G-quadruplexes is 
comparable to duplex DNA[3] and include similar stabilizing contributions like pi-
stacking, hydrophobicity and dispersion effects[4]. However, the unfolding kinetics of 
G-quadruplexes are very slow compared to DNA or RNA hairpins[3].    
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Figure 3.1: Four guanines can form a G-tetrad and multiple stacks of G-tetrads form a G-quadruplex  
 
   Described around the same time as Watson and Crick proposed their famous DNA 
model for the B-form duplex, G-tetrads remained a laboratory curiosity for many 
decades. It changed with the finding of genomic sequences with the ability to form G-
quadruplexes under physiological conditions[5, 6]. This has motivated intensive 
investigations of G-rich sequences and their associated secondary structures, rapidly 
becoming a "hot topic" in current DNA research.  
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   G-quadruplexes can be formed from one, two or four different DNA- or RNA-
strands, and display a wide variety of topologies with variable orientations and 
differing connectivity of the strands. Variable loop arrangements also contribute to 
the characteristic 3-dimensional structures.  
 
    
 
Figure 3.2: left side: some different topologies of G-quadruplexes resulting from different numbers and 
orientations of DNA-strands[7], right side: different common names for loop topologies including lateral, 
diagonal or chain reversal loops[8]. 
 
   There are three main categories of G-quadruplexes including "intramolecular" 
structures that have a putative quadruplex sequence of GmXnGmXoGmXpGm with m as 
the number of G-residues directly involved in G-tetrad interactions. Xn, Xo and Xp can 
be combinations of any residues of unequal length forming the loops between the G-
tracts. The second and third categories are the bimolecular (or dimeric) and the 
tetramolecular (tetrameric) quadruplexes, where the G-tracts are divided into two or 
four separate oligonucleotide chains. Quadruplexes are also classified according to 
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their strand polarties when possible. For example, adjacent parallel strands can be 
termed a "parallel" G-quadruplex. For intramolecular structures, these require 
connecting loops that link the G-tetrads with chain reversal loops, also called 
"propeller" type loops. In cases where one of the G-tracts is oriented in an anti-
parallel fashion the whole structure can be designed as an "anti-parallel" G-
quadruplex. This type of topology is commonly found in bimolecular quadruplexes 
and in many of the unimolecular structures determined to date[7, 9]. These topologies 
require one or more lateral loops, also termed as "edge-wise" loops.  Another 
possible loop is the "diagonal loop", capping the G-quadruplex and connecting two 
opposite tracts in the tetrad. 
   In parallel G-quadruplexes, guanosine glycosidic angles are normally all in an anti 
conformation. Anti-parallel quadruplexes typically have a mixture of both, syn and 
anti guanosines, arranged in a characteristic pattern for each structure[7].  
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Figure 3.3: syn- and anti-guanosine  
 
   All G-quadruplexes have four grooves that are defined by the phosphodiester 
backbones. Groove dimensions are highly variable and depend on the overall 
topology of the quadruplex, strand orientation and nature of the loops.  
   The stability of G-quadruplexes in H2O is highly dependent on the presence, 
concentration and nature of the cations incorporated between layers of G-tetrads. 
This is a result of the strong negative electrostatic potential from the guanine O6 
oxygen atoms that all point towards the centre of the G-tetrad, as well as the global 
electrostatic field of the anionic phosphates concentrated in the geometric centre of 
the structure. Central positioning of cations minimizes electrostatic repulsion. In the 
case of Na+, the position of the ion can differ from structure-to-structure, with sodium 
ions lying either in the plane of one G-tetrad, or between two successive G-tetrads. 
K+ ions, in contrast, are always positioned in between two planes defined by two G-
tetrads. G-quadruplexes are better stabilized by K+ as compared to Na+ ions due to 
their lower desolvation energies[10].  
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3.1.2  Potential biological relevance 
   Sequences with the potential to form G-quadruplex structures can be found 
throughout the genome[11, 12]. Huppert and Balasubramanian estimated that 376’000 
putative G-quadruplex sequences GmXnGmXoGmXpGm are present in the human 
genome, somewhat less than expected by random chance[11, 13]. These sequences 
are mainly found in telomeric regions and in transcriptional regulatory sites. While 
evidence for the existence of G-quadruplex structures in multicellular organisms is 
still sparse, a growing number of studies provide indirect evidence for potential 
biological relevance. G-quadruplexes are possibly involved in the regulation of 
telomeric length[14-16] and may play a role in the regulation of gene transcription[17, 18], 
and may serve as a trigger for somatic recombination[19-21]. Binding interactions 
between G-quadruplex-forming sequences and nucleolin possibly influence the 
transcription of rDNA and the processing of rRNA[22]. 
 
3.1.2.1 Telomeres 
   The main function of telomeres includes the protection of chromosomal ends from 
recombination, degradation and end-to-end fusions. This is achieved by a protein-
DNA complex termed "shelterin"[23, 24]. Telomere stability and regulation are also 
related to the end replication problem. Due to RNA-primed DNA synthesis, telomeres 
get shorter with each round of cell division, until they become too short and loose 
their capping function. This can result in chromosome fusion, cell senescence and/or 
apoptosis. The end replication problem can therefore limit the number of cell 
divisions a somatic cell can undergo. Stem cells and other immortalized tissues 
require a mechanism to correct this loss. Most immortal tissues, including ~80% of 
cancers overexpress a ribonucleoprotein complex called telomerase that is able to 
elongate the telomeres using a RNA template and reverse transcriptase activity. 
Molecules known to bind to and to stabilize G-quadruplexes in vitro can reduce the 
activity of telomerase in cells[23, 25].  
   The telomeres of vertebrates contain repetitive units of d(GGGTTA)n-3’. A human 
telomere has approximately 1000 copies of this unit[26, 27] and ends with a single 
stranded 3'-overhang of 100-200 nucleotides[24, 28]. This sequence is capable of 
forming stable G-quadruplexes in vitro[29, 30]. The potential abilities of telomeric 
structures to prevent degradation, fusion or other damage remains largely 
speculative[24]. One potential mechanism is the formation of so called "t-loop" or "D-
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loop" type structures where the single stranded 3’ end is integrated into the terminal 
duplex region of the double stranded telomeric DNA. This might result in a triple 
stranded region containing a G-quadruplex formed by the displaced strand. Many 
proteins are associated with the telomeric "shelterin" complex. These include the 
POT1 protein that can bind to the single stranded 3’ overhang, while TRF1 and TRF2 
proteins bind to the double stranded telomeric DNA[31]. Studies on POT1 showed that 
this protein disrupts the formation of a G-quadruplex structure by binding the single-
stranded 3’ overhanging telomeric sequence[32]. Interestingly, the treatment of human 
EcR293 cells by a selective G-quadruplex binding molecule "telomestatin" induces a 
dramatic and rapid delocalization of POT1 from its normal telomere sites, but 
telomestatin does not affect the telomere localization of TRF2. This suggests that the 
overhang can exist in either POT1-bound or G-quadruplex forms[33]. The 
maintenance of proper telomere stability likely requires a dynamic cap that allows 
access to telomeric DNA during synthesis and telomeric extension.  
 
3.1.2.2 Promoters 
   G-quadruplex forming motifs have been found in the promoter regions of a large 
number of human oncogenes like c-MYC, VEGF, HIF-1a, Ret, KRAS, Bcl, c-Kit, 
PDGF-A and c-Myb. Genomics analyses have revealed that 43% of the human gene 
promoters contain a putative G-quadruplex forming sequence GmXnGmXoGmXpGm[13]. 
This is 6.1 times more frequently than it would be expected for genomic DNA[34]. The 
enrichment of G-quadruplex motifs is highest close to the transcription start site 
(TSS), while relatively few of these motifs are found in exons. Genes involved in 
cancer evolution and growth are even more likely to have promoter G-quadruplex 
motifs with approximately 67% of these promoters containing a G-quadruplex motif 
according to Huppert and Balasubramanian.  
   In 2007 Johanna Eddy and Nancy Maizels published their research on potential G-
quadruplex forming sequences in the -1000 to +1000 bp surrounding the TSS and 
addressed the possible contributions of the template and nontemplate strand[35]. 
They suggested, that G-richness upstream from TSS can be accounted for by well-
defined functional motifs in duplex DNA including "CpG-islands" for methylation[36, 37] 
as well as G-rich motifs recognized by well-characterized transcription factors that 
are specific for duplex DNA, including SP1, KLF, EKLF, EGR-1 and AP-2[38-40]. 
Downstream of the TSS they found many other human genes containing G-rich 
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putative G-quadruplex-like motifs, located on the nontemplate strand on the 5'-end of 
the first intron (referred to as 'GrIn1'). These sequences could not be explained as 
sequences recognized by known transcription factors such as those mentioned 
above. An estimated 8% of all human genes contain a GrIn1-type sequence. The 
authors speculated that these sequences, being located on the nontemplate strand, 
potentially can play a role in the regulation of transcription when forming G-
quadruplex structures following RNA polymerase denaturation of duplex DNA or 
subsequently during splicing of the pre-m-RNA.  
   One of the most investigated systems is c-MYC, an important oncoprotein and 
transcriptional factor that plays a central role in cell proliferation and induction of 
apoptosis. Overexpression of c-MYC is associated with a significant number of 
human malignancies like breast, colon, cervix and small-cell lung cancers. The 
control of c-MYC expression is mediated by many different proteins and DNA 
sequences, including the nuclease hypersensitivity element III1 (NHE III1) that is 
located between -142 and -115 base pairs upstream of the c-MYC transcription start 
site. It has been claimed that NHE III1 controls up to 80-90% of the transcriptional 
activity of the c-MYC gene[41-45]. Studies by Simonsson and his group showed that 
this G-rich strand can readily form a G-quadruplex structure in vitro under 
physiological conditions and that the formation of this structure is K+ dependent[46]. 
Experiments by Hurley and co-workers suggest that this G-quadruplex can have a 
regulatory effect on transcriptional initiation. In these experiments, gene expression 
profiles in HeLa cells were evaluated after treatment with TMPyP4, a molecule 
known to stabilize the G-quadruplex, and revealed downregulation of transcription. 
Site directed mutagenesis experiments had similar effect, where mutations that 
destabilized G-quadruplex formation increased gene expression. Control 
experiments using TMPyP2[47], a constitutional isomer of TMPyP4 showed no impact 
on gene expression, presumably due to the lower G-quadruplex affinities of these 
compounds[48]. Together these results suggest that c-MYC expression may be 
mediated by a G-quadruplex structure formed in the c-MYC promoter. Hurley and Qin 
proposed that TMPyP4 has an impact on the dynamic equilibrium between duplex, 
unwound single-stranded and G-quadruplex and i-motif structures[49] (Figure 3-4). 
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a)   5’ – TGGGGAGGGTGGGGAGGGTGGGGAAGG – 3’ 
 
 
Figure 3.4: a) sequence of the c-MYC NHE III1 and b) proposed c-MYC promoter dynamics showing 
duplex DNA undergoing transcription versus a transcriptionally silent G-quadruplex in the NHE III1 
sequence[49] 
 
3.1.2.3 Recombination 
   Homologous recombination requires co-localization of homologous DNA segments. 
The DNA conformations associated with pre-recombination complexes remain poorly 
understood. Triplex-induced recombination has been studied in some detail[50], but 
involvement of G-quadruplex structures has only been recently proposed. In 2006 
Shukla and Roy investigated the influence of a potential G-quadruplex on 
recombinatorial events in plasmids. They report an increasing recombination rate 
upon insertion of a G-quadruplex forming sequence between two direct repeats, 
which suggests that the formation of a G-quadruplex is able to bring the two repeats 
together and therefore might facilitate recombination.  
   In 2009 Chowdhury et al. published a genome-wide analysis of recombination 
prone regions to predict the role of DNA structural motifs in recombination[21]. They 
found that potential G-quadruplex DNA forming sequences were significantly 
enriched near hotspots of recombination as compared to AT-rich DNA regions. They 
found that within a 50 base pairs of putative G-quadruplex DNA sequences, there is 
an enrichment of previously reported short sequence motifs known to be 
recombination hotspots (like for example, the long terminal repeat of two retrovirus-
like retrotransposons, THE1A and THE1B, or  CT- and GA-rich repeats[51]). There 
was also a significant co-localization of quadruplex motifs with target sites for three 
known transcription factors: c-Rel, NF-kappa B (p50&p65) and Evi-1[21]. Based on 
these findings, Chowdhury et al. proposed that G-quadruplex formation could be one 
b) 
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of the key determinants of recombination where the single stranded "fold back" 
structure could assist in strand separation and homologous pairing. 
   A seminal paper proving a relationship between putative quadruplex sequences 
and recombination was recently published by Cahoon an Seifert in Science[52]. Their 
model system was the pilin antigenic variation (AV) in Neisseria gonorrhoeae. Hyper-
variation of surface proteins is a mechanism by which the bacterium can protect itself 
from the host's immune defenses. There are 46 predicted G-quadruplex forming 
sequences in the genome of this gram-negative bacterium and one of them seems to 
be closely associated with antigenic variation. One such G/C-rich sequence (3'-
TTTTA AGGGG T GGG TT GGG T GGG A TAAGA-5') is located upstream of pilE, 
the gene encoding for the variable pilin proteins. This sequence was shown in vitro to 
form G-quadruplexes and mutations in this specific G-quadruplex sequence, 
disrupting the formation of the G-quadruplex structure, resulted in no more AV. 
Growing the bacteria at a non-toxic concentration of N-methyl mesoporphyrin IX 
(NMM), a molecule stabilizing the G-quadruplex structure, a significantly decreased 
"pilus phase" and AV frequency were observed. These results suggest that formation 
of the pilE G-quadruplex structure is required for wild-type pilin AV. It is likely that the 
structure forms only when the DNA duplex is melted, possibly during DNA replication 
or transcription.  
 
3.1.2.4 Ribosomal DNA 
   In all eukaryotes the entire transcribed region of the rDNA is very rich in guanine 
residues accounting for 34% of human rDNA. The guanines are concentrated within 
the "spacer" regions, as well as the regions that template the mature rRNAs. These 
G-rich sequences are consistently located on the non-template strand, and most of 
them are within runs of three or more consecutive G's. rDNA is transcribed in an 
extraordinary high frequency. According to electron microscopic analysis[53] the 
polymerases follow each other with spaces of only about 100 base pairs between 
them. The non-template strand must therefore be constantly denatured or stabilized 
in a different secondary structure due to such high transcriptional activity. Hanakaha 
et al. showed, that the rDNA-associated protein nucleolin is able to bind very strongly 
to various G-quadruplex sequences with a dissociation constant Kd of 1 nM[22]. The 
authors therefore hypothesize, that the formation of G-quadruplex-nucleolin 
complexes stabilizes the non-transcribed strands of rDNA. Nucleolin is known to be 
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abundant in the dense fibrillar component of the nucleolus, where rDNA transcription 
occurs. It is also abundant in the peripheral granular component of the nucleolus, 
where rRNA is processed. Since nucleolin shows two separable domains which can 
bind to G-quadruplexes, the protein is also thought to have an organising ability for 
G-quadruplex domains. In this way it could have a scaffolding effect helping the 
processing of the G-rich rRNA strand.   
   Other observations give further support for the formation of G-quadruplex within 
rDNA such as highly conserved RecQ helicases that have been found to prefer G-
quadruplex forming DNA sequences as substrates. As member of this family "WRN" 
is predominantly localized in the nucleolus of human cells[54]. WRN helicase is known 
to be deficient in Werner’s syndrome, a disease which leads to rapid senescence. 
Interestingly, shortened telomeres are also reported as a consequence of WRN 
helicase deficiencies[55]. 
 
3.2 G-quadruplex ligands 
 
3.2.1 Technical definitions of affinity and specificity 
   Before our survey of G-quadruplex ligands, the descriptive parameters for 
assessing binding affinity and specificity will be discussed. These measurements can 
be performed in vitro to help evaluate whether the molecule is a candidate for more 
extended characterization in vivo.  
   The first key-measure is the affinity which is normally described as equilibrium 
constant Ka (association constant) or Kd (dissociation constant).  
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   To measure equilibrium binding constants, spectroscopic methods measuring 
fluorescence emission[56] or UV absorption differences are widely used. Another tool 
is surface plasmon resonance, where the interaction of the ligand with the surface 
bound DNA leads to a change in the evanescent wave of the surface that can be 
measured using reflectance of plane polarized light[57]. ESI-MS was also recently 
used to determine the kinetics of quadruplex formation and ligand binding[58]. 
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   A factor related to affinity is the potential of a given molecule to thermodynamically 
stabilize G-quadruplex structures. This is normally reported as the increase of the G-
quadruplex melting temperature (Tm) in the presence of ligand. The Tm can be 
measured using different spectroscopic methods: UV absorption, fluorescence, or 
FRET (fluorescence resonance energy transfer) where the loss of a secondary 
structure leads to a decrease in acceptor fluorophore emission. Other methods 
include circular dichroism (CD)[59], and differential scanning calorimetry (DSC). The 
resulting ∆Tm is related to the difference in ligand affinity between folded and 
unfolded states, as well as ligand concentration.   
   A critical aspect that is often neglected is G-quadruplex binding selectivity or in 
other words how much stronger the ligand binds to the G-quadruplex structure as 
compared to duplex DNA or single stranded DNA. This is a very important factor 
since duplex DNA will be much more abundant than G-quadruplex DNA in cells. One 
definition of selectivity is the ratio of Kd values between of a given molecule to 
different DNA secondary structures. This can be accomplished by measuring the Kd 
values[56], or alternatively, the relative specificity can be assessed by a competition 
dialysis assay based on the principle of equilibrium dialysis[60-62].   
   In addition to thermodynamic assays, there are functional assays such as 
telomerase inhibition. The value describing telomerase inhibition is the IC50 value, 
defined as the concentration of the compound needed to inhibit telomerase activity 
by 50%. Small IC50 values therefore represent potent inhibition properties of the 
compound. The IC50 value is usually determined by the TRAP assay (telomere repeat 
amplification protocol)[63]. The process requires two steps in which first an initial 
telomere primer is elongated by telomerase, and second, the products of the 
telomerase elongation are amplified by a PCR step. This assay was originally 
designed for molecules binding to and inhibiting the enzyme. For molecules binding 
to DNA there is an additional step needed to remove ligands that can interference 
with the PCR process. This additional step was established by Stephen Neidle and 
his co-workers in 2008 and allowed the realization that all previous reported IC50 
values overestimated the potency of reported quadruplex ligand-telomerase inhibition 
activities[64]. 
   A good overview of methods used to determine the G-quadruplex affinity and 
specificity of small molecules is presented by Lian-quan Gu et al.[65]. 
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3.2.2  Structures and affinities of G-quadruplex ligands 
   In 1991 Zahler and his co-workers demonstrated that potassium cations have a 
stabilizing effect on G-quadruplex structures and that they are able to inhibit the 
activity of telomerase[25]. Since then, G-quadruplexes have emerged as interesting 
targets for small molecule inhibitors of telomerase. Many different groups and 
institutions have been developing G-quadruplex ligands as potential drug candidates 
due to their ability to inhibit telomerase or to deactivate G-quadruplex-related gene 
expression. Candidate molecules can be classified in several different ways; since 
the rational design of G-quadruplex-interacting compounds has been guided by 
potential pi-stacking and electrostatic interactions, Teulade-Fichou and Monchaud 
have cataloged them according to their charge[66]. In addition to neutral and anionic 
compounds, there are three categories of cationic compounds resulting from (1) in 
situ protonation of a basic functional group, (2) N-methylation of an aza-aromatic 
moiety, (3) the presence of a metal ion. The more classical approach is to categorize 
ligands according to the core structures, as recently done by Lian-quan Gu et al.[65]. 
A review by Nielsen and Ulven[67], in contrast, only focused on the most potent G-
quadruplex ligands that are flat macrocyclic structures with a size corresponding to 
the G-tetrad. In their review they divided these compounds into two main groups: (1) 
the porphyrins and related pyrrol- and isoindole based macrocycles and (2) 
telomestatin and amide based macrocycles. 
 
3.2.2.1 Various compound classes 
   Antraquinons are among the first quadruplex-interactive ligands ever reported. 
Investigations started with the compound BSU-1051 having a reported telomerase 
inhibitory value IC50 of 23 µM[68].  
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Figure 3.5: Antraquinone G-quadruplex ligands 
 
   A systematic structure-activity study was conducted by varying the position of the 
substituents and the NR2 groups[69, 70]. The core was also exchanged with 2,7-
fluorenones with the aim of reducing the cytotoxicity by lowering the potential for 
redox chemistry. Cytotoxicity was decreased by as much as a factor of 10 and the 
best IC50 values for telomerase inhibition were around 8-12 µM, somewhat less 
active than the analogous 2,7-antraquinones[71]. 
2
3
4
1
N
10
9
5
6
7
8
acridine
N
N N
N
H
N
H
OO R
N
H
O
N
H
O
F
N
F
3,6-bisamindoacridines 3,6,9-trisaminoacridines RHPS4
N N
H
O
NN
H
O
N N
NH
N
H
O
NN
H
O
N
N
BSU6039 BRACO-19
NR2NR2 N N
 
Figure 3.6: Acridine based G-quadruplex ligands 
  
   A related class of ligands are the acridines. The key difference with the 
antraquinons is that acridines possess a partial positive charge due to protonation of 
the pyridine nitrogen (pKa of acridinium: 5.6). This charge was proposed to interact 
with the high electron density at the core of the G-tetrad. Various substituted 
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acridines were synthesised and found to have variable G-quadruplex affinity and 
specificity[72-74]. For example, the 3,6-disubstituted acridines show approximately the 
same affinity for duplex and quadruplex DNA, while the 3,6,9-trisubstituted acridines 
exhibit a 30-40-fold greater affinity for quadruplex DNA. One key aspect of the ligand 
design was a crystal structure of a G-quadruplex with BSU6039[75]. The structure 
showed the aromatic core stacked on the G-tetrad with the acridine side chains 
pointing out into the grooves. On this basis, BRACO-19 was designed, which utilizes 
interactions with three grooves. BRACO-19 showed good stabilization (∆Tm = 27°C) 
of G-quadruplexes measured using a FRET-based assay, as well as a 31-fold 
preference for the G-quadruplex according to SPR experiments and a telomerase 
IC50 value of 0.15 µM. The newest ligands from this class show IC50 values in range 
of 10-20 nM[76]. An important preclinical drug candidate is the pentacyclic acridine 
3,11-difluoro-6,8,13-trimethyl(8H)quino[4,3,2-kl]acridinium methylsulfate (RHPS4) 
with an IC50 of 0.33 µM. Interestingly, RHPS4 inhibits cell proliferation within 2-3 
weeks of application at non-cytotoxic concentrations, possibly as a result of telomere 
destabilization[77-81]. According to NMR studies, RHPS4 binds to quadruplexes by 
stacking onto the external G-quartets[82, 83]. 
   To enhance stacking interactions, the aromatic core of the acridines was extended 
to four fused rings. Quindoline and its analogs (Figure 3-7) bear some of the same 
substituents as the antraquinones and the acridines. 8-[2-(trimethylammonium) 
ethoxy]benzo[b]naphtha[2,3-d]furan, having a positively charged ammonium side 
chain, was reported to have an IC50 value of 7 µM[84], while the disubstituted 
compounds were in the range of 6 – 16 µM[85, 86]. 
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   Quindolines having an amine at the 11-position exhibited surprisingly good 
telomerase inhibition activities with IC50 values ranging from 0.44 to 12.3 µM[87, 88]. 
This can be rationalized by the electron donating substituent in the 11 position which 
increases the basicity of the pyridine ring of the quindoline so that it is protonated 
under physiological conditions. These compounds were found to induce G-rich 
telomeric repeat sequences to fold into a quadruplex, and can also stabilize the c-
MYC G-quadruplex which leads to down-regulation of c-MYC in the some cell 
lines[89].  
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   Quinacridines (Figure 3-8) bind and stabilize human intramolecular quadruplex, as 
evidenced by changes in G-quadruplex melting temperatures (∆Tm) that correlate 
quite well with telomerase inhibitory activities. The two most active quinacridies, 
MMQ3 and its analog MOQ1 have ∆Tm values of 19.7 and 12.5°C and IC 50 of 0.028 
and 0.5 µM[90]. The connection of two quinacridine units by a polyamine linker in 
BOQ1 may provide better selectivity for quadruplex structures since two planar 
quinacridines might stack on the G-tetrads, while the polyamine makes electrostatic 
interactions with the negatively charged phosphate groups of the DNA. BOQ1 exhibits 
a ten fold higher binding affinity for intramolecular Q-quadruplexes than duplex DNA, 
whereas the monomeric substances are unable to discriminate. BOQ1 exhibited a 
very strong stabilizing effect on the quadruplex (∆Tm of +28°C) [91], as well as a 
submicromolar IC50 value for telomerase inhibition of 0.13 µM. In 2007 Teulade-
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Fichoue et al. reported the first ligand which was shown to interact through 
noncovalent stacking interactions as well as covalent Pt binding: Pt-MPQ[92]. This 
interesting approach could lead to a new class of ligands directing cis-platinum 
compounds towards specific structures in the genome.   
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Figure 3.9: The perylene-based G-quadruplex ligand PIPER 
 
   In 1998 Hurley et al. reported a series of substituted perylene G-quadruplex 
ligands having an extended aromatic core structure[93]. The most important example 
is "PIPER" (Figure 3-9). Upon in situ protonation of the piperidine substituents, 
PIPER showed a moderate telomerase inhibitory activity with an IC50 of around 20 
µM. In NMR titration studies, binding stoichiometries of 1:2, 1:1 and 2:1 ligand/G-
quadruplex were observed, depending on the sequence of the G4-DNA. PIPER is 
also capable of accelerating the assembly of G-quadruplex structures in vitro[94] and 
can induce the transition from duplex to G-quadruplex structures in the Pu27 
sequence from the c-MYC promoter[95]. 
   Berberine is an alkaloid isolated from Chinese herbs that has long been used as 
an antimicrobial agent. In 1999, berberine was reported to have an inhibitory effect 
on telomerase[96]. Subsequently, some substituted berberines were prepared and 
found to bind to G-quadruplexes, and to be capable of inducing G-quadruplex 
folding[97, 98].  
O
O N
OMe
OMe
Cl
berberine
O
O N
OMe
OMe
Cl
N
O
O N
O
OMe
Cl
NR2
13-substituted berberie 9-substituted berberine
 
Figure 3.10: Berberine-based G-quadruplex ligands 
 
   Quinobenzoxazines are known for their unusual anti-bacterial activities[99]. Hurley's 
group designed the fluoroquinolone derivative QQ58 as the first example of a 
quinoanthroxazine (Figure 3-11)[100-102]. A NMR study revealed end-stacking of this 
compound onto the G-tetrads as the main binding mode of QQ58. Fluoroquinolones 
are also known to interact with topoisomerase II, as well as bacterial DNA gyrase[100, 
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102-104]
. The FQAs were found to have enhanced stacking interactions with G-
quadruplexes and thus improved telomerase inhibition while maintaining the 
poisoning effect on topoisomerase II.  
   One compound from this class has been evaluated in human clinical trials. 
Quarfloxin CX-3543[105] was identified in optimization studies by Cylene 
Pharmaceuticals as having minimal topoisomerase II activity but enhanced G-
quadruplex selectivity[100]. Since quarfloxin is accumulated in the nucleolus, its 
mechanism of action is thought to be selective disturbance of nucleolin DNA-
complexes by binding to the G-quadruplexes of the ribosomal DNA. This has two 
proposed consequences: first, transcription of DNA by RNA polymerase I is inhibited, 
and secondly, nucleolin is transferred into the nucleoplasm where it might bind to the 
c-MYC G-quadruplex thereby turning off c-MYC transcription. The speculative story 
is nicely summarised by Stephen Neidle[106]. Quarfloxin is the first and only G-
quadruplex ligand that has entered phase II clinical trials for treatment of 
neuroendocine/carcinoid tumours (ClinicalTrials.gov identifier: NCT00780663)[105]. 
Unfortunately it did not proceed to phase III due to poor bioavailability.  
Figure 3.11: Quinoanthroxazine G-quadruplex ligands 
 
   A more recent group of selective G-quadruplex ligands is the bistriazole ligands, 
reported 2006 by Stephen Neidle et al.[107]. FRET analysis showed a moderate 
stabilizing effect of a G-quadruplex melting point with ∆Tm between +22 and 25°C at 
a concentration of 2 µM. Compared to BRACO-19 the bistriazoles show a small ∆Tm 
but better selectivity for G-quadruplex DNA. BRACO-19, increases the melting point 
of double stranded DNA by approximately 15°C, while  all the bistriazoles had no 
effect on the melting of duplex DNA. The inhibition of telomerase according to TRAP 
assays is only modest with IC50 values ranging between 13 and 24 µM. 
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Figure 3.12: Bistriazole G-quadruplex ligands 
 
   Some triazine bisquinoidinium ligands (12459, 115405, Figure 3-13) were found 
to induce G-quadruplex formation in human telomeric DNA. They showed good 
telomerase inhibition with IC50 values in the nanomolar range. A newer series 
containing a pyridine in the center (compounds 307A, 360A, Figure 3-13) shows 
better selectivity for G-quadruplexes having a 33-150 fold preference compared to 
duplex DNA[108]. This represents about a ten fold improvement compared to the 
triazine compounds.  
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Figure 3.13: Bisquinolidinium G-quadruplex ligands 
 
   Bisquinolidiniums are likely to adopt a syn-syn conformation with amide hydrogen 
bonds to the central aromatic nitrogen resulting in a shape appropriate to end-stack 
on a G-tetrad. An enlargement of the central aromatic system to form a bipyridine or 
phenanthroline (Figure 3-14) was therefore conducted[109]. The strong stabilization 
properties of the resulting phenanthroline derivatives can be explained by enhanced 
stacking interactions with G-tetrads. 
   In addition to these families of derivatives, some other small molecules reported to 
bind to G-quadruplex DNA include: DODC, a carbocyanine dye specificially interacts 
with hairpin G-quadruplexes[110], quercetin[111], a natural product flavonoid and its 
glycosylated homolog rutin[112] (Figure 3.15).  
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Figure 3.14: Bisquinolidinium G-quadruplex ligands with an enlarged aromatic core 
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Figure 3.15: Structures of DOCD, quercetin and its homolog rutin 
 
   Metal complexes comprise a large group of G-quadruplex ligands. These include 
Ni(II)-salphen[113] and Cu-ttpy[114]. Ni(II)-salphen exhibits outstanding characteristics 
in terms of quadruplex stabilization: an impressive ∆Tm of 33°C and a good selectivity 
for G-quadruplexes according to FRET-melting and SPR. Ni(II)-salphen is also a very 
potent telomerase inhibitor with an IC50 of 0.12 µM. The simple Cu(II)-terpyridine is 
less active, with a ∆Tm of 15°C and a preference for G-quadruplex over dup lex of 
about 22.  
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Figure 3.16: Two metal complex G-quadruplex ligands: Ni(II)-salphen and Cu-ttpy 
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3.2.2.2 Porphyrins and related macrocycles 
   Planar aromatic systems are ideal molecules for end-stacking onto G-tetrads. 
Porphyrins are well known as binding agents of duplex DNA. In 1998 Hurley et al. 
reported that the porphyrin TMPyP4 (tetra-(N-methyl-4-pyridyl)porphyrin, Figure 3-17) 
was a selective G-quadruplex ligand[115]. This molecule became one of the most 
intensely studied G-quadruplex ligands to date. 
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Figure 3.17: The porphyrin-based G-quadruplex ligands TMPyP4, TMPyP2 and TPrPyP4 
 
   Subsequent studies demonstrated that the binding stoichiometry of TMPyP4 is not 
clearly defined, and can range from 1-2[116-119], 4[119], even up to 5[120, 121] equivalents 
per quadruplex. These differences may be a consequence of non-selective DNA 
binding properties[62]. In fact, two distinctly different binding modes could be 
observed: 1) in a crystal structure TMPyP4 interacts with the bases of the connecting 
loops in a bimolecular 5'-d(TAG3T2AG3)  telomeric DNA G-quadruplex[122] and 2) in 
an NMR structure, TMPyP4 stacks on the external G-tetrad planes of the Pu24I 
modified c-MYC G-quadruplex. The measured affinities for G-quadruplex and duplex 
DNA are Kd = 0.073 µM and 0.37 µM[123], indicating a only 5-fold preference for G-
quadruplex. TMPyP4 stabilizes the G-quadruplex with a ∆Tm of +17°C, and it inhibits 
telomerase with an IC50 of 6.5 µM[115]. On the other hand, the isomer TMPyP2, with 
the N-methyl groups in the 2-position showed very weak activity[124, 125]. TMPyP4 was 
also tested in cells and showed a supression of the c-MYC[126] in the Ramos tumor 
cell line[127] and in the K562 leukemic cell line[128]. The BCL-2 promotor has also been 
found to interact with TMPyP4[129] and the ligand exhibits antitumor activity in 
retinoblastoma cell lines[130].  
   Structurally very similar to TMPyP4 is a tetra-propyl homolog TPrPyP4 (Figure 3-
17). It is not very surprising, that the binding abilities of TPrPyP4 are similar to 
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TMPyP4: in a direct comparison with CD analysis both showed binding to a 
(TGGGGT)4 in a ratio of 3:1: one ligand end-stacked and two lower affinity binding 
sites in the grooves[131].  
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Figure 3.18: The porphyrin G-quadruplex ligands TQMP and a pentacationic manganese(III) complex 
 
   A chemically reactive, TMPyP4 analog TQMP (Figure 3-18), exhibits similar non-
covalent binding interactions, but it can be activated for covalent cross-linking upon 
photoexcitation. A Mn(III) porphyrin complex was reported to bind strongly to G-
quadruplex DNA (Kd = 1 nM) with a 10'000 fold selectivity over duplex DNA and to 
inhibit efficiently telomerase (IC50 = 580 nM)[57]. A more recent publication reports 60-
fold lower affinity and specificity for G-quadruplexes (Kd = 60 nM), but slightly higher 
telomerase inhibition activity (IC50 = 210 nM)[132]. 
   Porphyrin-related oligopyrroles have also been synthesized and evaluated, (Figure 
3-19). Corrole-type ligands, contracted by one methine group, exhibit good affinity (Kd 
= 0.46 µM)[127]. Examining positional effects in TMPyP4 related compounds revealed 
that trans-pyridinium groups are required for high affinity quadruplex interactions, 
trans-DMPyP4 has a Kd of 0.83 ± 0.10 µM, while cis-DMPyP4 has a Kd of 18.9 ± 2.80 
µM[133]. 
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Figure 3.19: Selection of different porphyrin-related G-quadruplex ligands 
 
   A series of macrocyclic oligopyrroles was synthesised and analysed for quadruplex 
binding by Sessler and co-workers[134]. Dodecaethylcyclo[6]pyrrole was found by ESI 
mass spectrometry to have a higher affinity than the corresponding Cyclo[7]- and -
[8]pyrrole macrocycles. This result was rationalized in terms of size complementarity 
with G-tetrads. While the vast majority of G-quadruplex ligands are cations, N-methyl 
mesoporphyrin (NMM) has negative charges on the side chains under physiological 
conditions. It was one of the very first G-quadruplex ligands ever reported, and it 
exhibits excellent G-quadruplex selectivity[62] but poor affinity[135-137]. 
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Figure 3.20: The Se2SAP ligand  
 
   Porphyrins do not have ideal shape complementarity with G-tetrads. Significant 
improvements can be obtained by expanding the macrocyclic core[138, 139]. Se2SAP 
was considered a breakthrough in the field of G-quadruplex ligands because it 
exhibits a better selectivity for quadruplex over duplex (around a 50-fold according to 
SPR studies). Se2SAP is also able to discriminate various topologies G-quadruplex-
DNA. Unfortunately the synthesis of Se2SAP is very low yielding, a potential 
drawback for future exploration of its biological potential.  
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Figure 3.21: Porphyrazine / phthalocyanine G-quadruplex ligands 
 
   Phthalocyanines and their derivatives exhibit much better shape complementarity 
with G-tetrad DNA than do porphyrins. The methylated derivatives of non-
symmetrical 3,4-tetrapyridinoporphyrazine (3,4-TPyPz), with four positive charges, 
induce the formation of antiparallel conformation of telomeric DNA and bind in a 1:1 
ratio (Kd = 0.17 ± 0.02 µM for 3,4-TMPyPz and Kd = 0.40 ± 0.02 µM for 3,4-TMPyPz 
zinc(II)). The lower affinity of the Zn-containing ligand was explained by the higher 
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degree of self aggregation observed with this molecule. Phthalocyanines are 
generally potent G-quadruplex stabilizers, especially when coordinated to a Zn or Ni 
metal such as in the case of ZnPc, which has an affinity with a Kd = 0.12 µM and a 
telomerase IC50 = 0.23 µM[140, 141]. In 2009 Luedtke, Alzeer and co-workers published 
a new guanidinium-substituted phthalocyanine, Zn-DIGP, which has a Kd < 0.002 µM 
for c-MYC G-quadruplex DNA[56]. This is the strongest binding interaction between a 
G-quadruplex structure and a small molecule reported to date. Zn-DIGP is also 
outstanding in terms of specificity having a more than 5000-fold lower affinity for 
duplex than for quadruplex DNA. Another interesting feature of the Zn-DIGP is its 
fluorescence properties making it possible to demonstrate its cellular uptake in living 
NIH 3T3 and HeLa cells[142]. Unlike most other G-quadruplex ligands, Zn-DIGP is 
relatively non-toxic to cell cultures and is well tolerated upon intravenous injection 
into mice. 
   Phthalocyanines, porphyrins and perlyene derivatives exhibit a strong tendency to 
self-associate in aqueous solution. Whereas perlyene diimide exhibit increased 
binding specificity towards G-quadruplex structures upon aggregation, porphyrins 
and phthalocyanines loose their affinity upon aggregation. In 2010 Alzeer and 
Luedtke published their research on APcs (Figure 3-21)[143]. The self association of 
APcs is strongly pH dependent. Positive charges of protonated amino groups help 
prevent aggregation and the pKa values of the substances depend on the terminal 
amino groups. With one methylene group separating the amine from the amide (n = 
1), pH values ≥ 6.8 lead to aggregates incapable of binding to G-quadruplex DNA. 
Increasing the number of methylene units the pKa is also increased, thereby 
decreasing aggregation and increasing G-quadruplex affinity.  
 
3.2.2.3 Telomestatin and amide based macrocycles 
   In 2001, Shin-ya and his co-workers reported the identification and characterization 
of the natural product telomestatin. At the time, telomestatin was the most potent 
telomerase inhibitor reported to date with an IC50 of 5 nM[144]. Unfortunately, as 
already described in section 3.2.1, the initially measured IC50 was misleading 
because of PCR inhibition and has subsequently been revised to 0.9 – 1.2 µM[145] or 
0.6 µM[64]. Notably, telomestatin exhibits an almost complete absence of affinity for 
duplex DNA[66], which is due to its neutral character and its cyclic shape. 
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Telomestatin was reported to have at least a 70-fold preference for G-quadruplex 
over duplex[146]. 
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Figure 3.22: Telomestatin: the revolutionary quadruplex ligand 
 
   Telomestatin (1) exhibits a wide variety of biological effects including: (1) inhibition 
of cell growth in cancer cells but not in normal fibroblasts, (2) no significant telomere 
attrition in either cancer or non-cancer cells under short-term conditions, (3) reduction 
of 3' telomeric overhangs, (4) induction of POT1 dissociation from telomeres, (5) 
induction of anaphase bridge formation and apoptosis[147]. The reasons behind these 
biological activities is probably the high affinity of telomestatin for intramolecular G-
quadruplex structures, having a ∆Tm = + 24°C. Telomestatin changes the normal 
conformational preferences of DNA[148]. It causes telomere uncapping and release of 
telomeric proteins (POT1) and leads to G-overhang degradation which is associated 
with DNA damage response[23, 148]. Telomestatin was also found to have an effect on 
cancer cells that lack telomerase overexpression known as ALT (Alternative 
Lengthening of Telomeres). In ALT cells, telomestatin also induces G-overhang 
degradation and provokes a massive DNA damage response[148]. Interestingly, 
telomestatin does not disturb the replication process of telomeres, even after 
extended treatments[149]. These results suggest that the proposed models for 
telomerase inhibition and telomere shortening may not be viable.  
   One major drawback of telomestatin is that it is difficult to obtain. Despite many 
unsuccessful attempts[150-156], there is only one total synthesis described in 
literature[157]. This route is clearly incompatible with large scale production. The 
bacterial production of the molecule is also quite low due to inefficient fermentation. 
This approach is also incompatible with the production of derivatives.  
   Given the extraordinary G-quadruplex specificity and biological activities of 
telomestatin, some related analogs were synthesised and characterised. One of the 
first examples was hexaoxazole HXDV, reported 2006 by Rice and co-workers[158] 
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(Figure 3-23). This macrocycle binds selectively to quadruplexes by stacking onto the 
terminal G-tetrads, and it does not bind to duplex or triplex DNA[159, 160].   
Figure 3.23: HXDV and related telomestatin analogs 
 
   Rice compared HXDV with the tetra-isopropyl substituted compound 2 and found 
that HXDV stabilized a telomeric G-quadruplex by ∆Tm = + 17.5°C, while 2 did not 
have any stabilizing effect[158]. While EC50 values for HXDV ranged from 0.3 – 8 µM, 
a related derivative 3 was found to be somewhat more toxic having EC50 between 
0.025 – 3.3 µM[161]. Unfortunately, it is not reported if the increase in cytotoxicity is 
cancer cell specific or not. The bistrioxazole acetate was also tested for telomerase 
inhibition and revealed an IC50 of 2 µM[162]. 
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Figure 3.24: Telomestatin analogs with cationic side chains 
 
   While porphyrin-based G-quadruplex ligands typically have a planar core with 
positively charged side chains, telomestatin-like molecules are typically neutral and 
therefore more drug-like, but exhibit very limited water solubility. Cationic side chains 
could help to improve water solubility while, at the same time, enhancing the affinity 
and selectivity between different types of G-quadruplex topologies. A series of 
cationic derivatives was therefore synthesised and evaluated. 
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Diaminobutylhexaoxazole 4 exhibited a superior ability to stabilize telomeric DNA as 
compared to HXDV and related analogs containing only one amino group[163]. It also 
exhibited a preference for the antiparallel telomeric G-quadruplex structure over the 
parallel one[164]. The effect of the side chain variation was recently demonstrated by 
Rice and co-workers[165]. The [(dimethyl)amino]ethyl-isopropylhexaoxazole 5 
displayed high potency with respect to G-quadruplex stabilization, reaching ∆Tm 
values of +21.5°C and + 34.5°C for hTel and AurA DN A, as well as potent cytotoxic 
activities. 5 demonstrated in vivo a potential as anti-cancer agent: in mice containing 
human tumor xenografts it reached a T/C-value (average tumor volume as compared 
to control group) of 21.6%. Heptaoxazole 6[166], was also found to stabilize 
antiparallel telomeric G-quadruplexes. The free amino group which can be 
protonated under physiologic conditions, plays a significant role in the binding 
interaction since a corresponding N-acetylated derivative has revealed three-fold 
lower potency. 6 has cytotoxic activity in telomerase-positive HeLa cells (IC50 = 
0.0022 µM) whereas telomerase-negative Saos-2 cells are unaffected.   
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Figure 3.25: A dimeric hexaoxazole G-quadruplex ligand 
 
   A clever idea was reported recently by Shin-ya et al.[167] connecting two 
hexaoxazoles by linkers in different length. A ten-fold higher selectivity for telomeric 
DNA as compared to a mutated telomeric sequence was reported for dimer 7 versus 
the corresponding monomer. The two connected hexaoxazoles are expected to 
interact as terminal caps on the same quadruplex, whereas the monomer interacts 
with a 2:1 binding mode similar to telomestatin and HXDV.  
   A series of trisoxazole macrocyclic ligands shown in Figure 3-26 was shown to 
interact selectively with the parallel versus antiparallel telomeric G-quadruplex 
structure[168]. Having four CH2 units between the macrocycle and amine was found to 
be much better than having just one. A series of four diastereoisomers was tested 
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and found to be very similar. The (S,S,S) compound exhibited a G-quadruplex 
stabilization of ∆Tm = + 10.8°C as compared to the ( R,R,R)-compound with ∆Tm = + 
8.7°C. These compounds also exhibited similar affin ity (Kd(S,S,S) = 5 ± 2 µM and 
Kd(R,R,R) = 4 ± 2 µM).   
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Figure 3.26: Substituted trioxazole G-quadruplex ligands  
 
   Upon screening a dynamic combinatorial library with G-quadruplex templates, 
guanidinium-containing trisoxazole 8 was identified to be a preferred binding partner 
for both antiparallel and parallel G-quadruplexes[169]. The related 24-membered 
macrocycle 9 (Figure 3-27) containing four furan units[170] proved to be selective for 
telomeric DNA with Kd value of 3.1 µM, but exhibited no telomerase inhibition 
activities. The 18-membered quinoline-based macrocycle 10 was shown to stabilize 
parallel (c-Kit) and antiparallel (h-telo) DNA quadruplexes with ∆Tm values of + 
21.4°C and + 33.8°C respectively [171]. This ligand has an even better stabilizing effect 
than telomestatin itself, which has "only" ∆Tm of + 20.4°C and + 30.3°C [172]. More 
recently, the pyridine- and oxazole-containing 24-membered macrocycle 11 was 
published by Rice and co-workers[173]. It also exhibited high stabilization of DNA and 
RNA quadruplex structures, having a ∆Tm = + 20.5°C (in case of h-telo DNA) or ∆Tm 
= + 37.0°C (in case of AurA RNA). This compound als o exhibited anticancer activities 
in mice having human breast cancer xenograft, with no reported toxic effects.  
Introduction  Chapter I – 3.  
 
 - 32 / 181 - 
HNNH
H
N
N
H
O
O
O
O
O
O
O
O
NH
O
NH2
HN
O
H2N
N
NH
O
HNO
N N
H
N
O
O NH2
O
H2N
O
NH2
N
N
OO
N
O
N N
O
O NH O
N
H
N
9 10 11
 
Figure 3.27: 24- and 18-membered macrocyclic G-quadruplex ligands 
 
3.3  Synthetic strategies for telomestatin type ligands 
 
   What makes the synthesis of telomestatin and related compounds difficult and how 
are these problems solved? In the following three sections the synthetic paths to 
these compounds are described.  
 
3.3.1 Synthesis of telomestatin-related hexaoxazoles 
   A series of hexaoxazoles was synthesised by Shin-ya and co-workers using a 
convergent synthesis[162]. The compound can be built from eight serine amino acids 
applying different protecting groups. The amino acid couplings were performed using 
1-[3-(diethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDCl). The resulting 
diserine 12 (Scheme 3.1) was converted to an oxazole amino acid using a two step 
reaction with the fluorinating agent DAST followed by DBU / BrCCl3. The resulting 
compound 13 was deprotected and dimerised to give 14. Following serine 
deprotection, a third oxazole unit was generated using DAST / DBU, BrCCl3 to give 
15, representing half of the target molecule. Trioxazole 15 was again dimerized 
giving the linear hexaoxazole 16 (Scheme 3.2). After deprotection 
macrolactamization was performed under high dilution (1 mM) using N,N-bis(2-oxo-3-
oxazolidinyl)phosphinic chloride (BOPCl) and diisopropylethylamine in a mixture of 
CH2Cl2 and DMF. A final deprotection provides the opportunity to insert different side 
chains, for example an acetyl group, to give compound 17. Shin-ya claims that these 
compounds were designed on the structural basis of telomestatin in search for a 
possibility to increase the binding interaction by insertion of side chains. Around the 
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same time, Rice et al. published HXDV (Figure 3-23) following more or less the same 
synthetic strategy[158]. Two years later, Shin-ya described analogous macrocycles 
having amine-containing side chains instead of the alcohols[164]. 
 
Scheme 3.1: Synthesis of the trisoxazole[162] 
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 Scheme 3.2: Synthesis of hexaoxazoles[162] 
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3.3.2 Synthesis of telomestatin-related heptaoxazoles 
 
Scheme 3.3: Synthesis of heptaoxazoles[166] 
 
   Following his total synthesis of telomestatin and related hexaoxazoles, Shin-ya and 
co-workers moved to the synthesis of heptaoxazoles[166]. The reported convergent 
synthesis of heptaoxazoles is similar to that used for the hexaoxazoles. The key 
difference is the use of two different trioxazoles resulting in orthogonally protected 
side chains on the macrocycle. As one of the trioxazoles the serine-derived TBS-
protected alcohol 15 was used. The other trioxazole 18 was synthesised, having a 
Boc-protected aminobutyl group derived from L-lysine[162, 164] (Scheme 3.3). In six 
steps the two halfs were transformed into macrocycle 19. Having now two 
orthogonally protected side chains, the alcohol was deprotected and eliminated using 
mesylation and DBU to furnish the enamide 20. This could be reacted with N-
bromosuccinimide (NBS) and Cs2CO3 in MeCN at 65°C to generate the heptaoxazole 
21. This unconventional path was likely chosen since the typical reagents like DAST 
probably did not work in the case of the hexaoxazole. It is thought that the strained 
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structure of the β-hydroxyamide moiety is not compatible with this reaction[150, 155, 157-
159, 163]
. 
 
3.3.3 Total synthesis of telomestatin 
 
   The natural product telomestatin is more complicated than the simplified analogs 
described so far. The symmetry of the compound is much lower, having one 
thiazoline ring and two methyl oxazole substituents. Biosynthetically it is most likely 
synthesised from the three amino acids serine, threonine and cystein as shown in 
Scheme 3.4[174].   
 
Scheme 3.4: Retrosynthesis to the most probable building blocks for biosynthesis of telomestatin 
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Scheme 3.5: Synthesis of the methyl substituted trioxazole as building block for telomestatin 
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   To date, only a single total synthesis of telomestatin has been reported[157]. The 
previously described convergent synthesis (Scheme 3.1, 3.2, 3.3) can also be 
applied in the case of telomestatin (Scheme 3.5, 3.6). The lower symmetry makes 
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the fragment synthesis somewhat more difficult. The formation of the thiazoline, the 
only non-oxidized, and potentially labile ring, is the last to be closed.  
   The synthesis of building blocks for telomestatin was performed in analogy to the 
previously reported trioxazoles: the amino acids were coupled and the side chains 
cyclized and oxidized. For the formation of 5-methyl-1,3-oxazole 22 the secondary 
alcohol 23 was first oxidized to the ketone with SO3-pyridine and DMSO (Parikh-
Doering oxidation) and immediately cyclodehydrated using Ph3P and I2 in presence 
of Et3N (Scheme 3.5). Shin-ya does not give any reasons for this unusual strategy. 
Again it could be due to the failure of the DAST and DBU, BrCCl3 procedure.  
   The synthesis of trioxazole 24 (Scheme 3.6) differs from the other examples only in 
the protection of the N-terminal amino and hydroxy group as acetonides forming an 
oxazolidine. Two such units, 25a and 25b were fused. The rest of the synthesis was 
performed in analogy to building block 26.   
 
Scheme 3.6: Synthesis of the second trioxazole building block for telomestatin 
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   The fusion of trioxazoles 24 and 26 (Scheme 3.7) was conducted analogously to 
the previously described syntheses. The macrolactamization was done under high 
dilution (3 mM) in a mixture of CH2Cl2 and DMF at rt over 3 days using DPPA[175] – 
HOBt and DIEA in the presence of DMAP as coupling reagents in an overall yield of 
48%. The subsequent diamide dehydration to the oxazoline did not work with DAST 
or Burgess reagent, resulting only in elimination. Oxidation of the primary alcohol 27 
followed by cyclodehydration also failed. The enamide 28 could be reached in 92% 
by mesylation of the alcohol with DBU. According to an earlier report by Shin-ya[150], 
the enamide 28 could be used to form an α-methoxy-β-bromo cyclic peptide in 90%. 
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For this process, it is crucial to add molecular sieves (4 Å), otherwise the sulphide 
moiety is partially oxidized leading to decomposition. The α-methoxy-β-bromo cyclic 
peptide was subsequently cyclized to afford the 4-methoxyoxazoline 29 using K2CO3 
at 60°C. The methoxy group could be selectively eli minated in toluene at 70°C with 
camphorsulfonic acid and molecular sieves (5 Å) to give the heptaoxazole 30. Again, 
molecular sieves were important, this time to prevent the oxazoline from being 
hydrolyzed back to the alcohol. The thiazoline was formed using a modified method 
described by Kelly[176], using Ph3PO, Tf2O and anisole in CH2Cl2 at room 
temperature. The yield of this last synthetic step was only 20% due to the limited 
solubility of telomestatin during purification.  
 
Scheme 3.7: Total synthesis of telomestatin by Takahashi[157] 
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   The spectroscopic data from this product were in agreement with those from the 
isolated natural product. The total synthesis could therefore also confirm the 
stereochemistry of telomestatin, the only stereocenter having an R-configuration, 
consistent with a natural Cys precursor (Scheme 3.7). 
 
3.4 Current problems and goals 
 
   After ten years of intensive research in the field of G-quadruplex ligands, there is 
still no compound that has reached drug status. Clinical research into telomestatin 
ended at the pre-clinical stage due to toxicity in animal models. 
   Unlike many G-quadruplex ligands, telomestatin and its derivatives are "drug-like" 
(according to Lipinski's rules, telomestatin has a molecular weight of 582.504 g/mol, 
no H-bond donors, 16 H-bond acceptors, no rotatable bonds). Telomestatin is an 
attractive scaffold for further diversification. New telomestatin-like G-quadruplex 
ligands are therefore needed to address the following goals: 
- To further improve the binding affinity towards G-quadruplexes and selectivity 
between different G-quadruplex sequences; 
- To improve the solubility of the molecule; 
- To achieve good pharmacokinetics; 
- To reduce the toxicity of the compounds. 
   We will attempt to increase G-quadruplex binding affinity by increasing the planarity 
of molecules having telomestatin-like core structures. Selectivity between G-
quadruplexes will be achieved by placing substituents on the core to interact with the 
DNA back bone or groove regions. Proper choice of substituents will also improve 
the solubility properties and modulate the pharmacokinetics and toxicity of derivatives 
in vivo.  
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4.  Design of New Telomestatin Analogs 
 
4.1  Structural features of telomestatin 
 
   The natural product telomestatin exhibits excellent G-quadruplex affinity and 
specificity[146, 177]. Telomestatin stacks onto the terminal G-tetrads of intramolecular 
G-quadruplexes. A two to one binding stoichiometry was determined by Valérie 
Gabelica et al. by electronspray mass spectrometry[58]. 
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Figure 4.1: Telomestatin (left), the G-tetrad (right) and an overlay of the two structural representations, 
drawn in accordance with in silico calculations described by Maiti[178] 
 
   There are no high resolution NMR or X-ray structures of any telomestatin-G-
quadruplex complexes available to date. Only two in silico investigations have been 
reported, that use known G-quadruplex structures and manual docking of 
telomestatin[29, 177, 178]. These modelling studies suggest that telomestatin has 
approximately the right size to fit onto the G-tetrads of G-quadruplexes. It has been 
reasoned that the relative flatness of the macrocycle facilitates good stacking 
interactions between the oxazole and the guanine aromatic heterocycles. In this 
respect, telomestatin has good, but not optimal shape. Due to the presence of a 
single thiazoline unit, telomestatin is not a planar molecule (Figure 4.2). This should 
limit the potential stacking interactions between telomestatin and planar G-tetrads. 
While the exact function of telomestatin in context of Streptomyces anulatus 3533-
SV4 is unknown, it is a reasonable question to ask why the sulphur-containing ring is 
not oxidized like the other rings. Potential limitations to this oxidation reaction include 
ring-strain (discussed in section 4.2) and solubility. Limited solubility properties have 
been reported in context of the total synthesis of telomestatin by Shin-ya et al.[157]. 
The final step of the synthesis yields only 20% due to purification difficulties 
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associated with poor solubility during both normal and reversed phase 
chromatography. 
 
 
Figure 4.2: Side view on telomestatin (Density Functional / SVWN/DN**-optimized structure) 
 
   Another potential reason for the lack of high resolution structural data of 
telomestatin-quadruplex complexes is the lack of symmetry. The two methyl 
substituents and the thiazoline reduce the symmetry of telomestatin to C1. Combined 
with the pseudo C4 symmetry of G-tetrads, defined positioning of telomestatin is 
difficult and probably results in multiple stacking orientations between telomestatin 
and G-tetrads. These properties complicate the structural elucidation of the 
complexes in terms of X-ray analysis and NMR-based structural studies. Increasing 
the symmetry of the ligand, to C4 for example, would be an advantageous feature of 
new telomestatin analogs. 
 
4.2 Macrocyclic ring-strain of telomestatin  
 
   DFT-optimized structures of telomestatin suggest a shape that is nearly planar over 
2/3 of the molecule (Figure 4.2 and 4.3). A linear analog was generated in silico by 
cutting a single bond in the macrocycle and re-optimizing the structural energy. The 
resulting structure shows a strong tendency to open, revealing the presence of 
macrocyclic ring-strain in telomestatin (Figure 4.3 on the right). Similar virtual 
experiments using a telomestatin analog with 10 oxazole units suggest the addition 
of two oxazoles to telomestatin would relax all ring-strain. This change also alters the 
size of the molecule and docking studies suggest that [0.10](2,4)1,3-oxazolophan (31) 
would not necessarily have good shape complementarity with G-tetrads (Figure 4.4). 
A more quantitative virtual experiment to estimate ring-strain has been conducted by 
calculating the number of five-membered rings needed to form a perfectly circular 
macrocycle. In a geometry-optimized 2,4-dimethyl-1,3-oxazole, the angle φ is defined 
as the two perpendicular bisectors of the bonds between each methyl group and 
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oxazole (Figure 4.5). The calculated angle φ is 35.14°, so 10.2 oxazoles are expected 
to fill a circle of 360°. These estimates are subst antiated by angles derived from 
crystallographic data (Figure 4.6). 
 
 
Figure 4.3: Density Functional / SVWN/DN**-optimized geometries of telomestatin  
and its linear analog 
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Figure 4.4: [0.10](2,4)1,3-Oxazolophan (31) on the G-tetrad 
 
O
N φ
  
Figure 4.5: The calculated angle φ 
 
   Adding more oxazole units to the macrocyclic ring system is one possible option to 
reduce ring-strain. Another approach is to change the identities of the heterocycles to 
increase the angle φ. This can be achieved by exchanging the oxygen of the oxazole 
with other heteroatoms. Replacing O with NH, for example, does not make a large 
difference to the ring geometry since nitrogen is from the same period. Changing 
oxygen to sulphur however causes a significantly different orientation of the 
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substituents in 2- and 4-position, and a larger angle φ is predicted. This effect is even 
larger with selenium and the selenazole system. Simulations of imidazole, thiazole, 
and selenazole were performed (Figure 4.6) and compared to reported 
crystallographic data (Table 4.1).  
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Table 4.1: Calculations for angle φ 
 Oxazole Imidazole Thiazole Selenazole 
φ (simulated) 35° 39° 48° 51° 
Expected ring units 10.2 9.1 7.5 7.0 
φ (crystal) 36° 41° 49° 50° 
Expected ring units 10.1 8.7 7.3 7.3 
 
   These calculations predict significant differencies between oxygen (and nitrogen) 
versus sulphur, but small differences between sulphur and selenium. While ten 
oxazoles are predicted to be required for closing a macrocycle, in theory, only seven 
or eight thiazole units are needed. A ring-strain simulation was conducted with 
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[0.8](2,4)1,3-thiazolophan by cutting one bond connecting single thiazoles and re-
optimizing the structure (Figure 4.7). The resulting structure does not open up as in 
the case of telomestatin (Figure 4.3). 
 
 
Figure 4.7: Density Functional / SVWN/DN**-optimized geometry of [0.8](2,4)1,3-thiazolophan 
 
4.3 Rational design of C4-symmetric telomestatin analogs  
 
   As discussed in section 4.1, there are three structural features of telomestatin that 
can be improved: the symmetry, planarity, and predicted ring-strain. The topic of 
symmetry is easily addressed by designing a macrocycle composed of four identical 
ring segments giving C4 symmetry. To reduce the ring-strain, half of the oxazoles will 
be replaced by thiazole units. Alternating oxazole and thiazole units should therefore 
provide planar C4-symmetric molecules with little or no ring-strain (Figure 4.8).  
 
 
Figure 4.8: Density Functional / SVWN/DN**-optimized geometry of 
 [0.4]{(2,4)1,3-thiazolo[0](2,4)1,3-oxazolo}phan and its linear analog 
 
   Calculations based on the angle φ (Table 4.1) suggest that a macrocycle containing 
four thiazoles together with four oxazole or imidazole units should have no ring-
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strain. This should make the synthesis of such compounds more feasible. Imidazole 
units should have comparable angles as oxazole but will exhibit better solubility 
properties in water, making the [0.4]{(2,4)1,3-thiazolo[0](2,4)-1H-1,3-imidazolo}phan 
an important target molecule. The NH groups of the imidazole units could also be 
used to attach different substituents, giving access to a series of water soluble 
telomestatin analogs.  
 
Table 4.2: Predicted total angles of macrocycles composed of variable heterocycles 
 
4 φ(thiazole) 
+ 
4 φ(oxazole) 
4 φ(thiazole) 
+ 
4 φ(imidazole) 
8 φ(thiazole)  8 φ(oxazole) 10 φ(oxazole) 
      Calculations based 
on simulation 332° 348° 384° 280° 350° 
      Calculations based 
on crystal structure 340° 360° 392° 288° 360° 
 
   These calculations have motivated the synthesis of three target molecules: 
[0.4]{(2,4)1,3-thiazolo[0](2,4)1,3-oxazolo}phan (4TOP, 32) and [0.4]{(2,4)1,3-
thiazolo[0](2,4)-1H-1,3-imidazolo}phan (4TIP, 33), which are likely to be planar 
systems, and [0.8](2,4)1,3-thiazolophan (8TP, 34) which will be slightly non-planar 
(Figure 4.9).  
 
 
Figure 4.9: Three new telomestatin analogs as synthetic targets 
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4.4 Specific questions and aims 
 
   With the design and synthesis of these three new telomestatin analogs, we aim to 
get three macrocyclic G-quadruplex ligands with improved the symmetry and shape 
as compared to telomestatin. Following synthesis, these three new macrocycles 
should allow us to answer the following three questions: 
 
(1) Are cyclic polyazole systems with no or low ring-strain more synthetically 
accessible than those with high ring-strain? 
(2) Are the proposed macrocyclic polyazoles planar?  
(3) Do planar ring systems stack more tightly to G-tetrads and therefore provide 
improved binding properties for G-quadruplex structures?  
 
   Based on our computation analysis and experience with other G-quadruplex 
ligands, we predict the answer will be "yes" to all three questions. The following work 
was performed with the intension of providing an experiment-based assessment of 
these questions and predictions. 
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4.5  Retrosynthetic analysis 
 
   At the time this project was started the total synthesis of telomestatin was just 
published[157], as well as the first series of synthetic hexaoxazole-derivatives[162]. In 
both cases, the assembly of the two halfs of the macrocycle, each containing three 
oxazole units, was utilized as the basic strategy (Scheme 4.1). Since telomestatin 
has a C1 and synthetic hexaoxazoles a C2 symmetry, this is an efficient approach. In 
the case of C4-symmetric target molecules, an alternative strategy was developed. 
As presented in Scheme 4.2, the target molecules containing eight azole units were 
reduced to four heterocycles connected by four amide bonds. The disconnected units 
can be seen as artificial amino acids containing a thiazole ring.   
 
Scheme 4.1: Published strategy for polyazole macrocycles[157, 162] 
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Scheme 4.2: Retrosynthetic analysis of C4-symmetric macrocycles 
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   This proposed synthesis of a C4-symmetric, macrocyclic scaffold from four identical 
subunits is highly economic. In theory, a single azole containing amino acid subunit 
can be used to synthesize a linear peptide followed by macrolactamization. The key 
step of this series is near the end of the sequence, where four azole rings are 
generated in one step. In the end, the development of novel synthetic methodology 
was needed to accomplish this challenging goal. 
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5.  Synthesis of Telomestatin Analogs 
 
5.1 Target 1: [0.4]{(2,4)1,3-Thiazolo[0](2,4)-1H-1,3-imidazolo}phan (33) 
 
5.1.1 Retrosynthetic analysis 
   [0.4]{(2,4)1,3-Thiazolo[0](2,4)-1H-1,3-imidazolo}phan (4TIP, 33) is expected to be a 
planar macrocycle. Of the three proposed telomestatin analogs, macrocycle 33 is 
least likely to have any ring strain (Table 4.2). Upon protonation, the imidazole 
groups should increase the solubility of this compound in aqueous solutions. They 
also provide the opportunity for alkylation of the macrocycle, giving rise to a series of 
tetracationic, water soluble derivatives. 
 
Scheme 5.1. Two alternative retrosynthetic analyses of macrocycle 33  
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   33 can be derived by assembling four units of an imidazole (A) or a thiazole (B) 
amino acid (Scheme 5.1). Imidazole amino acids of type "A" can be synthesised by 
fusing 2,3-diaminopropionic acid with serine (Scheme 5.2). Thiazole amino acids of 
type "B" can be prepared by coupling a 2,3-diaminopropionic acid with a serine 
residue, followed by thiazole formation on the dipeptide (Scheme 5.3). 
 
Scheme 5.2. Retrosynthesis of imidazole amino acids 
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Scheme 5.3. Restrosynthesis of thiazole amino acids (A = activating group) 
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5.1.2 Synthesis of azole amino acids 
 
5.1.2.1 Boc-I(NMts)Ser(OBn)-OMe (35) 
   The synthesis of methyl 2-{2-(benzyloxy)-1-[(tert-butoxycarbonyl)amino]ethyl}-1-
mesityl-1H-imidazole-4-carboxylate (Boc-I(NMts)Ser(OBn)-OMe, 35a / 35b) was 
accomplished starting from two orthogonally protected amino acids (Scheme 5.4). 
2,3-diaminopropionic acid dihydrochloride (36) was first esterified using SOCl2 in 
MeOH[179] giving methyl 2,3-diaminopropionate dihydrochloride (37) in 97%. 
Separately, L-Boc-Ser(OBn)-OH (38) was converted to the corresponding amide 
using Boc2O and [NH4][HCO3] in dioxane to furnish L-Boc-Ser(OBn)-NH2 (39) in a 
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yield of 92%[180, 181]. 39 was activated for nucleophilic attack by ethylation with 
"Meerwein salt" Et3OBF4. The resulting O-ethyl-(2S)-3-benzyloxy-2-[(tert-
butoxycarbonyl)amino]propanimidoate (40) is very reactive towards water and is 
readily converted into the corresponding ethyl propionate. Compound 40 was 
therefore not isolated and reacted with the diamine 37 in a one-pot reaction in the 
presence of 2.5 equiv. Et3N. Due to the basic reaction conditions, racemization of 
both stereogenic centers was observed. The mixture of diastereomers 41 was 
oxidized to the corresponding imidazole 42 using 10 equiv. of MnO2 as an oxidazing 
agent[182] (Scheme 5.4). 42 could be produced in three steps with an overall yield of 
27%. The structure of 42 was confirmed with x-ray crystallography (Figure 5.1).  
 
Scheme 5.4. Synthesis of the Imidazole containing amino acid 35 
 a) 7.5 equiv. SOCl2, MeOH, 0°C, 20 min, 75°C, 5 h; b) 1.5 equiv. Boc 2O, 0.66 equiv. Pyridine, 1.25 
equiv. [NH4][HCO3], dioxane, rt, N2, 16 h; c) 1. 39, 1.1 equiv. Et3OBF4, 3 equiv. CH2Cl2, rt, Ar, 9 h; 2. 
1.05 equiv. 37, 2.5 equiv. Et3N, 9, CH2Cl2, rt, N2; d) 20 equiv. MnO2, CH2Cl2, rt, 96 h; e) 2 equiv. MtsCl, 
2 equiv. Et3N, CH2Cl2, rt, N2, 24 h; f) 1,1 equiv. DBU, 1.2 equiv. BrCCl3, CH2Cl2, N2, rt, 16 h. 
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corresponding imidazoles 35a and 35b was then performed using DBU and BrCCl3 in 
CH2Cl2, giving in four steps an overall yield of 33%. In 1H/13C NMR spectra of 35, 
only one type of signals can be found suggesting the formation of only one of the two 
possible forms, likely 35a. This corresponds to position of NH in the single tautomer 
of rac-42 observed in our crystal structure (Figure 5.1). 
 
 
Figure 5.1: ORTEP Plot of the molecular structure of rac-42 (50% probability ellipsoids) 
 
5.1.2.2 Synthesis of Boc-TDAP-OMe (44) 
   The thiazole containing amino acid methyl 2-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-
(tosylamino)ethyl}-1,3-thiazole-4-carboxylate (Boc-TDAP(NTs)-OMe, 44) was 
synthesised starting with serine and asparagine (Scheme 5.5). Commercially 
available serine methylester (45) was protected with a Boc group, giving 46, and with 
an acetate group on the alcohol to furnish 47. Separately, N-boc-asparagine was 
reacted in a Hofmann type rearrangement using (diacetoxyiodo)benzene "PIDA"[183] 
to furnish 3-amino-2-[(tert-butoxycarbonyl)amino]propionic acid (Boc-DAP-OH, 48) in 
66% yield. The new amino group was tosylated[184] to give (2S)-2-[(tert-
butoxycarbonyl)amino]-3-(4-toluenesulfonylamino)propionic acid (Boc-DAP(NTs)-OH, 
49) in 88% yield. Separately, 47 was deprotected using TFA to furnish amine 50. 
Amino acid coupling was performed using TBTU, and the resulting amide carbonyl of 
51 was selectively thionated using Lawesson's reagent in boiling toluene. Using 
precisely 0.5 equiv. of this reagent provides the thioamide 52a[185] without affecting 
the carbonyl groups in the ester and carbamate functional groups. Typical reaction 
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times are two to three hours to give isolated yields of approximately 80%. Longer 
reaction times favor the formation of the thiazoline product 52b. Using 3.5 equiv. 
DBU and 1.2 equiv. BrCCl3, the mixture of thioamide 52a and thiazoline 52b is 
converted to thiazole 44. Using this approach, 44 is synthesised with an overall yield 
of 23% in six steps (Scheme 5.5). 
 
Scheme 5.5. Synthesis of the thiazole-containing amino acid 44 
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a) 1.1 equiv. Boc2O, 2.2 equiv. Et3N, dry CH2Cl2, 0°C, N 2, 3 h; b) 1.5 equiv. Ac2O, 2 equiv. Et3N, 3 
mol% DMAP, CH2Cl2, 0°C to rt, N 2, 1.5 h; c) 1. TFA/CH2Cl2 1:3, rt, N2, 3 h; 2. Dowex anion exchange 
resin, MeOH, rt, N2, 16h; d) 1.2 equiv. PIDA, AcOEt/MeCN/H2O 2:2:1, 15°C, 30 min, rt, 16 h; e) 1.05 
equiv. TsCl, MeCN/H2O/aq. sat. NaHCO3 4:1:1, 0°C to rt, 6 h; f) 1 equiv. TBTU, 5 equiv. NMM, 
CH2Cl2, rt, N2, 16 h; g) 0.5 equiv. Lawesson reagent, toluene, reflux, N2, 2 h; h) 3.5 equiv. DBU, 1.2 
equiv. BrCCl3, rt, N2, 3 h.   
 
   Building block 35 is potentially a regioisomeric mixture and a racemate (Scheme 
5.4). In contrast, building block 44 is an enantiomerically pure substance (Scheme 
5.5). 44 was selected as the primary building block for [0.4]{(2,4)1,3-thiazolo[0](2,4)-
1H-1,3-imidazolo}phan (4TIP, 33) so that all intermediates are generated in 
enantiomerically pure forms.  
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5.1.3 Synthesis of Boc-[TDAP(NTs)]4-OMe (53) 
   The oligomerization of building block 44 was accomplished using standard amino 
acid chemistry (Scheme 5.6). 44 was selectively deprotected, either in MeOH/LiOH 
or with TFA in CH2Cl2. The resulting free acid (54) and amine (55) were coupled to 
furnish dimer 56 using either DCC, PyBroP or TBTU as coupling reagent. For optimal 
yield and purification reasons (97% isolated yields), TBTU was selected to scale up 
the reaction. 
 
Scheme 5.6. Synthesis of the macrocycles 58 
 
a) 44, 5 equiv. LiOH, MeOH/H2O 1:1, rt; b) 44, TFA/CH2Cl2 1:2, rt, 3 h; c) 1 equiv. TBTU, 5 equiv. 
Et3N, CH2Cl2, rt, 16 h; d) 56, 6 equiv. LiOH, MeOH/H2O 3:1, rt; e) 56, TFA/CH2Cl2 3:1, rt, 6 h; f) 1.5 
equiv. PyBOP, 6 equiv. NMM, DMF, rt, N2, 16 h; g) 6 equiv. LiOH, hot MeOH/H2O 2:1 (c = 4 mM), rt; 
h) TFA/CH2Cl2 1:1, rt, N2, 6 h; i) Anion exchange: Dowex, MeOH, rt, 16 h; j) 5 equiv. PyBOP, 20 equiv. 
NMM, DMF (c = 1.5 mM), rt, N2, 16 h. 
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   Dimerization of 56 delivered tetramer 53 in analogous way (Scheme 5.6). The key 
coupling step was achieved in better yield when 1.5 equiv. PyBOP were used in 
DMF. With tetramer 53, solubility started to become limited in solvents like AcOEt, 
CHCl3 and MeOH. Very strong solvents like DMF or DMSO were needed to fully 
dissolve this peptide-like product.  
 
5.1.4 Macrolactamization 
   Macrolactamization was first conducted in CH2Cl2 with 1 equiv. TBTU and yielded 
around 30% of the macrocycle. Reactions were also attempted in DME with 3 equiv. 
HOBt and 1.2 equiv. of diisopropylcarbodiimide or with 4 equiv. DPPA as the 
coupling reagent[155]. These two procedures were not efficient for lactamization: only 
traces of the desired product could be detected on TLC. Optimised yields in the 
range of 40 and 50% were obtained using a 1.5 mM solution of 57 in DMF, 10 equiv. 
of NMM and 5 equiv. PyBOP (Scheme 5.6). The isolated product was consistent with 
the stereochemically pure "all-S"-58. 1H-NMR indicates exactly one set of 
overlapping signals for all of the four repeating units (Figure 5.2). As a side product, 
another slightly less polar substance could be isolated. According to ESI-MS data it 
contains macrocycle 58, but the 1H-NMR indicates a complex mixture, showing at 
least four sets of signals (Figure 5.3). This suggests that a small amount of 
racemization occurs during the macrolactamization reaction. 
 
 
Figure 5.2: 1H-NMR of the all-S-58 in DMSO 
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Figure 5.3: 1H-NMR of a mixture of diastereoisomers of 58 in DMSO 
 
5.1.5 Strategies for formation of imidazole units 
   Macrocycle 58 requires three additional reactions to be converted into target 
compound 4TIP (33) (Scheme 5.7): cyclodehydration, oxidation, and deprotection the 
tosyl groups. Due to the limited solubility and/or folding properties of these 
compounds, these steps were highly challenging. According to 1H-NMR, compounds 
60 and 58 adopt 3-dimensional structures in organic solvents like MeOH, as 
indicated by complex and broadened signals.  
 
Scheme 5.7. Final modifications on the macrocycles  
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   To test possible reaction conditions for imidazole formation, several test molecules 
were synthesized (Figure 5.4). Compounds 63 and 64 are very robust models for 
reactions starting with β-hydroxyamides. As compared to the macrocycle, a pi 
acceptor attached to the NHCH is missing in 63, this CH is therefore much less acidic 
than in the macrocycle. This lack of an acidic CH was corrected in molecule 64. The 
ester group in this compound is a better pi-acceptor than a thiazole unit and is also 
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more reactive toward nucleophilic attack. Diserine 65, with its additional functional 
groups, is a more sensitive and reactive system. 66 is the most similar test substrate 
to macrocycle 58. Last, but not least, the linear building blocks 56 (and 53) can also 
be used as model compounds.  
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Figure 5.4: Different model compounds used for test reactions 
 
Scheme 5.8: Strategies for the formation of imidazolines and imidazoles 
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   β-Hydroxy- and β-(tosylamino)amides require different strategies for ring-closure 
(Scheme 5.8). Activation of the amide oxygen and attack by the tosylamine delivers 
the imidazoline, which is then oxidized to the imidazole. A more reactive primary 
amine for ring-closure could be provided by deprotection of the amine, or 
alternatively, by converting a primary hydroxyl into a primary amine. All of these 
paths require an oxidation as the last step. Alternatively, an amide and aldehyde can 
react to give imidazole in one step. 
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   In the case of macrocycle 58, with its four β-(tosylamino)amides, cyclodehydration 
reactions were envisioned to provide the tetraimidazoline macrocycle 62. One 
challenge to this approach is the selective activation of the amide oxygen for 
elimination, while not affecting the sulfonyl oxygens.  
 
5.1.6 Results and discussion 
 
5.1.6.1 Using β-hydroxyamides to synthesize imidazolines 
a. Aldehydes as intermediates to imidazoles 
 
Scheme 5.9: Aldehyde, imine formation and reductive amination  
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a) 1.15 equiv. Dess-Martin, CH2Cl2, 0°C to rt, N 2, 16 h;  
b) 2 equiv. TsNH2, 2.2 equiv. NaBCNH3, MeOH, 0°C to rt, N 2. 
 
   By using Dess-Martin periodinane in CH2Cl2, model compound 63 was converted 
into the corresponding aldehyde 67 in 61% isolated yield. This aldehyde is quite 
reactive and adds to MeOH almost quantitatively to give 67b, according to ESI-MS. 
Aldehyde 67 was reacted in a 1:1 mixture of CH2Cl2 and MeOH and 0.2 equiv. Et3N 
with TsNH2[186], resulting in a mixture of 67 and 68 and each corresponding MeOH 
adduct 67b and 68b. Reductive amination of 67, with tosylamide or ammonia in the 
presence of NaBCNH3 furnished mixtures containing products 69 and 70. The main 
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byproduct in the case of TsNH2 was again the MeOH adduct 69b. In the case of 
ammonia dimer 70b was the main product (Scheme 5.9).  
   Oxidation followed by reductive amination was then tried on more difficult test 
substrate, 65, using the same procedure. According to TLC, oxidation could be 
observed, but the product though was not stable enough to be isolated and 
characterised. Reductive amination was therefore attempted on the crude mixture, 
but many side products were observed by TLC. The desired product could be 
identified, but the yield was too low to pursue this strategy in the context of the 
macrocycle. 
 
b. Reacting alcohol with azide to synthesize imidazolines 
   β-Azidoamides can be used in Aza-Wittig reactions to prepare imidazolines[187]. 
Substitution of the alcohol of 64 using DPPA was therefore attempted. Using 
reported reaction conditions[188], the elimination product 71 was obtained in yields 
ranging between 80 and 90% (Scheme 5.10). The desired azido-product was not 
observed. 
 
Scheme 5.10. Formation of the dehydroproduct 71 
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c. Using oxazolines as intermediates towards imidazolines 
   Oxazolines can be opened using sulphur or thiols as described in chapter 5.2.7.2. 
Since oxazolines were easily accessible on the level of test substrates (see chapter 
5.3), ring opening was tried using amines to give β-hydroxyamidines. Accordingly, 
oxazoline 72 was dissolved in CH2Cl2, 1.25 equiv. TsNH2 and 2.5 equiv. Et3N were 
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added. The mixture was stirred for two days at rt under N2 but no reaction could be 
observed. This strategy was therefore not further persued.   
 
d. Activation of amide oxygens by chlorination  
   Double chlorination of the β-hydroxyamide was attempted according to published 
procedures by Boland[189] or Menges[190]. According to these procedures, it should be 
possible to convert an isolated dichloride intermediate into imidazoline by refluxing it 
with a primary amine. Unfortunately, in the case of our test molecule 64 we could 
only isolate the β-chloroamide 73 (see also chapter 5.3.3.1). This same 
transformation was also possible using DAST in a 0.5 M LiCl solution in THF. This 
latter method is much more gentle, and also applicable to the macrocycle. It was 
possible to obtain the tetrachloride 74 using this procedure in 30% yield (Scheme 
5.12).  
 
Scheme 5.11: Chlorination, double chlorination and ring formation 
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Scheme 5.12: Chlorination of 59 
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a) 4 x 1.5 equiv. DAST, 0.5 M LiCl in DMF, 0°C to r t, N2, 4 h 
 
   Attempts were made to react chloride-containing test substrates with benzylamine, 
isopropylamine and methylamine. Performing these reactions under basic conditions 
in the presence of Et3N[189, 190], ring-closure to the oxazoline 75 and elimination to 71 
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were observed, and none of the amine-substituted products could be identified. In the 
absence of Et3N, the desired β-aminoamides could be synthesized by adding a 
primary amine. By performing the reaction at 0°C th ere was only a trace of the 
undesired elimination product observed. The reaction could be accomplished using 
methylamine or isopropylamine giving 76 in 34% and 77 in 82% (Scheme 5.13). The 
reaction was then attempted with the macrocyclic tetrachloride 74. Following 
aqueous workup, a complex mixture of products was obtained, including the 
tetraalcohol 59 and multiple oxazoline units towards 61 or 78, and also one or two 
additions of MeNH2. Given this complex product distribution, this strategy was not 
pursued further.  
 
Scheme 5.13: Chlorination and substitution of the β-alcohol 
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a) 1.5 equiv. DAST, 0.5 M LiCl in DMF, 0°C to rt, N 2 
 
5.1.6.2 Using β-(tosylamino)amides to synthesize imidazolines 
 
a. Activation of the amide oxygens by chlorination  
   Starting with β-(tosylamino)amide compounds, the chlorination of the amide should 
be an alternative route to enable the tosylated amino group to attack and close the 
imidazoline ring (Scheme 5.14). The reaction was tested on the dimer 56 and its 
respective benzoyl-derivative 79. Performing the reaction in MeCN with 5 equiv. 
POCl3 and heating at 100°C for three hours gave a mixtur e of starting material, the 
desired product 80 in about 70% yield and traces of byproduct 81. Since the ring-
closure worked reasonable well, the chlorination reaction was attempted using 
macrocycle 58. It was dissolved in a 1:1 mixture of MeCN and POCl3 and stirred at 
75°C overnight and heated to 100°C for two hours. A fter careful aqueous workup, 
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ESI-MS revealed a mixture of all steps of water elimination, including a trace of the 
product 62 with 1221.3 ([M62 + H]+) (Figure 5.5). Attempts were made to optimize this 
reaction. Variable equivalents of POCl3, temperature, and reaction times were 
screened. Alternative chlorination reagents like PCl3, PCl5, SOCl2, (COCl)2 were also 
evaluated. Attempts were made to increase reactivity by adding pyridine and Et3N, 
but lowered yields and loss of the tosyl group were observed. In some cases, there 
was even elimination or direct ring-closure with formation of oxazoline byproducts. 
Apparently, under basic conditions, the differences between the reactivities of the 
amide and sulphonamide are not large enough to give good selectivity with these 
chlorinating reagents. 
 
Scheme 5.14: Chlorination of the amide to realise imidazoline formation 
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a) 5 equiv. POCl3, MeCN, 100°C, N 2, 3 h.  
 
 
Figure 5.5. ESI-MS of partial reactions to 62 
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b. Using Mitsunobu conditions to activate amide oxygens 
   Starting with the β-(tosylamino)amide compounds, Mitsunobu-activation of the 
amide-oxygen should be an alternative route to close the imidazoline ring. 
Macrocycle 58 was dissolved in a saturated solution of LiCl in THF and DEAD and 
Ph3P were added[191]. Only partial dehydration towards 62 was observed.   
 
c. Detosylation of amines 
   The p-toluenesulfonyl protecting group attached to a primary amine is quite difficult 
to remove. In literature, only few examples are described. One is the removal of the 
tosyl group by ethanthiol[192]. According to this procedure, 66 was reacted with 6 
equiv. K2CO3 and 1 equiv. ethanthiol in MeCN at rt. After two weeks no change could 
be observed on TLC. A second deprotection procedure first adds a Boc group to the 
tosyl protected amine to facilitate detosylation[193]. The diprotected test substrate 82 
was then dissolved in MeOH and sonicated together with powdered Mg[194, 195]. The 
starting material is consumed but a mixture of different substances was obtained and 
the desired product 83 could not be detected (Scheme 5.15). It is expected that the 
thiazole ring is also susceptible to reduction and that a one electron reduction may 
initiate decomposition of the compound. 
 
Scheme 5.15: Expected detosylation from the diprotected β-aminoamide 
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a) 1.1 equiv. Boc2O, 0.1 equiv. DMAP, MeCN, rt, N2, 4 h 
 
d. Activation of the amide oxygens by thionation  
   Gavin and Hill[196] describe another, yet infrequently used method for imidazoline 
synthesis. They convert the amide to the thioamide and then activate the sulphur by 
complexation with mercury (Scheme 5.16). This procedure was first evaluated using 
model compound 66. Thionation was performed using two equivalents of P2S5 in 
refluxing pyridine for 4.5 h. The resulting thioamide, 84, was isolated in about 75% 
yield. Ring-closure was attempted in refluxing EtOH with one equiv. of HgO and Et3N 
according to the published procedure by Ewin[196]. Under these conditions, a mixture 
of products was observed on TLC. This reaction was also attempted in pyridine or 
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with Hg(TFA)2 as source of Hg2+, but this did not improve the yield. A very good yield 
of 96% for 85 was obtained using 1.2 equiv. HgO and Et3N in hot pyridine (100°C) for 
2h. The thionation reaction was then conducted using macrocycle 58 using 20 equiv. 
of P2S5 and refluxing the solution for 5 h at 150°C. Under  these conditions, a 26% 
yield of the tetrathioamide 86 was achieved. The mercury-promoted cyclization 
reaction was attempted in EtOH and pyridine using Et3N as base, but failed to give 
the desired product. It is possible that due to secondary structures reactions across 
the ring did occur that lead to decomposition. 
 
Scheme 5.16: Thionation followed by activation with mercury 
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a) 2 equiv. P2S5, pyridine, reflux, N2, 2 h; b) 1.2 equiv. HgO, 1.2 equiv. Et3N, pyridine, 100°C, N 2, 2 h; 
c) 20 equiv. P2S5, pyridine, reflux, N2, 5 h. 
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e. Using phosphoanhydrides for amide activation  
   A new method for imidazoline synthesis is the procedure described by Jeffery W. 
Kelly in 2004[182, 197]. Kelly makes use of a phosophoanhydride first proposed by 
Hendrickson in 1987 when he was looking for alternatives to Mitsunobu 
conditions[198-201]. The phosphoanhydride is produced by reacting two equivalents of 
a phosphine oxide with one equivalent of trifluoromethane sulfonic anhydride to 
furnish the triflate salt of the phosphoanhydride (Scheme 5.17). A corresponding 
intramolecular phosphoanhydride 87 was reported by Loughlin to be a more stable 
but equally reactive species[202].  
 
Scheme 5.17: Hendrickson-type phosphoanhydrides used for cyclodehydration 
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Scheme 5.18. Kelly reactions on dimer 56 and tetramer 53 
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a) 6 equiv. Ph3PO, 3 equiv. Tf2O, CH2Cl2, 0°C to rt, Ar;  
b) 12 equiv. Ph3PO, 6 equiv. Tf2O, CH2Cl2, 0°C to rt, Ar, 2.5 h.   
 
   Kelly used these phosphoanhydrides that were produced in situ to conduct 
cyclodehydrations with β-(tosylamino)amides. This procedure was tested on the 
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dimer 56 according to the published reaction conditions[182, 197]. Using CH2Cl2 as 
solvent, the conversion to a new product was quite fast, but the yield was only 
around 50%. The isolated product was found to be the urea derivative 81. The same 
reaction was attempted with the tetramer 53, giving the analogous product 88 in 
about 30% yield (Scheme 5.18).  
   Initial experiments using the Kelly reaction and macrocycle 58 showed no 
consumption of starting material due to the poor solubility of compound 58 in CH2Cl2. 
Different solvents were therefore tested with model compound 66. Both Ph3PO and 
87[197, 202] were used for phosphoanhydride formation. The phosphoanhydrides 
require very dry solvents and do not tolerate nitriles or ethers. Using pyridine leads to 
decomposition of 66. The same was observed for a 1:1 mixture of CHCl3 and Tf2O. 
Pure CHCl3 worked well, but was not polar enough to dissolve 58. We then 
investigated the use of highly polar, but non-coordinating ionic liquids. Since these 
solvents tend to be hygroscopic, they first were treated with Tf2O. The resulting TfOH 
and excess of Tf2O were removed in vacuo, and the β-(tosylamino)amide was added. 
Experiments with different ionic liquids (Figure 5.6) gave only partial conversion of 
66. In the case of the macrocycle, 58, the desired product was not observed. There 
was no relevant difference observed between phosponium anhydrides derived from 
Ph3PO and 87 as they behaved quite comparably in all these reactions.  
 
Figure 5.6: The ionic liquids: 3-ethyl-1-mehtylimidazolium trifluoromethanesulfonate,  
3-butyl-1-methylimidazolium tetrafluoroborate and hexafluorophosphate 
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   Unfortunately, 62 could not be produced applying the Kelly conditions. It is not 
known if the reaction is inhibited by the poor solubility of the macrocycle or if the 
phosphoanhydride is too reactive and decomposes faster than the reaction occurs. 
Based on the findings with the test substrate, 62 is even more polar than 58. This 
may further complicate the completion of four ring-closures as each unit formed may 
further decrease solubility.  
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5.2 Target 2: [0.8](2,4)1,3-Thiazolophan (34) 
 
5.2.1 Retrosynthetic analysis 
   [0.8](2,4)1,3-Thiazolophan (8TP, 34) is expected to be distorted from planarity, and 
may therefore exhibit enhanced solubility properties as compared to planar analogs. 
Thanks to the high symmetry of 34, this compound can be derived from four identical 
thiazole-containing amino acids. A suitable building block type "C" contains a 
protected serine side chain which gives the possibility to form thiazole units upon 
thionation and cyclodehydration with the amide groups (Scheme 5.19). Macrocycle 
type "D" is also a possible starting point for target molecule 33, as we saw in the last 
chapter. This makes building block type "C" and macrocycle type "D" very valuable 
intermediates.  
 
Scheme 5.19. Retrosyntesis of macrocycle 34 
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   Thiazole amino acids of type "C" can be synthesised by fusing an activated N- and 
O-protected serine with a cysteine to provide a thiazoline that can be oxidized to the 
thiazole 89 (Scheme 5.20). Alternatively, allyl protected 90 can be obtained by 
thionation of a fully protected diserine followed by nucleophilic attack of the thioamide 
sulphur to the activated serine side chain (Scheme 5.20).  
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Scheme 5.20. Retrosynthesis of building block type "C" 
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5.2.2 Synthesis of thiazole-containing amino acids 
 
5.2.2.1 Synthesis of Boc-TSer(OBn)-OMe (89) 
   To synthesize methyl 2-{(rac)-2-(benzyloxy)-1-[(tert-butoxycarbonyl)amino]ethyl}-
1,3-thiazole-4-carboxylate (Boc-TSer(OBn)-OMe, 89) the activated acid carbon in O-
ethyl (2S)-3-benzyloxy-2-[(tert-butoxycarbonyl)amino]propanimidoate (40) was 
reacted with H-Cys-OMe.HCl under basic conditions. The resulting thiazoline was 
then oxidized using DBU and BrCCl3[182, 203]. This procedure is highly efficient as it 
provides compound 89 over four steps in 61% total yield (Scheme 5.21). The critical 
step is the fusion of the two amino acids to form thiazoline 91. This reaction is 
amenable to scale-up. Optimized procedures for the preparation of 75 g of 91 in one 
batch were established. The structure of 89 was confirmed with x-ray crystallography 
(Figure 5.7). 
   This ring-closure stratety is convenient and high yielding, but the basic reaction 
conditions cause racemization of the stereogenic centers (Scheme 5.21), and lead to 
a mixture of diasteroisomers for 91 and pair of enantiomers for 89. This should not 
pose a serious problem as all stereogenic centers are lost during formation of the 
final products 32, 33 and 34 (Scheme 5.7).  
Synthesis of Telomestatin Analogs  Chapter I – 5.  
 
 - 68 / 181 - 
Scheme 5.21. Synthesis thiazole-containing amino acid 89 
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a) 1.5 equiv. Boc2O, 0.66 equiv. pyridine, 1.25 equiv. [NH4][HCO3], dioxane, rt, N2, 16 h; b) 1.1 equiv. 
Et3OBF4, 3 equiv. CaCO3, CH2Cl2, rt, Ar, 9 h; c) 1.1 equiv. Cys-OMe.HCl, 1 equiv. Et3N, CH2Cl2, rt, N2, 
16 h; d) 2 equiv. DBU, 1.05 equiv. BrCCl3, CH2Cl2, 0°C to rt, 1.5 h. 
 
 
 
Figure 5.7: ORTEP Plot of the molecular structure of rac-89 (50% probability ellipsoids) 
 
5.2.2.2 Synthesis of L-Boc-TSer(OAll)-OMe (90) 
   To produce an enatiomerically pure homolog of 89, the synthesis of methyl 2-{2S-
2-(benzyloxy)-1-[(tert-butoxycarbonyl)amino]ethyl}-thiazole-4-carboxylate (L-Boc-
TSer(OAll)-OMe, 90) was performed. Serine was protected as either Boc-Ser(OAc)-
OMe (47) or Boc-Ser(OAll)-OH (92). Mild coupling conditions using TBTU and NMM 
in CH2Cl2 resulted in retention of configuration in each product. The resulting Boc-
Ser(OAll)-Ser(OAc)-OMe (93) was treated with Lawesson's reagent in boiling 
toluene. Using precisely 0.5 equiv. of the reagent provides the thioamide 94[185] 
without affecting the carbonyl groups in the ester or carbamate groups. Typical 
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reaction times are two to three hours. Longer reaction times result in the formation of 
thiazoline 94b by elimination of acetic acid. A mixture of 94a and 94b can be carried 
forward directly into the next step. By taking 3.5 equiv. DBU and 1.2 equiv. BrCCl3 
the thioamid 94a and thiazoline 94b are converted directly into thiazole 90 in 72% 
over two steps (Scheme 5.22). This type of ring-closure strategy will also be used in 
the final steps of the ultimate target molecules (32, 33, 34, Scheme 5.7). 
 
Scheme 5.22. Synthesis of the thiazole-containing amino acid 90 
  
a) 1.1 equiv. Boc2O, 2.2 equiv. Et3N, dry CH2Cl2, 0° to rt, N 2, 3 h; b) 1.5 equiv. Ac2O, 2 equiv. Et3N, 3 
mol% DMAP, CH2Cl2, 0°C to rt, 1.5 h; c) TFA/CH 2Cl2 1:3, rt, N2; d) 2.5 equiv. NaH, 1 equiv. AllBr, dry 
DMF, 0°C to rt, 16 h; e) 1 equiv. TBTU, 4 equiv. NM M, CH2Cl2, rt, N2, 5 h; f) 0.5 equiv. Lawesson 
reagent, toluene, reflux, N2, 2 h; g) 3.5 equiv. DBU, 1.2 equiv. BrCCl3, CH2Cl2, rt, N2, 3 h. 
 
   The overall yield of the seven step synthesisof enantiomerically pure L-Boc-
TSer(OAll)-OMe (90) is 40%. Building block 89 is produced as racemate, yielding 
60% in four synthetic steps. As stated before, it is not necessarily a drawback to work 
with racemate intermediates since all stereogenic centers will be lost in the last steps 
of the total synthesis. For solubility reasons, a mixture of stereoisomers can even be 
advantageous. For macrocycle synthesis, building block 89 was therefore selected. 
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5.2.3 Synthesis of Boc-[TSer(OBn)]4-OMe (95) 
   The amino acid 89 was selectively deprotected using either LiOH in MeOH/H2O or 
TFA in CH2Cl2. The resulting free acid 96 and amine 97 were coupled to form the 
dimer 98 using either DCC, PyBroP or TBTU as a coupling agent (Scheme 5.23). For 
optimal yields and purification reasons (70% isolated yields) TBTU was selected for 
scale up of the reaction. An interesting side product, ketone 99, was also isolated. 
This type of product was not observed in previous reactions, and the mechanism of 
its formation is unknown. We speculate that the pathway to 99 involves elimination of 
HOBn leading to an enamine. Its tautomer, the imine, is then hydrolysed to release 
product 99 (Scheme 5.24). Even though 99 was initially an unwanted product, it 
turned out to be a useful test substrate for macrocycle 60. More details on these 
reactions will be given in sections 5.2.7 and 5.3.3. 
 
Scheme 5.23. Synthesis of the tetramer 95 
 
a) 6 equiv. LiOH, MeOH/H2O 1:2, rt, N2; b) TFA/CH2Cl2 1:3, rt, N2; c) 1 equiv. TBTU, 5 equiv. NMM, rt, 
N2, 16 h; d) 6 equiv. LiOH, MeOH/H2O 1:2, rt, N2; e) TFA/CH2Cl2 1:3, rt, N2; f) 1.5 equiv. PyBOP, 6 
equiv. NMM, dry DMF, rt, N2, 16 h. 
 
   The second dimerization of 98 to compound 95 was first performed under the same 
reaction conditions using 1 equiv. TBTU in CH2Cl2 with 5 equiv. Et3N or NMM at 
room temperature. Upon scale up of this reaction, the yield dropped below 50%. 
Taking dry DMF with NMM and 1.5 equiv. of PyBOP as coupling reagent increased 
the yield to 65% (Scheme 5.23). With the tetramer 95, solubility started to become an 
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issue. The molecule is still somewhat soluble in CHCl3, but line broadening and 
splitting in 1H-NMR spectra suggest the formation of secondary structures.  
 
Scheme 5.24. Proposed mechanism for formation of side product 99 
 
 
5.2.4 Macrolactamization 
   The limited solubility of 95 necessitated the use of HPLC to monitor the progress of 
the deprotection reactions for the free acid 100 and the amino acid 101 (Scheme 
5.25). For optimal deprotection of 95, the concentration of starting material was 
decreased below 5 mM in a 6:1 mixture of MeOH and H2O. For subsequent Boc 
deprotection, CH2Cl2 and TFA were used in a ratio of 8:1. This reaction could be 
performed at higher concentrations of about 20 mM due to the solubilizing effects of 
TFA. The TFA salt was converted to the HCl salt using Dowex ion exchange resin. 
For macrolactamization, a 1.5 mM solution of 101 in DMF was reacted for 30 h with 5 
equiv. PyBOP and 10 equiv. NMM in the dark at rt under N2. The reaction was again 
monitored by HPLC. Under these conditions, yields up to 65% for the conversion of 
95 to 60 could be achieved (Scheme 5.23). 
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Scheme 5.25. Formation of macrocycle 60 
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a) 5 equiv. LiOH, MeOH/H2O 1:3, rt, N2; b) TFA/CH2Cl2 1:1, rt, N2; c) Anion exchange: Dowex, MeOH, 
rt, 16 h; d) 5 equiv. PyBOP, 10 equiv. NMM, dry DMF (c = 1.5 mM), rt, N2. 
 
   The 1H-NMR of macrocycle 60 is consistent with a mixture of diastereoisomers 
(Figure 5.8). A set of seven signals for the thiazole-H between 8.4 to 8.2 ppm and the 
benzyl aromatic CH between 7.3 and 7.1 ppm were observed. 
 
 
Figure 5.8: 1H-NMR of the mixture of diastereoisomers of 60 in DMSO. 
NH groups are not visible since a drop of MeOD was added. 
 
   The set of seven signals can be explained by the presence of four possible 
diasteroisomers and corresponding enantiomers: RRRR/SSSS, RSRR/SRSS, 
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RSRS/SRSR and RRSS/SSRR (Figure 5.9). It is likely that some of the thiazole 
proton signals are overlapping, but there should theoretically be one resonance for 
the RRRR (C4 symmetry) diasteroisomer, four for the RSRR (C1), two for RSRS (C2) 
and four for RRSS (C1), giving eleven signals all together. 
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Figure 5.9: Possible diastereoisomers of macrocycle 60 
 
   Following purification, macrocycle 60 exhibited poor solubility properties in solvents 
like AcOEt, MeCN, and CHCl3, but partial solubility in mixtures of CHCl3 or AcOEt 
and MeOH. Very powerful solvents like DMF, DMSO or TFA were necessary to fully 
dissolve 60.  
   Compound mixture 60 exhibits a Rf value of 0.8 in CHCl3:MeOH 10:1. It is less 
polar than compound 58, that exhibits a Rf value of 0.25 in CHCl3:MeOH 10:1. In 
addition to differencies in apparent polarity, the mixture of diasteroisomers in 60 also 
increases the solubility of the macrocycle. 
 
5.2.5 Strategies for formation of thiazole units 
 
Scheme 5.26 Strategies towards the thiazole 
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   On the basis of the tetrabenzylmacrocycle 60, three possible pathways to the target 
molecule 8TP (34) were considered (Scheme 5.26). The first is the conversion of the 
β-acetoxyamide to the β-acetoxythioamide, followed by intramolecular substitution of 
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the acetoxy group to form the thiazoline. The second is the ring-opening of oxazole 
with sulphur, followed by cyclodehydration. The third path is substitution of one of the 
oxygen atoms by sulphur followed by cyclodehydration, where P2S5 serves as both 
thionating and dehydrating agent.  
   Five model compounds were used to test these potential pathways (Figure 5.10). 
63 is the most robust compound having few reactive functional groups and no 
sulphur in the compound. The test substrate most similar to macrocycle 60 is 
compound 99. The core is an exact copy of the macrocycle, though without the 
expected ring strain and formation of secondary structures. However, unlike 
macrocycle 60, the methylketone of 99 tends to enolize upon deprotonation and can 
lead to irrelevant side reactions.   
 
Ph N
H
HO
Ph
O
63 65
Boc
N
H
O
Bn
O
H
N
HO
O
O
106
Boc
N
H
S
Bn
O
H
N
HO
O
O Ph NH
O
HO
O
O
64
99
S
N
O
N
H
O
Bn
S
N
O
OO
 
Figure 5.10: Model compounds for thiazole formation 
 
5.2.6  Debenzylation of the alcohols 
   To convert β-hydroxyamides to thiazoles or oxazoles the "serine" alcohols of 
macrocycle 60 were first deprotected. Catalytic hydrogenation of macrocycle 60 
using 10% Pd on activated charcoal in MeOH or AcOEt failed to work for both 60 and 
the test substrate 89. Elevated temperatures, AcOH and H2 at 45 bar did not improve 
this result. Transhydrogenation with cyclohexene and Pd(OH)2 in EtOH[204] also did 
not work. Apparently, the thiazole sulphur poisons the Pd catalyst.  
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Scheme 5.27. Deprotection of the benzyl protecting group 
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a) 7.5 equiv. anisole, 6 equiv. AlCl3, CH2Cl2, rt, N2, 16 h; b) 11 equiv. Tf2O, 10 equiv. BF3.Et2O, 
CH2Cl2, 0°C to rt, N 2, 16 h; c) 40 equiv. BF3.Et2O, CH2Cl2:Ac2O 1:1, rt, N2, 16 h; d) 40 equiv. Tf2O, 36 
equiv. BF3.Et2O, ClCH2CH2Cl, rt, N2, 4 h; e) 10 equiv. LiOH, MeCN:MeOH:H2O 1:1:1, 45°C, 8 min. 
 
   Alternative procedures for benzyl removal were evaluated. Test reactions were first 
performed on simple model compounds 102, 89 and 991 (Scheme 5.27). 102 could 
be deprotected upon treatment with Raney-Nickel in a mixture of MeOH and H2O 
under 1 atm of H2. Analogous treatment of 89 did not give the desired product, but 
instead, the reduction of the thiazole to the thiazoline compound 91 was observed. 
102 could also be deprotected using a mixture of PhI(OAc)2, TsNH2, tin powder, 
Al2O3 and Cu(CF3SO3)2 according to He[205]. The analogous experiment with 89 gave 
no desired product. Deprotection of 89 and 99 to furnish 103 and 104 was 
accomplished using anisole and AlCl3 in CH2Cl2[206]. This reaction was attempted in 
more polar solvents like CHCl3, DME, MeCN and DMF. Only CHCl3 and CH2Cl2 were 
found to be compatible. Deprotection of macrocycle 60 using anisole in CH2Cl2 
resulted in partial conversion, where one or two of the four benzyl groups could be 
removed. To optimize this reaction, BF3.Et2O was used as the Lewis acid in a mixture 
                                            
1
 Some of these reactions were evaluated by Renate Brokamp, a student doing her advanced 
practicum in our lab. 
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of Ac2O and CH2Cl2[207]. This process delivers not directly the alcohol but rather the 
tetraacetate macrocycle 105 (Scheme 5.27) that could be isolated in yields of up to 
60-70%. The best yields for hydrolysis of the tetraacetate were obtained by 
suspending 105 in a 40°C mixture of MeCN, MeOH, and H 2O (4:4:1), and adding 10 
equiv. of LiOH in H2O to the suspension. After 5 to 6 min at 40°C, 10 e quiv. of HCl 
were added to neutralize the reaction. This procedure yielded 60-80% of the 
tetraalcohol 59 after column chromatography.  
   Having developed this procedure, we speculated that other anhydrides might be 
used to convert the benzyl group into an activated alcohol for subsequent ring 
closure. Deprotection with BF3.Et2O and (CF3CO)2O, (CF3SO2)2O, (CH3SO2)2O, 
(C7H7SO2)2O and (C9H11SO2)2O failed to give clean conversions to the desired 
products. With the trifluoroacetates and trifluoromethanesulfonyl groups, the 
tetraalcohol 59 could be isolated in moderate yields following aqueous workup of the 
reaction. This type of deprotection was optimised by replacing CH2Cl2 with 
ClCH2CH2Cl to give maximal yields of 60-65%. While this one step deprotection 
reaction was time saving, purification of the tetraalcohol 59 on SiO2 was much more 
challenging and less amenable to scale-up as compared to tetraacetate 105. 
 
5.2.7 Results and discussion 
 
5.2.7.1 Reactions using β-acetoxyamides 
   It is known that β-acetoxyamides form thiazolines upon refluxing with Lawesson 
reagent in toluene[185] (e.g. in Scheme 5.28 with 106, 107, 108 and 109). This 
approach was used for the synthesis of building blocks 44 and 90 (chapter 5.1.2.2 
and 5.2.2.2). Thionation and thiazoline ring-closure were attempted with 
macromolecule 105. Using 0.5 equiv. of Lawesson's reagent in refluxing toluene 
resulted in only partial conversion. Adding more Lawesson's reagent did not push the 
reaction to completion. Most of the recovered material was, according to ESI-MS, the 
starting material with one oxygen exchanged by sulphur ([M105 – O + S + Na]+). 
There were also traces of a single-thiazoline containing macrocycle ([M105 – O + S – 
HOAc + Na]+) and a single-thiazoline containing ring with a second oxygen 
exchanged by sulphur ([M105 – 2 O + 2 S – HOAc + Na]+). The lack of reactivity was 
ascribed to the poor solubility of 105 in toluene. Other solvents were tried, but no 
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product could be detected using benzonitrile and P2S5, or using ethers solvents[208] 
containing chaotropic salts like LiCl or LiOTf. 
 
Scheme 5.28. Formation of thioazoles using β-acetoxyamides 
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a) 2.5 equiv. Ac2O, pyridine, 0°C to rt, N 2; b) 0.5 equiv. Lawesson's reagent, toluene, reflux, N2, 2 h;  
c) 2 equiv. DBU, 1.05 equiv. BrCCl3, CH2Cl2, rt, N2, 1 h. 
 
5.2.7.2 Oxazolines as intermediates towards thiazolines 
   Published procedures for the conversion of oxazolines into thiazolines involve 
exchanging the oxygen by sulphur in a one pot reaction, or opening the oxazoline 
with sulphur to give a β-hydroxythioamide followed by ring-closure[209]. Experiments 
using test substrates were used to evaluate the feasibility of these approaches. 
Oxazoline 72 was treated with a mixture of Et3N, AcOH and Na2S x 9 H2O in MeOH 
(Scheme 5.29). The reaction was not complete after 16 h, so the mixture was heated 
at 60°C for 6 h. 59% of the oxazoline was isolated again and only 36% of the desired 
product 110 was isolated. The thioamide carbon of 110 exhibits a downfield 
resonance at 199 ppm as compared to 168 ppm for 63.  
   A slightly different procedure was used for oxazoline 75[210, 211]. 75 was dissolved in 
a 1:1 mixture of MeOH and Et3N, the solution was purged with H2S for 20 min and 
stirred at rt for 16 h. TLC indicated complete conversion to 111. The isolated product 
111 could be converted quantitatively to 112 using the DAST reaction, and 
subsequently oxidized to 113 using BrCCl3 / DBU with a yield of about 70%.  
 
Synthesis of Telomestatin Analogs  Chapter I – 5.  
 
 - 78 / 181 - 
Scheme 5.29. Oxazoline opening by H2S 
 
a) 1.25 equiv. DAST, CH2Cl2, -5°C to rt, N 2; b) 5 equiv. Na2S.9H2O, 50 equiv. Et3N, 10 equiv. AcOH, 
MeOH, 0°C to rt, N 2, 4 d; c) H2S (g), MeOH/Et3N 1:1, rt, 2 h; d) 1.5 equiv. DAST, CH2Cl2, -10°C to rt; 
e) 2 equiv. DBU, 1.2 equiv. BrCCl3, CH2Cl2, 0°C to rt, N 2, 2 h; f) 2 equiv. P2S5, pyridine, reflux, N2, 2 h. 
 
5.2.7.3 Thionation and dehydration of β-hydroxyamides 
   Xu, Du et al. reported the formation of thiazolines directly from β-hydroxyamides by 
refluxing with P2S5 in pyridine[212]. They used this procedure for the synthesis of 4,5-
dihydrothiazoles in yields of approximately 50% for most examples given. Since the 
tetraalcohol 59 is highly soluble in pyridine, this approach seemed to be quite 
promising. This conversion was first evaluated using test compound 64 and yielded 
almost 70% of the desired thiazoline 112 (Scheme 5.29, path f)). Attempts to improve 
the yield by using Lawesson’s reagent were fruitless. Jan Bergman et al. claimed that 
a faster degradation of the Lawesson’s reagent is observed at elevated temperatures 
as compared to P2S5[213]. In addition, they reported a complex of pyridine and P2S5 as 
an analog of Lawesson's reagent but being more stable and reactive (Figure 5.11). 
The reactive pyridine phosphosulfide reagent 114 can be isolated and used in other 
solvents leading to better yields and cleaner conversions than other thionation 
reagents. 114 was produced according to Bergman[213] and its reaction with 64 was 
tested using MeCN and Me2SO2 as solvents. The reaction showed very clean 
conversion and an improved yield of 90% for the desired thiazoline. The subsequent 
oxidation of 112 was accomplished using 2 equiv. DBU and 1.2 equiv. BrCCl3 to give 
113 in 70% yield.  
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Figure 5.11: Reagents used for thionation reactions 
  
Scheme 5.30. Formation of 8TP (34) 
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a) 8 equiv. P2S5, pyridine, reflux, N2, 5 h 
 
   Macrocycle 59 was therefore treated with P2S5 in pyridine. The solution was 
refluxed for 5 h. A ladder of different products was observed. Aqueous workup was 
no problem in the case of the test substrates, but was avoided in the case of the 
macrocycle to prevent hydrolysis. The purity and yield of this reaction could be 
improved using reagent 114 and performing the reaction in MeCN. The resulting 
material 115 (Scheme 5.30) was subjected to oxidation – and was lost! It was 
dissolved in dry DMF and cooled down to 0°C in an i ce bath. Addition of DBU 
resulted in an immediate red colouration of the solution, possibly indicating the 
removal of the α proton resulting in enlarged and negatively charged pi system. 
Addition of the BrCCl3 gave a brown solution which got darker by time. ESI-MS 
revealed a weak signal possibly belonging to the desired product. Changing the order 
of addition, first adding an excess of BrCCl3 present then a solution of DBU didn’t 
improve the results.  
   These observations lead to the crucial question of the nature of the target 
molecule. Does it tend to aggregate, precipitate or is it lost during isolation, or is it 
simply not formed because the negatively charged intermediates are too fragile or 
unstable? 
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5.3 Target 3: [0.4]{(2,4)1,3-Thiazolo[0](2,4)1,3-oxazolo}phan (32) 
 
5.3.1 Retrosynthetic analysis 
   Among the three proposed target molecules, [0.4]{(2,4)1,3-thiazolo[0](2,4)1,3-
oxazolo}phan (4TOP, 32) is closest relative to telomestatin. According to our 
calculations, the ring strain in 32 should be drastically reduced compared to 
[0.8](2,4)1,3-oxazolophan (Table 4.2), but still the eight rings do not completely fill 
360°, so the molecule is expected to be planar.  
 
Scheme 5.31. Retrosynthesis of macrocycle 32 
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   Due to the C4 symmetry, macrocycle type "D" can be derived by assembling four 
identical thiazole-containing amino acid building blocks of type "C". By modifying the 
protected alcohol side chains on macrocycle "D", oxazolines are formed to furnish 
macrocycle 61, which is then oxidized to the target macrocycle 32 (Scheme 5.31). 
This approach is very similar to the synthesis of 8TP (34, Scheme 5.19). The same 
building block 89 and the same macrocyclic precursors 60, tetracetate 105 and 
tetraalcohol 59, all described in the last chapter, could be used for the synthesis 32. 
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5.3.2 Strategies for formation of oxazole units 
   Methods to generate an oxazole starting from a β-hydroxyalcohol include 
conversion of the alcohol into a good leaving group "LG" followed by substitution with 
the amide oxygen leading directly to the oxazoline. The same result is obtained by 
activation of the amide oxygen and substitution by the alcohol. The resulting 
oxazolines can be subsequently oxidized to the corresponding oxazoles[203, 214]. 
Some other strategies include elimination of the β-alcohol, addition of two potential 
leaving groups followed by ring-closure and elimination leading directly to the 
oxazole. This approach was successful in case of the total synthesis of 
telomestatin[157]. To avoid the oxidation step, the alcohol can be transformed into an 
aldehyde or acid before cyclization, leading to either an oxazole or hydroxy- or 
alkoxy-substituted oxazole.   
 
Scheme 5.32. Strategies for oxazole synthesis 
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   As model compounds for the macrocycle, 63, 65, 106, 64, 99 and 116 (Figure 5.12) 
were used to test ring closing reactions. 
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Figure 5.12: Model substrates for oxazole synthesis 
 
5.3.3 Results and discussion 
 
5.3.3.1 Substitution of OH with Cl to promote oxazoline formation 
 
Scheme 5.33. Monochlorination of β-hydroxyamides 
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a) 2 vol% DMF, SOCl2, reflux, N2, 16 h or 1.5 equiv. DAST, 0.5 M LiCl in DMF, 0°C t o rt, N2, b) DMAP, 
DMF, 0°C, N 2; c) 6 equiv. DAST, 0.5 M LiCl in DMF, 0°C to rt, N 2. 
 
   Converting the alcohol of a β-hydroxyamide into a good leaving group is one way to 
promote oxazoline formation. There are many different ways to convert alcohols into 
chlorides. Using thionylchloride in CH2Cl2 or CHCl3 is probably the most common 
one. 64 was successfully converted into β-chloroamide 73 (Scheme 5.33). This 
reaction was performed using a large excess of SOCl2 in CHCl3 or in neat SOCl2 
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containing a catalytic amount of DMF. For macrocycle 59, this reaction was not 
possible since 59 exhibited poor solubility in mixtures of SOCl2 and CHCl3.  
   Another method to produce the tetrachloride 74 was accidentally discovered when 
the solubility of 59 in THF was increased by adding LiCl as chaotropic salt. According 
to this procedure, model compound 64 was dissolved in a 0.5 M LiCl solution in THF. 
Addition of 1 equiv. DAST gives the chlorinated product 73 in 76% yield. This 
reaction demonstrates that DAST activates the β-hydroxyamide at the alcohol not 
amide (Scheme 5.34). Using this procedure, it might be possible to access other 
halogenides (Br, I) under mild and selective conditions.  
 
Scheme 5.34. Mechanism of the DAST activation: for the formation of the oxazoline activation of 
alcohol or amide oxygen are theoretically possible, the substitution by chloride shows that activation of 
the alcohol is faster.  
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   Macrocycle 59 was not soluble in a 0.5 M solution of LiCl in THF, but the 
chlorination reaction could also be performed using DMF as the solvent. Under these 
conditions, tetrachloride 74 could be isolated in 30% yield. 
   Cyclization of the β-chloroamides to give oxazolines was then investigated. 
Treatment of 73 with tertiary amines in CHCl3 gave only the elimination product 71. 
The same results were obtained using DMAP in DMF at 0° and with K 2CO3 in AcOEt 
at 75°C. Refluxing 73 in AcOEt without base showed no consumption of starting 
material. Ring-closure by halogen exchange using iodide was also attempted, but 
conversion to the elimination product 71 was again observed. Apparently, one must 
remove HCl, but even mild bases cause β elimination of HCl instead of cyclization. 
This strategy was therefore not further developed for the macrocycle tetrachloride 74. 
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5.3.3.2 Elimination of H2O and addition of "MeOBr" to form oxazoles 
   As described in section 3.3.3, the method used for forming the last ring in the total 
synthesis of telomestatin was performed by elimination of H2O to form a 
dehydroalanine unit followed by addition of Br+ and MeO-. We therefore investigated 
this pathway. A common way to facilitate elimination is to convert the alcohol into a 
sulfonyl group and then perform an E2 type elimination with a sterically hindered base 
like DBU. In our case we aimed to combine this reaction with benzyl deprotection. A 
series of reactions were conducted using the model compound 99 and BF3.Et2O as a 
Lewis acid, (CF3CO)2O, Tf2O or Ms2O as anhydride and CH2Cl2 or ClCH2CH2Cl as 
solvents. The benzyl deprotection was followed by addition of 1 M DBU solution in 
DMF at 0°C giving complex mixtures containing the d esired elimination product 117 
as well as oxazoline 118 and alcohol 104 (Scheme 5.35). The distribution of products 
was evaluated using TLC, but there were no significant differences for the different 
solvents and anhydrides evaluated.  
 
Scheme 5.35. Elimination of H2O and formal addition of BrOMe 
a) 15 vol% (CF3CO)2O, 15 equiv. BF3.Et2O, CH2Cl2, rt, N2, 36 h;  
b) 1.4 equiv. DPPA, 1.4 equiv. DBU, THF, 0°C to rt,  N2, 15 h;  
c) 1.05 equiv. NBS, molecular sieves (A4), CH2Cl2/MeOH 8:1, 0°C to rt, N 2, 3 h. 
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   Elimination product 71 can cleanly be synthesised by reacting alcohol 64 with 
DPPA followed by addition of DBU in THF as described in section 5.1.6.1 b[188]. The 
same reaction using 64 could also be performed in MeCN and DMF to give the 
elimination product 71 in yields in around 80%. The dehydroalanine product, 71, can 
be converted into the bromo- and methoxy-substituted derivative 119 using NBS in a 
mixture of CH2Cl2 and MeOH at 0°C over powdered molecular sieves [157]. 
Subsequent transformation into oxazole 120 was not attempted. 
   The elimination of four water molecules from tetraalcohol 59 using DPPA was first 
tried in MeCN. The mixture of products contained some of the desired material 78 
according to ESI-MS. The reaction was tried again in DMF, but none of the desired 
material was observed, only lighter materials could be isolated, indicating 
decomposition of the macrocycle.  
 
5.3.3.3 Ring-closure by Mitsunobu type reactions 
   Mitsunobu reactions are good candidate for this type of chemistry. Following the 
protocol by Oyo Mitsunobu[215] conversion of 64 to the oxazoline 75 was attempted in 
DME at rt using 1.5 equiv. DEAD and Ph3P. The desired oxazoline 75 was isolated in 
65% yield, and the elimination product 71 was isolated in 25 – 30% yield. Using 
exactly the same reaction conditions, no product could be isolated when macrocycle 
59 was used as the starting material. 
 
5.3.3.4  Oxidation to aldehyde to promote oxazole formation 
   A very attractive route to the oxazole is the oxidation of the alcohol prior to ring-
closure. The loss of H2O would then lead directly to the desired oxazole. Test 
reactions were first performed using compound 63. Oxidation to the aldehyde 67 was 
possible with Dess-Martin reagent[216] (Scheme 5.36). The conversion was very good 
according to TLC analysis, and NMR analysis was consistent with the aldehyde 
product, while in ESI-MS the methanol adduct was observed, demonstrating the high 
reactivity of 67. This substance was treated with DAST following the procedure of 
Ballut[217] and a mixture containing the desired oxazole 121 and the 5-fluorooxazoline 
122 was observed due to the absence of base in this reaction.  
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Scheme 5.36. Oxidation prior to ring closure: aldehyde or acid 
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a) 1.15 equiv. Dess-Martin reagent, CH2Cl2, 0°C to rt, N 2, 16 h;  
b) 1.25 equiv. DAST, CH2Cl2, 0°C to rt, N 2, 1 h. 
 
   All other attempts to convert 65 and 64 to the corresponding aldehydes (e.g. 123, 
Scheme 5.36) failed. Complete oxidation to acid 124 could potentially deliver a 
precursor for 5-hydroxyoxazole 125. This is also a very attractive target giving the 
possibility to install different substituents on the macrocycle. Test reactions in this 
direction were performed on 64 (Scheme 5.36). Whereas KMnO4 did not give 
complete conversion, a procedure using CrO3 and HIO6[218] showed consumption of 
all starting material 64. The crude material was treated with Ac2O and Et3N[219] but no 
oxazole product could be isolated. Another oxidation method using TEMPO and 
phenyliododiacetate (PIDA)[220-222] lead to decomposition. An attempt using CrO3 and 
HIO6 on the macrocycle 59 showed many different products including the starting 
material. The poor conversion of the alcohol units was also assigned to the poor 
solubility of 59 in a mixture of H2O and MeCN. The number of products is probably 
increased since any acid units will be susceptible to decarbonylation due to the 
neighbouring pi-acceptor (thiazole or ester group) forming a 1,3 dicarbonyl system.  
 
5.3.3.5 Oxazoline ring-closure using TsCl and MsCl  
   A common method for the synthesis of oxazolines is the activation of the β-alcohol 
using tosylchloride (or other sulfonylchlorides) followed by intramolecular 
displacement by the amide group. Dissolving molecules like 63, 65, 106, 104 or 64 in 
CH2Cl2, DMF or pyridine, adding 2 equiv. DMAP or Et3N and 1 – 1.5 equiv. TsCl 
gives corresponding oxazolines in yields up to 95%. No tosylated product could be 
isolated but the formation of elimination side product 71 could sometimes be 
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observed. With macrocycle 59 this reaction was performed in MeCN using Et3N and 
a catalytic amount DMAP. Traces of [M59 – 4 H2O + Na]+, [M59 – 4 H2O + TsOH + 
Na]+, [M59 – 4 H2O + 2 TsOH + Na]+ could be observed in ESI-MS among 
unidentified compounds. All attempts at optimizing this reaction were not successful. 
DMF, pyridine and DMSO were tested as solvents, and reaction temperatures were 
screened between -5°C and 125°C. Variable bases wer e added at the beginning or 
during the reaction. Mesylchloride was also evaluated, but the results were always 
the same. The crude material was adsorbed onto SiO2 and filtered over SiO2 with 
solvent mixtures of CHCl3 and MeOH or AcOEt and MeOH but the clean product 61 
(Scheme 5.31) could not be isolated. It is possible that compound 61 is not very 
stable and can hydrolyse back on SiO2 to 59. The best results were achieved when 
the crude material from a reaction of macrocycle 59 with MsCl and DMAP at -5°C in 
pyridine was filtered over SiO2, dissolved in DMF and treated again with DMAP to 
ensure complete formation of tetraoxazoline 61. The crude material was again 
filtered over SiO2 and oxidized using 12 equiv. DBU and 6 equiv. BrCCl3 in DMF. 
After 24 hours, the solvent was removed and an oily residue was suspended in 
CHCl3 and filtered. A colourless solid was isolated on the filter and eluted with TFA. 
This solution contained traces of a substance with a mass consistent with target 
macrocycle 32: 601.0 as [M32 + H]+ and 623.0 as [M32 + Na]+ according to MALDI-MS 
(Figure 5.13). 
 
 
Figure 5.13: MALDI-MS of a partial conversion to 32 in matrix PAC HCCA 
 
   Further optimization attempts were aimed at alcohol activation using groups that 
are stable enough to be isolated, yet reactive enough for base-mediated ring-closure 
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to 61. 59 was therefore reacted with eight equivalents of mesitylchloride and 12 
equiv. Et3N in MeCN at 60°C. The crude product revealed in ES I-MS signals for [M59 
+ Na]+, [M59 - H + Mts + Na]+, [M59 - 2 H + 2 Mts + Na]+ and [M59 - 3 H + 3 Mts + Na]+. 
There was also a trace of [M61 + MtsOH + Na]+ (831.1) amongst the signals, 
indicating that ring-closure takes place. Sulfonylation was also attempted using 
triisopropyl-benzenesulfonylchloride. 59 was reacted with 20 equiv. of the 
triisopropylbenzenesulfonylchloride and eight equiv. Et3N in pyridine for 5 h at rt and 
for 30 min at 85°C. The crude product was isolated upon aqueous workup and 
fractionated over SiO2. The desired product could, according to 1H-NMR, not be 
identified. It is hypothesised that the basic conditions and heat are needed for the 
formation of the sulfonyl substituted compounds is sufficient for ring-closure and/or 
elimination reactions to occur.  
 
Scheme 5.37. Debenzylation and sulfonylation of test compounds 99 and 116 
 
   To avoid basic reaction conditions, the benzyl deprotection reaction was modified 
to generate a stable sulfonyl substituted tetraalcohol in analogy to the formation of 
the tetraacetate 105 (see chapter 5.2.6). To test this approach, model molecule 99 
was reacted with Ms2O and BF3.Et2O in CH2Cl2 at rt. The reaction was heated to 
reflux for 5 h. Following purification, only 15% of the desired, mesylated product 126 
could be isolated (Scheme 5.37). The main byproduct was oxazoline 118. Model 
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compound 116, Ts2O and BF3.Et2O were reacted in CH2Cl2 at rt for 16 h to furnish 
the desired tosylcompound 127 in approximately 35% isolated yield. As byproducts, 
alcohol 128 and elimination product 129 were identified (Scheme 5.37). The 
deprotection and tosylation procedure was also tried on 99. Complete consumption 
of 99 was observed if the solution was refluxed overnight. A complex mixture 
including 16% of the tosylated product 130, and 31% of corresponding oxazoline 131 
and alcohol 128 were isolated (Scheme 5.37). The whole range of sulfonylation, ring-
closure, hydrolysis, and elimination is therefore observed.  In the case of macrocycle 
58, Ms2O was not strong enough to completely remove the benzyl groups, even upon 
heating in CH2Cl2. Considering the probable mechanism of the debenzylation 
(Scheme 5.38) it is hypothesized that a boron-alkoxide complex is the primary 
product of the deprotection resulting from nucleophilic attack at the benzylic CH2 
group. In a second step the alkoxide reacts with a second anhydride moiety. This 
presents a conundrum, as the more reactive electrophile (like Ms2O) will be less 
nucleophilic towards the boron activated ether. Acetic anhydride appears to provide 
an optimal balance of reactivity.  
 
Scheme 5.38. Proposed mechanism of the benzyl deprotection using lewis acid and anhydrides 
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   One-pot reactions that combine the deprotection of the benzyl group, alcohol 
activation and ring-closing were developed. Test compound 99 was reacted with 
Tf2O, (CF3CO)2O or Ms2O and BF3.Et2O in CH2Cl2 or ClCH2CH2Cl. When conversion 
was detected on TLC, a 1 M solution of DMAP was slowly added to the reaction. 
When using Ms2O, the desired oxazoline 118 could be isolated in a yield of about 
65%. This approach was attempted using macrocycle 60. Deprotection worked best 
using Tf2O and BF3.Et2O in ClCH2CH2Cl. When complete consumption of 60 was 
detected using TLC, the solvent was removed under reduced pressure and the 
remaining BF3 was removed by a N2 flow. The crude mixture showed in ESI-MS 
signals for [M59 + Na]+, [M59 + H]+, [M59 – H2O + H]+, [M59 – 2 H2O + H]+, [M59 – 3 H2O 
+ H]+ and [M59 – 4 H2O + H]+ = [M61 + H]+ (Figure 5.14). The reaction mixture was 
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then cooled down to -95°C and pyridine was added to  facilitate ring-closure. 
According to HPLC this didn’t have a significant effect. Tf2O and DMAP were 
therefore added[223, 224]. Some material was purified on reversed phase preparative 
HPLC, and again a mixture of the macrocycle with one or two oxazolines and two or 
three alcohols was observed. A slight improvement could be achieved by isolating 
the tetraaclcohol on prep. HPLC, suspending it in CH2Cl2 and adding Tf2O and 
pyridine at -95°C. Procedures like this increased t he complexity of the mixture. It was 
unfortunately not possible to get a clean conversion to 61 using this approach. 
 
  
Figure 5.14: ESI-MS of partial conversion to 61 
 
5.3.3.6 Ring closure using DAST 
   The most commonly used reagent for ring-closure of β-hydroxyamides to 
oxazolines is (diethylamino)sulphurtrifluoride (DAST). While the precise nature of the 
reactive species of DAST is unknown (Scheme 5.39), the alcohol oxygen reacts with 
the highly electrophilic sulphur. The sulphur substituent on the alcohol activates the 
oxygen, making the system susceptible to substitution. DAST was originally used for 
the conversion of alcohols into fluorides as an alternative to gaseous and very toxic 
SF4[225-227]. In the context of β-hydroxyamides, the intramolecular attack of the 
nucleophilic amide oxygen is faster than the substitution by the fluoride. In some 
examples, the resulting HF is quenched by addition of powdered K2CO3. Normally 
this is not necessary and the produced HF does not react with the products or the 
equipment, and is removed during aqueous workup[157, 209, 228-230].   
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Scheme 5.39. Activation mechanism with the reagent DAST 
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   In a typical DAST-promoted cyclodehydration reaction, the starting material in dry 
CH2Cl2 is reacted with 1.1 equiv. DAST under dry atmosphere between -20°C and rt. 
These conditions were successfully applied to the test molecules 63, 65, 64, 104 
(Figure 5.11) with almost quantitative yields. All these test molecules show good 
solubility in CH2Cl2. Unfortunately, these conditions did not work with tetraalcohol 59 
due to its poor solubility in CH2Cl2 or CHCl3. Several possible solutions for this 
problem were considered:  
   a) Use a different cyclodehydration method compatible with more polar solvents. 
   b) Increase the solubility of 59 by addition of chaotropic salts. LiCl in THF was not 
powerful enough to dissolve 59 but did lead to the discovery of a new chlorination 
reaction discussed in section 5.3.3.1. 
   c) Increase the solubility of 59 by protection of the alcohols with silyl protecting 
groups, which then, upon treatment with DAST, are deprotected due to the presence 
of fluorides. This will be described in section 5.3.3.7/8. 
   d) Test the compatibility of DAST with more polar solvents.  
   A series of DAST-mediated cyclizations was performed with test compound 64. 
Using mixture of CHCl3, Et3N and DAST in a ratio of 10:1:1 worked well, but 
macrocycle 59 was still insoluble in this solvent mixture. In DMSO, only partial 
conversion of 64 was observed, but a strong sulphur odour was detected indicating 
the decomposition of the solvent. In pyridine, ring-closure to give 75 was observed, 
but formation of the α-β elimination byproduct 71 was also observed. DMF was found 
to be compatible with DAST, 64 was nicely converted to 75 in 94% yield. 
Surprisingly, DMAc was much worse than DMF. All these reactions were performed 
under dry atmosphere (N2) at -5 to 0°C ( Scheme 5.40).  
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Scheme 5.40. Two-step reaction to the oxazole 
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a) 1.2 equiv. DAST, dry DMF, 0°C to rt, N 2, 2 h;  
b) 2 equiv. DBU, 1.1 equiv. BrCCl3, DMF, 0°C to rt, N 2, 16 h.  
 
   Macrocycle 59 is highly soluble in DMF and was consumed upon addition of DAST. 
Isolation of the resulting products proved to be difficult. Reversed phase HPLC using 
a H2O/MeCN gradient showed a mixture of many different products. On TLC, traces 
of less polar products were detected. These products appeared to be incompatible 
with aqueous workup, and were not detected on TLC anymore after workup. A 
subsequent oxidation step was therefore attempted immediately after the cyclization 
step without purification. The two-step, one-pot reaction was first evaluated with test 
substance 64. The reaction was monitored on TLC and showed a clean conversion 
to oxazole 120. Addition of powdered K2CO3 to the reaction promoted β-elimination 
to give 71 as a byproduct. The procedure was repeated with macrocycle 59 that was 
dissolved in DMF to a concentration of 15 mM and cooled down to -5°C in an ice-
brine bath. Eight equivalents DAST were added, and the solution was stirred under 
N2 and allowed to slowly warm to rt. After 4 h the solution was cooled down to -5°C, 
and 20 equiv. of DBU and eight equiv. of BrCCl3 were added. Three hours later the 
mixture was worked up under aqueous conditions. MALDI-MS analysis of the crude 
product includes signals belonging to the desired molecule and a ladder of signals 
601.1, 603.1, 605.1, 607.1, 609.1 belonging to [M32 + H, + 3 H, + 5 H, + 7 H, + 9 H]+, 
the last mass is the same as [M61 + H]+. The second and third ladders at higher 
masses belong to compounds that were not fully cyclodehydrated: 619.1, 621.1, 
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623.0, 625.0 belongs to [{M32 + H2O} + H, + 3 H, + 5 H]+ and 637.1, 639.1 to [{M32 + 
2 H2O} + H, + 3 H]+ (Figure 5.15). Given the complex mixture of products, this 
strategy was not pursued further.  
 
 
Figure 5.14: MALDI-MS of a partial reaction to 32 
 
5.3.3.7 Silyl protected alcohols as oxazoline precursors 
   In the previously described cyclodehydration reactions we have hypothesized that 
the failure for complete conversion from tetraalcohol 59 to tetraoxazoline 61 is related 
to poor solubility properties of macrocycle 59. We were therefore interested in a new 
concept of using silyl protected β-hydroxyamides for DAST mediated 
cyclodehydration reactions[231, 232]. According to this approach, silyl groups are used 
to protect alcohol groups on the macrocycle to help increase its solubility in organic 
solvents. Upon addition of DAST, the alcohols are then slowly deprotected due to the 
fluoride ions that result from cyclodehydration. The deprotected alcohols then react 
quickly with DAST to form the oxazolines. The rate of deprotection should be 
controllable using different silyl groups. To keep the macrocycle in solution, the rate 
of deprotection should be slower than the rate of ring-closure. 
   Preliminary experiments were performed with test compound 64. It was reacted 
with 5 equiv. chlorotriethylsilane in pyridine at 60°C to give the TES protected 
compound 132 in a yield of around 88% (Scheme 5.41). 132 was reacted with 1.1 
equiv. DAST to quantitatively furnish oxazoline 75. When completion was reached 
according to TLC, 3 equiv. DBU and 1 equiv. BrCCl3 were added to oxidize this 
oxazoline to the oxazole 120 (Scheme 5.41). Doing the same reaction in CHCl3, the 
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conversion was less clean, and in CH2Cl2 containing K2CO3 the elimination side 
product 71 was observed.  
   Macrocycle 59 was protected with TES groups using 20 equiv. TESCl in pyridine at 
60° for 2 h. Compound 133 could be isolated in yields around 50% (Scheme 5.42). 
Macrocycle 133 was soluble in CH2Cl2 and was treated with 20 equiv. DAST in 
CH2Cl2 at 0°C. After 5 min, the formation of a precipitat e was observed. This effect 
was ascribed to deprotection of several TES groups that occurs much faster than the 
reaction with DAST and formation of the oxazoline. As a consequence, a complex 
mixture of products was obtained. An alternative cyclodehydration reagent was 
therefore needed. 
  
Scheme 5.41. Protection with silyl groups to do the ring-closure to the oxazole  
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a) 5 equiv. TESCl, pyridine, 60°C, N 2, 1 h; b) 1 equiv. DAST, CH2Cl2, rt, N2, 20 min;  
c) 1.1 equiv. DAST, CH2Cl2, rt, N2, 20 min, 2. 3 equiv. DBU, 1 equiv. BrCCl3, CH2Cl2, 0°C to rt, N 2, 30 
min.; d) 1.2 equiv. silylchloride, 2 equiv. imidazole, DMF, rt, N2, 16 h. 
 
5.3.3.8 Silanols and XtalFluor for the synthesis of oxazolines 
   XtalFluor compounds (Figure 5.16) are next-generation fluorinating agents recently 
described by Michel Couturier[233]. They are more easily handled and significantly 
more stable than DAST. They should be more selective and exhibit superior 
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performance since they show less tendency to form the elimination side products[234]. 
The combination of silyl protected alcohols and XtalFluors for cyclodehydration 
reactions is therefore very attractive since it allows the use of less polar solvents 
together with a slow in situ deprotection of the alcohols and fast conversion to the 
oxazoline. To succeed, the rate of deprotection should be slower than the rate of the 
cyclization reaction. Otherwise, the intermediate alcohols or alkoxides might 
precipitate. The silyl group should therefore be chosen carefully. Different silyl groups 
were screened in reactions with DAST and XtalFluor. The following work was 
performed by Fabian Roth during his master thesis in our lab. 
 
N SF2 BF4 O N SF2 BF4
XtalFluor-E XtalFluor-M
 
Figure 5.16: Crystalline fluorinating agents XtalFluor-E and -M  
 
   Model compound 64 was protected using triethylsilylchloride (TESCl), 
isopropyldimethylsilylchloride (IPDMSCl), tert-butyldimethylsilylchloride (TBDMSCl), 
triisoproylsilylchloride (TIPSCl) and tert-butyldiphenylsilylchloride (TBDPSCl) with 2 
equiv. imidazole in DMF at rt overnight to furnish the respective compounds 132, 
134, 135, 136, 137 in yields between 70 and 90%[235] (Scheme 5.41). 
Using these compounds following trends for DAST or XtalFluor mediated oxazoline 
formation were observed:  
- For both DAST and XtalFluors, the intermediate alcohol could not be observed 
on TLC; 
- The rate of deprotection and ring-closure was fastest for TES and became 
slower for more sterically-hindered silyl groups;   
- For all silyl groups that are less reactive than IPDMS, reactions did not reach 
completion within 72 h.  
- XtalFluors exhibit a longer half-life in solution than DAST and are therefore 
more compatible with slower reactions. 
   The XtalFluor-mediated oxazoline formation was performed using the TES 
protected macrocycle 133. Reactions in CH2Cl2 (15 mM) using 16 equiv. of XtalFluor-
E which was added in one portion resulted according to TLC in clean conversion 
within 16 h. The solvent was removed, and the remaining material was adsorbed 
onto oven-dried neutral AlO3 and chromatographically purified on neutral AlO3. About 
Synthesis of Telomestatin Analogs  Chapter I – 5.  
 
 - 96 / 181 - 
44% of the macrocycle 61 could be isolated as a mixture of diastereoisomers 
(Scheme 5.42). Oxidation to the target molecule 32 was performed by adding 12 
equiv. BrCCl3 to a 3 mM solution of 61 in DMF and adding then 36 equiv. of DBU as 
a 50 mM solution in DMF over 10 min at 0°C. Immedia tly after the addition of BrCCl3 
the formation of a precipitate was observed, but the reaction was allowed to proceed 
overnight at rt. The product was isolated by filtration washing the solid with CHCl3, 
AcOEt and MeOH. 32 is slightly soluble in DMSO and highly soluble in TFA. In 
MALDI-MS the compound was identified as 601.0 [M32 + H]+ and 622.9  [M32 + Na]+ 
(Figure 5.17). 1H-NMR shows only two signals, consistently with a planar structure of 
32 (Figure 5.18).  
 
Scheme 5.42. Series of silyl protected β-hydroxyamides for XtalFluor-mediated ring-closures  
 
a) 16 equiv. TESCl, pyridine, 60°C, N 2, 2 h; b) 4.8 equiv. TESCl, 8 equiv. imidazole, DMF, rt, N2, 16 h; 
c) 16 equiv. XtalFluor-E, CH2Cl2, rt, N2, 16 h; d) 12 equiv. BrCCl3, 36 equiv. DBU, DMF, 0°C to rt, N 2, 
16 h. 
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Figure 5.17: MALDI-MS of 4TOP (32) in matrix PAC HCCA 
 
 
Figure 5.18: 1H-NMR of 4TOP (32) in d6-DMSO   
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6.  Outlook 
 
   Product 32 exhibits partial solubility in DMSO giving the possibility for biological 
evaluation. To characterize macrocycle 32, our lab is currently testing: 
a) Crystallization with and without G-quadruplexes; 
b) G-quadruplex affinity by fluorescence quenching assay; 
c) G-quadruplex specificity by comparing titrations using different DNA 
sequences known to form G-quadruplexes or duplex DNA; 
d) Cytotoxicity in cells by growing experiments in the presence of macrocycle 32; 
e) Impact on global gene expression by gene chip arrays. 
   The results from these experiments will evaluate the potential applications of planar 
telomestatin analogs in medicine and bioanalytics. Good characteristics in terms of 
affinity to and specificity for G-quadruplexes will motivate diversification of this 
scaffold. Substitution of the macrocycle, for example in the 5-position of four azole 
units, can potentially influence the binding preferences towards different G-
quadruplexes and the pharmacokinetic and toxicological properties of these 
compounds. 
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8 Synthetic Procedures and Analytical Data 
 
8.0 Synthesis of model compounds 
 
8.0.1 Models for β-hydroxyamides 
 
8.0.1.1 Synthesis of 63 
 
8.0.1.1.1 Synthesis of 138 
 
   3.01 g of L-phenylalanine ethyl ester hydrochloride (13.1 mmol) were suspended in 
60 ml THF in a dry two necked flask with a thermometer. 9.0 ml Et3N (65 mmol, 5 
equiv.) were added and 1.7 ml benzoylchloride (15 mmol, 1.1 equiv.), dissolved in 60 
ml THF, were dropped in slowly with a dropping funnel. The temperature was kept at 
25°C. The reaction was monitored on TLC (H:AcOEt 5: 1). To complete the 
conversion, the solution was heated up to reflux for 1 h. The solution was then diluted 
with AcOEt, washed two times with 0.1 M citric acid, once with sat. NaHCO3 and 
once with brine. All aq. layers were back extracted with AcOEt, the comb. org. layers 
dried over MgSO4, filtered and solvent removed in rv and hv. 4.13 g (12.5 mmol, 
96%) of the crude product were isolated. 3.62 g (11.0 g, 84%) of the pure N-benzoyl-
L-phenylalanine ethyl ester (138) were obtained after recrystallisation from H:AcOEt 
10:1. 
 
Rf(H/AcOEt 5:1): 0.32 
 
1H-NMR (300 MHz, CDCl3): 7.74 – 7.13 (m, 10 H, arom. CH); 
6.61 (br. d, 3J = 7.2, 1 H, NH); 5.07 (dt, 3J = 7.5, 3J = 5.6,  1 H, 
NCH); 4.21 (q, 3J = 7.1, 2 H, OCH2); 3.30 (dd, 2J = 13.8, 3J = 
5.8, 1 H, CH2Ph); 3.23 (dd, 2J = 13.8, 3J = 5.4, 1 H, CH2Ph); 
1.28 (t, 3J = 7.1, 3 H, CH3). 
 
13C-NMR (75.5 MHz, CDCl3): 171.62 (s, 1 C, COOEt); 166.79 (s, 1 C, CONH); 
135.91; 133.98 (2 s, 2 C, 2 arom. C); 131.75; 129.43; 128.62; 128.56; 127.15; 127.00 
(6 d, 10 C, arom. CH); 61.65 (t, 1 C, OCH2); 53.54 (d, 1 C, NCH); 37.95 (t, 1 C, 
CH2Ph); 14.15 (q, 1 C, CH3). 
 
MS (CHCl3 / MeOH 4:6 + NaI): 320.1 (100, [M + Na]+). 
 
8.0.1.1.2 Synthesis of 63 
 
   3.01 g of 138 (9.14 mmol) were dissolved in 100 ml THF (solv. syst.) under N2 and 
cooled down to 0°C in an ice bath. 6.8 ml 2 M LiBH 4 solution in THF (13.6 mmol, 1.5 
equiv.) were added and the solution was slowly let warm up to rt while stirring. The 
change could be monitored on TLC (H:AcOEt 1:1). The remaining LiBH4 was 
quenched by adding drops of H2O and 0.1 M citric acid. A part of the THF was then 
removed by rv and a precipitate formed. The aq. suspension was extracted once with 
AcOEt and once with TBME. The comb. org. layers were washed once with sat. 
NaHCO3 and once with brine, dried over MgSO4, filtered and solvent removed in rv 
and hv. The product was purified by recrystallisation from toluene. 1.81 g of the pure 
N-(1-hydroxy-3-phenylpropan-2-yl)benzamide (63) (7.09 mmol, 93%) were isolated. 
 
N
H
OO
O
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Melting temperature: 169.2 – 170.7°C 
Rf(H/AcOEt 1:1): 0.30  
 
1H-NMR (300 MHz, CDCl3 / 10% MeOD): 7.74 – 7.18 (m, 10 H, 
arom. CH); 4.34 (ddd, 3J = 11.8, 3J = 7.3, 3J = 4.5, 1 H, NCH); 
3.96 (br. s, 2 H, OH & NH); 3.69 (dd, 2J = 11.5, 3J = 4.2, 1 H, 
OCH2); 3.63 (dd, 2J = 11.5, 3J = 5.0, 1 H, OCH2); 3.01 (dd, 2J = 
13.8, 3J = 7.3, 1 H, CH2Ph); 2.95 (dd, 2J = 13.8, 3J = 6.5, 1 H, CH2Ph). 
 
13C-NMR (75.5 MHz, CDCl3 / 10% MeOD): 168.29 (s, 1 C, CONH); 137.80; 134.09 (2 
s, 2 C, arom. C); 131.32; 129.03; 128.23; 126.74; 126.24 (5 d, 10 C, arom. CH); 
62.65 (t, 1 C, OCH2); 52.84 (d, 1 C, NCH); 36.62 (t, 1 C, CH2Ph). 
 
MS (ESI, MeOH): 278.1 (7, [M + Na]+); 256.1 (100, [M + H]+). 
 
8.0.1.2 Synthesis of 64 
 
   2.01 g of H-Ser-OMe.HCl (12.9 mmol) were suspended in 75 ml CH2Cl2 (puriss. 
p.a.) and cooled down to 0°C in an ice bath under N 2. 1.5 ml benzoylchloride (13 
mmol, 1 equiv.) were added. 3.6 ml Et3N (26 mmol, 2 equiv.) were mixed with 40 ml 
CH2Cl2 (puriss. p.a.) and added over a time of 10 min to the suspension using a 
dropping funnel[229]. After stirring the suspension for 20 h at rt solvent was removed in 
rv, the remaining oily residue diluted with AcOEt, washed once with 0.1 M aq. citric 
acid, once with sat. NaHCO3 and once with brine. All aq. layers were back extracted 
with AcOEt, the org. layers combined and dried over MgSO4. Solid was filtered off 
and solvent removed in rv. The crude solid 64 was purified by recrystallisation from 
~30 ml refluxing mixture of hexane/CH2Cl2 1:1. 2.14 g of the pure colourless 
crystalline product methyl (2S)-2-(benzoylamino)-3-hydroxypropanoate (64) (9.60 
mmol, 74%) were isolated. 
 
Melting temperature: 87.1 – 89.2°C 
Rf(H/AcOEt 1:1): 0.07, Rf(H/AcOEt 1:3): 0.25  
 [α]D20 (CHCl3): + 46.7 
 
1H-NMR (300 MHz, CDCl3): 7.84 – 7.81 (m, 2 H, arom. o-CH); 
7.55 – 7.50 (m, 1 H, arom. p-CH); 7.46 – 7.41 (m, 2 H, arom. m-
CH); 7.18 (br. d, 3J = 6.7, 1 H, NH); 4.86 (dt, 3J = 7.2, 3J = 3.6, 1 
H, NCH); 4.08 (dd, 2J = 11.3, 3J = 3.7, 1 H, OCH2); 4.03 (dd, 2J = 
11.3, 3J = 3.5, 1 H, OCH2); 3.81 (s, 3 H, OCH3); 2.92 (br. s, 1 H, OH). 
 
13C-NMR (75.5 MHz, CDCl3): 171.04 (s, 1 C, COOMe); 167.67 (s, 1 C, CONH); 
133.40 (s, 1 C, arom. C); 131.98 (d, 1 C, arom. p-CH); 128.61 (d, 2 C, arom. o-CH); 
127.15 (d, 2 C, arom. m-CH); 63.43 (t, 1 C, CH2OH); 55.13 (d, 1 C, NCH); 52.85 (q, 1 
C, OCH3). 
 
MS (ESI-MS, MeOH + NaI): 246.1 (100, [M + Na]+).  
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8.0.1.3 Synthesis of 116 
 
8.0.1.3.1 Synthesis of 139 
 
   2.00 g of Boc-Ser(OBn)-OH (6.72 mmol), 1.54 g of DCC (7.47 mmol, 1.1 equiv.) 
and 83 mg of DMAP (0.68 mmol, 0.1 equiv.) were suspended in 45 ml dry MeOH 
(puriss. p.a.). The mixture was stirred at rt under N2 overnight[189]. The progress of 
the reaction was monitored on TLC (H:AcOEt 3:1). The solution was then filtered 
over Celite, the solvent removed in rv and the remaining material dissolved in AcOEt, 
washed with 0.1 M citric acid, sat. NaHCO3 and brine. All aq. layers were back 
extracted with AcOEt, comb. org. layers dried over MgSO4, filtered and the solvent 
removed in rv. The crude product was purified on SiO2 (H:AcOEt 4:1). 1.99 g of the 
pure product Boc-Ser(OBn)-OMe (139) (6.44 mmol, 95%) were isolated as colourless 
crystals. 
 
Rf(H/AcOEt 3:1): 0.5 
 
1H-NMR (300 MHz, CDCl3): 7.37 – 7.26 (m, 5 H, arom. CH); 5.40 
(br. d, 3J = 8.5, 1 H, NH); 4.55; 4.48 (2 d, 2J = 12.3, 2 H, OCH2Ph); 
4.47 – 4.42 (m, 1 H, NCH); 3.87 (dd, 2J = 9.4, 3J = 3.1, 1 H, 
OCH2C); 3.74 (s, 3 H, OCH3); 3.68 (dd, 2J = 9.4, 3J = 3.2, 1 H, 
OCH2C); 1.45 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 171.13 (s, 1 C, COOMe); 155.44 (s, 1 C, Carbamate-
CO); 137.51 (s, 1 C, arom. C); 128.37; 127.77; 127.54 (3 d, 5 C, arom. CH); 79.92 (s, 
1 C, OCMe3); 73.17 (t, 1 C, OCH2Ph); 69.90 (t, 1 C, OCH2); 53.94 (d, 1 C, NCH); 
52.38 (q, 1 C, OCH3); 28.26 (q, 3 C, OC(CH3)3). 
 
8.0.1.3.2 Synthesis of 116 
 
   669 mg of 139 (2.16 mmol) were dissolved in 6 ml CH2Cl2 and 2 ml TFA were 
added. The solution was stirred under N2 for 3 h, then TLC (H:AcOEt 3:1) showed 
complete conversion. The solvent was removed under reduced pressure freezing it 
out in a cooling trap. The remaining material was dissolved in MeOH, some of the ion 
exchanger Dowex in its Cl--form was added and the mixture stirred overnight. The 
solid was then removed by filtration and the solvent in rv. The free amine was directly 
used for peptide bond formation. 
279 mg of 1,2-thiazole-4-carboxylic acid (2.16 mmol, 1 equiv.) were suspended in 10 
ml CH2Cl2 (puriss. p.a.) and 0.6 ml NMM (5.4 mmol, 2.5 equiv.) were added.  
2.16 mmol of the amine were dissolved in 10 ml CH2Cl2 (puriss. p.a.), 0.6 ml NMM 
(5.4 mmol, 2.5 equiv.), 694 mg of TBTU (2.16 mmol, 1 equiv.) and the solution of the 
1,2-thiaole-4-carboxylic acid were added. The solution was stirred at rt under N2 
overnight. The progress of the conversion was monitored on TLC (H:AcOEt 1:1). 
The solvent was removed in rv, the remaining material dissolved in AcOEt, washed 
twice with 0.1 M citric acid, once with sat. NaHCO3 and once with brine. All aq. layers 
were back extracted with AcOEt, the comb. org. layers dried over MgSO4, filtered and 
the solvent removed in rv. The crude material was chromatographically purified on 
SiO2 (H:AcOEt 3:1 to 1:1). 660 mg of the pure product methyl 3-(benzyloxy)-2-[(1,3-
thiazol-5-yl)carbonyl]propanoic acid (116) (2.06 mmol, 95%) were isolated as 
colourless crystals. 
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Rf(H/AcOEt 1:1): 0.45, Rf(H/AcOEt 3:1): 0.15 
[α]D20 (CHCl3): + 11.9 
 
1H-NMR (300 MHz, CDCl3): 8.80 (d, 4J = 1.9, 1 H, Thiazole-C2H); 
8.20 (d, 4J = 1.9, 1 H, Thiazole-C4H); 8.17 (br. d, 3J = 8.7, 1 H, 
NH); 7.34 – 7.28 (m, 5 H, arom. CH); 4.96 (dt, 3J = 8.8, 3J = 3.4, 1 
H, NCH); 4.61; 4.54 (2 d, 2J = 12.3, 2 H OCH2Ph); 4.01 (dd, 2J = 
9.5, 3J = 3.6, 1 H, OCH2); 3.81 (dd, 2J = 9.5, 3J = 3.5, 1 H, OCH2); 
3.79 (s, 3 H, OCH3). 
 
13C-NMR (75.5 MHz, CDCl3): 170.44 (s, 1 C, COOMe); 160.67 (s, 1 C, CONH); 
152.81 (d, 1 C, Thiazole-C2H); 150.54 (s, 1 C, Thiazole-C5); 137.55 (s, 1 C, arom. C); 
128.41; 127.80; 127.62 (3 d, 5 C, arom. CH); 123.74 (d, 1 C, Thiazole-C4H); 73.24 (t, 
1 C, OCH2Ph); 69.60 (t, 1 C, OCH2); 57.02 (d, 1 C, NCH); 52.63 (q, 1 C, OCH3). 
 
MS (ESI, MeOH + NaI): 375.1 (6); 360.4 (13); 343.1 (100, [M + Na]+). 
 
8.0.1.4 Model compound 99 
 
   Methyl 2-{1-[(2-Acetyl-1,3-thiazole-4-yl)carbonylamino]-2-(benzyloxy)ethyl}-1,3-
thiazole-4-carboxylate (99) was isolated as a side product.  
 
Rf(H/AcOEt 1:1): 0.2; Rf(H/AcOEt 1:3): 0.65 
IR (KBr): 3394s; 3120w; 3100m; 3066w; 3033w; 2958w; 2924w; 2872w; 1713s; 
1681s; 1524s; 1499s; 1473s; 1455m; 1426m; 1384m; 1366m; 1355m; 1327s; 
1305m; 1265m; 1243s; 1208m; 1177m; 1140m; 1081s; 1054m; 1009m; 980m; 958w; 
940m; 913w; 894w; 883w; 861m; 839w; 818w; 802w; 785m; 765m; 753s; 723w; 
699m; 671w; 647w; 632m; 594m; 579m; 560w; 549w; 525w; 505w; 494w; 474w; 
461w. 
 
1H-NMR (300 MHz, CDCl3): 8.45 (s, 1 H, Thiazole-CH); 
8.31 (br. d, 1 H, NH); 8.15 (s, 1 H, Thiazole-CH); 7.30 – 
7.26 (m, 5 H, arom. CH); 5.72 (dt, 3J = 8.2, 3J = 4.7, 1 H, 
NCH); 4.60 (s, 2 H, OCH2Ph); 4.21 (dd, 2J = 9.4, 3J = 
4.2, 1 H, OCH2); 3.98 (dd, 2J = 9.4, 3J = 5.0, 1 H, OCH2); 
3.96 (s, 3 H, OCH3); 2.76 (s, 3 H, (CO)CH3). 
 
MS (CHCl3 / MeOH 4:6 + NaI): 468.1 (100, [M + Na]+). 
 
8.0.2 Models for β-tosylaminoamide 
 
8.0.2.1 Synthesis of 66 
 
8.0.2.1.1 Synthesis of 140 
 
   2.94 g of 491 (5.84 mmol) were dissolved in 50 ml Et2O under N2 and cooled down 
to 0°C. 24 ml of the ~0.25 M CH 2N2-solution were added (~6 mmol, 1.1 equiv.). An 
intense evolution of gas (N2) was observed and the yellow colour of the 
diazomethane was instantly lost. Another 2 ml of the ~0.25 M CH2N2-solution were 
                                            
1
 The synthesis of 49 is described in section 8.1.2.3  
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added. The colour remained partially. The solution was stirred for 10 min and 50 ml 
of 0.1 M aq. citric acid was added to quench the remaining diazomethane. The layers 
were separated, the org. one was washed again with 50 ml of 0.1 M aq. citric acid, 
once with sat. NaHCO3 and once with brine. All aq. layers were back extracted with 
Et2O, the comb. org. layers dried over MgSO4, filtered and dried in rv and hv. The 
crude product was chromatographically purified on SiO2 (H:AcOEt 2:1). 1.74 g (4.68 
mmol, 80%) of the pure methyl (2S)-2-[(tert-butoxycarbonyl)amino]-3-(4-
toluenesulfonylamino)propionate (Boc-DAP(NTs)-OMe, 140) were isolated.  
The structure of 140 was confirmed by x-ray crystallography. 
 
Rf(H/AcOEt 2:1): 0.4 
 
1H-NMR (300 MHz, CDCl3): 7.73; 7.31 (2 d, 3J = 8.4, 4 arom. H); 
5.45 (br. d, 3J = 7.3, 1 H, Amide-NH); 5.31 (br. t, 3J = 6.5, 1 H, Ts-
NH); 4.35 (br. s, 1 H, NCH), 3.73 (s, 3 H, OMe); 3.41 – 3.27 (m, 2 
H, NCH2); 2.42 (s, 3 H, Ts-Me); 1.43 (s, 9 H, C(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 170.48 (s, 1 C, COOMe); 155.31 (s, 
1 C, Carbamat-CO); 143.50 (s, 1 C, Ts-C-Me); 136.71 (s, 1 C, Ts-C-S); 129.68; 
126.95 (2 d, 4 C, arom. CH); 80.38 (s, 1 C, OC(CH3)3); 53.39 (d, 1 C, NCH); 52.70 (q, 
1 C, OCH3); 44.68 (t, 1 C, NCH2); 28.13 (q, 3 C, C(CH3)3); 21.38 (q, 1 C, Ts-CH3).  
 
X-ray crystallography: A nice crystal of 140, suitable for x-ray analysis, was obtained 
by evaporation of CDCl3 from an NMR tube. 
 
8.0.2.1.2 Synthesis of 66 
 
   1.08 g of 140 (2.90 mmol) were dissolved in 10 ml dry CH2Cl2 (freshly distilled over 
CaH2). A mixture of 5 ml CH2Cl2 and 5 ml TFA were added and the solution was 
stirred at rt for 3 h under N2, till TLC (H:AcOEt 1:1, staining with ninhydrin), showed 
no more 140. Solvent was removed by rv freezing it out in a cooling trap. The oily 
residue was dissolved in MeOH, mixed with Amberlyst-A26 in its Cl--form for 5 h, 
filtered and solvent removed again in rv. The isolated free amine was directly used 
for peptide bond formation.  
   374 mg of 1,3-thiazol-5-carboxylic acid (2.90 mmol) were dissolved in 20 ml CH2Cl2 
(puriss. p.a.). 0.81 ml of NMM (7.2 mmol, 2.5 equiv.), 931 mg of TBTU (2.90 mmol, 1 
equiv.) and 2.90 mmol of the amine (1 equiv.), dissolved in 20 ml CH2Cl2 and 0.81 ml 
of NMM (7.2 mmol, 2.5 equiv.) were added. Solution was stirred at rt under N2 
overnight. The reaction was monitored on TLC (H:AcOEt 1:2). Solvent was partially 
removed by rv, the remaining oil was diluted with AcOEt, washed twice with 0.1 M 
citric acid, once with sat. NaHCO3 and once with brine. All aq. layers were back 
extracted with AcOEt, comb. org. layers dried over MgSO4, filtered and solvent 
removed in rv. The crude product was further purified by dissolving it in boiling AcOEt 
and adding hexane till the solution got cloudy, then letting crystallize at -20°C. 963 
mg of pure colourless crystals of methyl (2S)-3-(tosylamino)-2-[(1,3-thiazol-5-
yl)carbonyl] propanoate (66) (2.51 mmol, 87%) could be isolated. 
 
Melting temperature: 161.8 – 162.7°C 
Rf(H/AcOEt 1:2): 0.18 
 [α]D20 (CHCl3): - 10.7 
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1H-NMR (300 MHz, CDCl3): 8.74 (d, 4J = 2.1, 1 H, Thiazol C2-H); 
8.17 (d, 3J = 8.6, 1 H, Amid-NH); 8.15 (d, 4J = 2.1, 1 H, Thiazol C5-
H); 7.72 (d, 3J = 8.1, 2 H, arom. o-CH); 7.24 (d, 3J = 8.1, 2 H, 
arom. m-CH); 5.82 (t, 3J = 6.6, 1 H, Sulfonamid-NH); 4.82 (dt, 3J = 
7.7, 3J = 4.9, 1 H NCH); 3.76 (s, 3 H, OCH3); 3.52 – 3.48 (m, 2 H, 
CH2); 2.38 (s, 3 H, Ts-CH3). 
 
13C-NMR (75.5 MHz, CDCl3): 169.99 (s, 1 C, COOMe); 161.04 (s, 
1 C, CONH); 152.98 (d, 1 C, Thiazole-C2H); 149.87 (s, 1 C, Thiazol-C5); 143.45 (s, 1 
C, Ts-C-Me); 136.71 (s, 1 C, Ts-C-S); 129.67 (d, 2 C, Ts-m-CH); 127.00 (d, 2 C, Ts-
o-CH); 124.11 (d, 1 C, Thiazole-C4H); 52.95 (q, 1 C, OCH3); 52.36 (d, 1 C, NCH); 
44.49 (t, 1 C, NCH2N); 21.46 (q, 1 C, Ts-CH3). 
 
MS (ESI, MeOH + NaI): 406.1 (100, [M + Na]+). 
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8.1 Target 1: [0.4]{(2,4)1,3-thiazolo[0](2,4)-1H-1,3-imidazolo}phan (33) 
 
8.1.1 Synthesis of azole amino acid "A" 
 
8.1.1.1 Synthesis of 37 
 
   In a oven dried flask equipped with a drying tube 0.503 g of 2,3-diaminopropionic 
acid hydrochloride (3.58 mmol) were suspended in 20 ml MeOH (puriss. p.a.) and 
cooled down to 0°C. 1.95 ml SOCl 2 (26.7 mmol, 7.5 equiv.) were added over 10 min 
through a dropping funnel. While stirring at 0°C fo r 20 min the diaminoacid dissolved. 
The solution was then heated to 75°C for 5 h [179]. The solvent was removed under 
reduced pressure, freezing it out in a cooling trap. The resulting colourless solid was 
dissolved in MeOH, filtered, the solvent was removed again and the substance dried 
in hv. 0.663 g of the pure methyl 2,3-diaminopropionate dihydrochloride (37, 3.473 
mmol, 97%) were isolated. 
 
1H-NMR (300 MHz, CD3OD): 4.49 (dd, 3J = 7.9, 3J = 5.6, 1 H, CH-
NH3); 3.94 (s, 3 H, OMe); 3.56 (dd, 2J = 13.6, 3J = 7.9, 1 H, 
CH2NH3); 3.48 (dd, 2J = 13.6, 3J = 5.6, 1 H, CH2NH3). 
 
13C-NMR (75.5 MHz, CD3OD): 167.89 (s, 1 C, COOMe); 54.55 (d, 1 C, CHNH3); 
51.10 (q, 1 C, OCH3); 39.47 (t, 1 C, CH2NH3). 
 
8.1.1.2 Synthesis of 39 
 
   14.34 g of 37 (48.55 mmol) were dissolved in 150 ml dioxane (puriss. p.a.), 2.5 ml 
pyridine (31 mmol, 0.66 equiv.), 15.487 g (Boc)2O (70.960 mmol, 1.5 equiv.) and 
4.965 g [NH4][HCO3] (62.80 mmol, 1.25 equiv.) were added and the mixture was 
stirred at rt under N2 for 16 h. The reaction was monitored on TLC (H:AcOEt 2:1) 
staining with ninhydrin. The solvent was removed by rv, the remaining solid dissolved 
in AcOEt, washed with 0.1 M citric acid till all pyridine was removed (controlled by 
TLC), once with H2O and once with brine. All aq. layers were back extracted with 
AcOEt, the comb. org. layers dried over MgSO4, filtered and dried in rv and hv.  
The remaining substance was dissolved in 30 ml CH2Cl2 and 450 ml hexane were 
added. The pure product was precipitated by removing a part of the CH2Cl2 in rv 
(45°C, 650 mbar). 13.20 g (44.85 mmol, 92%) of the colourless and solid L-Boc-
Ser(OBn)-NH2 (39) were isolated by filtration. 
 
Rf (H/AcOEt 2 : 1): 0.1 
[α]D20 (Methanol): + 20.48 
IR (KBr): 3389s; 3352s; 3289m, 3029w, 2969w; 2927w; 2864w; 2795w; 1686s; 
1664s; 1524s; 1477w; 1454m; 1429m; 1393w; 1366m; 1315m; 1295m; 1249m; 
1218m; 1170m; 1100m; 1049m; 1020m; 984w; 954w; 936w; 921w; 906w; 889w; 
871w; 840w; 808w; 778w; 750w; 699m; 650m; 615m; 602m; 550w; 485w; 468w.  
 
1H-NMR (300 MHz, CDCl3): 7.34 – 7.30 (m, 5 H, arom. CH); 6.42 
(br. s, 1 H, NH); 5.39 (br. s, 2 H, NH2); 4.61; 4.53 (2 d, 2J = 11.7, 2 
H, CH2Ph); 4.30 (br. s, 1 H, NHCHCH2); 3.92 (dd, 2J = 9.2, 3J = 
3.8, 1 H, NHCHCH2); 3.58 (dd, 2J = 9.2, 3J = 6.9, 1 H, NHCHCH2); 
1.45 (s, 9 H, C(CH3)3). 
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13C-NMR (75.5 MHz, CDCl3): 173.06 (s, 1 C, Amide-C); 155.46 (s, 1 C, Carbamate); 
137.31 (s, 1 C, arom. C); 128.52; 127.97; 127.81 (3 d, 3 C, arom. CH); 80.23 (s, 1 C, 
CMe3); 73.59 (t, 1 C, OCH2Ph); 69.71 (t, 1 C, OCH2CH); 53.58 (d, 1 C, CHCH2); 
28.23 (q, 3 C, C(CH3)3). 
 
MS (ESI, MeOH/CHCl3 1:3 + NaI): 317.3 (100, [M + Na]+); 217.1 (17, [M – COOCMe3 
+ H + Na]+). 
 
8.1.1.3 Synthesis of 41 
 
   In a 250 ml two necked flask 2.93 g of 39 (9.94 mmol) were dissolved in ca. 100 ml 
CH2Cl2 (purum) under Ar. 3.01 g of CaCO3 (30.1 mmol, 3 equiv.) and 2.10 g Et3OBF4 
(11.0 mmol, 1.1 equiv.) were added and the suspension was stirred at rt.Reaction 
was monitored by TLC (H:AcOEt 1:1). After 9 h, the solution containing intermediate 
40 was filtered over 2 cm SiO2 and diluted with CH2Cl2 to 200 ml.  
2.02 g of 37 (10.6 mmol, 1.05 equiv.) were suspended in 150 ml CH2Cl2. 3.5 ml Et3N 
(25 mmol, 2.5 equiv.) were added. The solution of 40 was added during 2 h. The 
suspension was then stirred overnight at rt under N2. The reaction was monitored on 
TLC (H:AcOEt 1:1). The solution was then washed four times with 0.1 M citric acid, 
the comb. aq. layers were basified with sat. NaHCO3 and back extracted three times 
with AcOEt. The org. layers were washed with brine, combined, dried over MgSO4, 
filtered and the solvent removed in rv and hv. 2.33 g of the quite sufficiently pure 
methyl 2-{2-(benzyloxy)-1-[(tert-butoxycarbonyl)amino]}-1H-imidazoline-4-carboxylate 
(41) (6.17 mmol, 62% in respect to 39) were isolated. 
 
Rf(H/AcOEt 1:1): 0.1 
 
1H-NMR (300 MHz, CDCl3): 7.35 – 7.32 (m, 5 H, arom. CH); 
5.58 (br. d, 3J = 13.1, 1 H, Carbamat-NH); 4.62 – 4.39; 3.92 
– 3.81; 3.69 – 3.59 (3 m, 8 H, CH2Ph, NCHCH2, 
Imidazoline-CHCH2); 3.75; 3.74 (2 s, 3 H, OMe (two 
diasteromers)); 1.44 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 173.20; 173.09 (2 s, COO (two diastereoisomers)); 
166.939; 166.743 (2 s, 1 C, CNN (two diastereoisomers)); 155.32 (s, 1 C, Carbamat-
CO); 137.54 (s, 1 C, arom. C); 128.29; 127.65; 127.00; 127.56 (4 d, 5 C, arom. CH 
(once diastereoisomers resolved)); 79.68 (s, 1 C, OCMe3); 73.21; 73.15 (2 t, 1 C, 
OCH2Ph (two diastereoisomers)); 70.68; 70.46 (2 br. t, 2 C, 2 CH2); 61.78 (br. d, 1 C, 
CONHCH); 52.20 (q, 1 C, OCH3); 49.08 (d, 1 C, CHNH); 28.17 (q, 3 C, C(CH3)3).  
 
MS (ESI, MeOH/MeCN 1:1 + 0.1% HCOOH): 378.2 (100, [M + H]+); 322.2 (20, [M – 
CMe3 + 2 H]+). 
 
8.1.1.4 Synthesis of 42 
 
   246 mg of 41 (652 µmol) were dissolved in 10 ml CH2Cl2 (tech.) and 636 mg of the 
90% MnO2 (6.58 mmol, 10 equiv.) were added[182]. The suspension was stirred at rt 
under N2. The reaction was monitored by TLC (H:AcOEt 1:1). After 72 h another 634 
mg of MnO2 (6.58 mmol, 10 equiv.) were added. The suspension was further stirred 
for 24 h, then filtered over celite and chromatographically purified (H:AcOEt 2:1). 84 
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mg (305 µmol, 47%) of the pure product methyl 2-{2-(benzyloxy)-1-[(tert-
butoxycarbonyl)amino] ethyl}-1H-imidazole-4-carboxylate (42) could be isolated. 
 
Melting temperature: 156.2 – 157.9°C 
Rf(H/AcOEt 1:1): 0.35 
 
1H-NMR (300 MHz, CDCl3): 7.63 (s, 1 H, Imidazole-CH); 
7.36 – 7.26 (m, 5 H, arom. CH); 5.64 (d, 3J = 6.6, 1 H, 
NHCH); 4.97 (dd, 3J = 12.8, 3J = 6.2, 1 H, NCH); 4.58; 4.53 
(2 d, 2J = 11.9, 2 H, OCH2Ph); 4.00 (br. t, J = 7.5, 1 H, 
Imidazole-NH); 3.87 (s, 3 H, OCH3); 3.86 – 3.71 (m, 2 H, 
CH2); 1.43 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3):  
 
X-ray crystallography: A nice crystal of 42, sutable for x-ray analysis, could be 
obtained by isothermal destillation of pentane into a solution of 42 in dioxane. 
 
 
8.1.1.5 Synthesis of of 43 (mixture) 
 
   2.27 g of 41 (6.01 mmol) were dissolved in 250 ml CH2Cl2 under N2 at rt. 1.7 ml of 
Et3N (12 mmol, 2 equiv.) and 2.63 g of mesitylenesulfonylchloride (12.0 mmol, 2 
equiv.) were added and the solution was stirred for 24 h. The reaction was monitored 
on TLC (H:EE 1:1). The solvent was partially removed in rv, the remaining solution 
diluted with TBME, washed three times with 0.1 M citric acid, twice with sat. NaHCO3 
and once with brine. All aq. layers were back extracted with TBME, the combined 
org. layers dried over MgSO4, filtered and the solvent was removed in rv. The product 
was chromatographically purified on SiO2 (H:AcOEt 5:1 to 2:1). 2.67 g of an 
otherwise pure mixture of the two isomers methyl 2-{2-(benzyloxy)-1-[(tert-
butoxycarbonyl)amino]ethyl}-1-mesityl-1H-imidazoline-4-carboxylate (43a) (4.77 
mmol, 79%) were isolated. 
 
Rf(H/AcOEt 1:1): 0.5 
 
1H-NMR (300 MHz, CDCl3): 7.33 – 
7.25 (m, 5 H, arom. Ph-CH); 6.98; 
6.96 (2 s, 2 H, arom. Mts-CH); 5.56 
– 5.66 (m, 1 H, NH); 5.33 – 5.23 (m, 
1 H, NCH); 4.69 – 4.37 (m, 4 H, 
OCH2Ph, Imidazoline-CH2); 3.81 – 
3.55 (m, 6 H, OCH3, OCH2, 
Imidazoline-CH); 2.63; 2.62 (2 s,  6 
H, 2 Mts-ortho-CH3); 2.31; 2.30 (2 s, 
3 H, Mts-para-CH3); 1.43 (s, 9 H, 
OC(CH3)3).  
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8.1.1.6 Synthesis of 35 
 
   2.67 g of 43 (4.77 mmol) were dissolved in 150 ml CH2Cl2 under N2. 0.80 ml of 
DBU (5.2 mmol, 1.1 equiv.) and 0.57 ml of BrCCl3 (5.7 mmol, 1.2 equiv.) were 
added[182] at rt and the solution was stirred overnight. Reaction was monitored on 
TLC (H:AcOEt 1:1).  
The CH2Cl2 was removed in rv, the remaining oily solution diluted with AcOEt, 
washed three times with 0.1 M citric acid, once with sat. NaHCO3 and once with 
brine. All aq. layers were back extracted with AcOEt, comb. org. layers dried over 
MgSO4, filtered and the solvent removed in rv. The product was chromatographically 
purified on SiO2 (H:AcOEt 4:1). 1.96 g of the pure product methyl 2-{2-(benzyloxy)-1-
[(tert-butoxycarbonyl)amino]ethyl}-1-mesityl-1H-imidazole-4-carboxylate (35a) (3.51 
mmol, 74%) could be isolated as a colourless foam. 
 
Rf(H/AcOEt 1:1): 0.6 
 
1H-NMR (300 MHz, CDCl3): 7.90 (s, 
1 H, Imidazole-H); 7.31 – 7.24 (m, 3 
H., arom. ortho/para CH); 7.17 – 
7.14 (m, 2 H, arom. m CH); 6.95 (s, 
2 H, arom. Mts-CH); 5.41 (d, 3J = 
8.8, 1 H, NH); 5.29 – 5.22 (m, 1 H, 
NCH); 4.40; 4.27 (2 d, 2J = 12.1, 2 
H, CH2Ph); 3.89 (s, 3 H, OCH3); 
3.59 – 3.55 (m, 2 H, CH2O); 2.53 (s, 
6 H, 2 Mts-ortho-CH3); 2.29 (s, 3 H, 
Mts-para-CH3); 1.38 (s, 9 H, C(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 162.18 (s, 1 C, COO); 154.47 (s, 1 C, OCON); 148.40 
(s, 1 C, CNN); 145.78 (s, 1 C, Mts p-C); 140.77 (s, 2 C, Mts o-C); 137.68 (s, 1 C, Ph 
o-C); 132.70 (d, 3 C, 2 Mts m-CH and Ph p-CH); 131.39; 130.85 (2 s, 2 C, Mts o-C, 
Im NC); 128.13; 127.44 (2 d, 4 C, Ph o/m-CH); 125.08 (d, 1 C, Im CH); 79.50 (s, 1 C, 
OCMe3); 72.71; 71.31 (2 t, 2 C, 2 OCH2); 52.06 (q, 1 C, OCH3); 47.60 (d, 1 C, 
NHCH); 28.13 (q, 3 C, C(CH3)3); 22.48 (q, 2 C, Mts o-CH3); 21.08 (q, 1 C, Mts p-
CH3). 
 
MS (ESI, MeOH): 596.2 (15, [M + K]+); 585.2 (5); 580.4 (66, [M + Na]+); 558.4 (100, 
[M + H]+). 
 
8.1.2.  Synthesis of azole amino acid "B" 
 
8.1.2.1 Synthesis of 50 
 
   The synthesis of the compounds 46, 47 and 50 is described in section 8.2.2.1, 
8.2.2.2 and 8.2.2.4. 
 
8.1.2.2 Synthesis of 48 
 
   34.89 g of Boc-Asn-OH (150.2 mmol) were suspended in 180 ml AcOEt, 180 ml 
MeCN and 90 ml H2O under N2 and cooled down to 14 – 16°C. The suspension was 
mechanically stirred and 58.06 g of PIDA (180.3 mmol, 1.2 equiv.) were added[183]. 
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After some minutes everything dissolved. The solution was kept at 14 – 16°C for 30 
min and then slowly warmed up to rt. A new colourless precipitate formed. The 
suspension was stirred overnight, then cooled down to 0°C and filtered. The 
colourless solid was washed with little AcOEt and dried in hv at 60°C. 20.19 g 3-
amino-2-[(tert-butoxycarbonyl)amino]propionic acid (Boc-DAP-OH, 48) (98.85 mmol, 
66%) were isolated. 
 
1H-NMR (300 MHz, MeOD): 4.88 (br. s, 3 H exchangabel NH2 and 
OH); 4.07 (br. t, 3J = 6.0, 1 H, NCH); 3.17 (br. d, 3J = 5.7, 2 H, 
CH2); 1.46 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, MeOD): 174.94 (s, 1 C, COOH); 157.96 (s, 1 C, Carbamat-CO); 
80.89 (s, 1 C, OCMe3); 53.90 (d, 1 C, NCH); 43.03 (t, 1 C, CH2); 28.68 (q, 3 C, 
OC(CH3)3). 
 
8.1.2.3 Synthesis of 49 
 
   5.02 g of 48 (24.6 mmol) were dissolved in 200 ml MeCN, 50 ml H2O and 50 ml 
NaHCO3. The solution was cooled down to 0°C and vigorousl y stirred using a 
mechanical stirrer. 4.90 g of TsCl (25.7 mmol, 1.05 equiv.) were added[184]. The 
solution was slowly warmed up to rt and reaction monitored on TLC (CH2Cl2:MeOH 
5:1 staining with ninhydrin). After 6 h a part of the solvent was removed in rv and the 
remaining colourless mixture was diluted with 0.1 M citric acid. A new white oily 
precipitate formed, which was extracted three times with CH2Cl2. The org. layers 
were washed with brine, dried over MgSO4, filtered and the solvent removed in rv 
and hv. 7.56 g (21.1 mmol, 86%) of (2S)-2-[(tert-butoxycarbonyl)amino]-3-(4-
toluenesulfonylamino)propionic acid (Boc-DAP(NTs)-OH, 49) were isolated as a solid 
colourless foam. 
 
1H-NMR (300 MHz, CDCl3): 7.73 (d, 3J = 8.5, 2 H, Tosyl-o-CH); 
7.28 (d, 3J = 8.5, 2 H, Tosyl-m-CH); 5.84 (br. t, 3J = 5.9, 1 H, 
NHCH2); 5.76 (br. d, 3J = 7.2, 1 H, NHCH); 4.35 (br. s, 1 H, NCH); 
3.39 – 3.36 (m, 2 H, NCH2); 2.41 (s, 3 H, Tosyl-CH3); 1.45 (s, 9 H, 
OC(CH3)3). 
 
13C-NMR (75.5 MHz, DMSO): 171.73 (s, 1 C, COOH); 155.14 (s, 
1 C, Carbamate-CO); 142.71 (s, 1 C, Ts-p-CMe); 137.14 (s, 1 C, Ts-i-C); 129.63; 
126.50 (2 d, 4 C, Ts-CH); 78.25 (s, 1 C, OCMe3); 53.54 (d, 1 C, NCH); 43.61 (t, 1 C, 
NCH2); 28.09 (q, 3 C, OC(CH3)3); 20.93 (q, 1 C, Ts-CH3).  
 
MS (ESI, CHCl3/MeOH 3:1 + NaI): 739.2 (6, [2 M + Na]+); 567.3 (30); 381.1 (100, [M 
+ Na]+); 325.2 (21, [M – C(CH3)3 + H + Na]+). 
 
8.1.2.4 Synthesis of 51 
 
   5.03 g of 49 (14.0 mmol) were dissolved in 80 ml CH2Cl2 (purum) under N2, 3.9 ml 
of NMM (35 mmol, 2.5 equiv.) and 4.508 g of TBTU (14.04 mmol, 1 equiv.). 1 equiv 
of 79, as described above, dissolved in 80 ml CH2Cl2 and 3.9 ml of NMM (35 mmol, 
2.5 equiv.) were added. The reaction was monitored on TLC (H:AcOEt 1:1). The 
solution was stirred under N2 overnight. A part of the solvent was removed by rv, the 
remaining solution diluted with TBME, washed once with 1 M aq. NaHSO4, once with 
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aq. 0.1 M citric acid and once with brine. All aq. layers were back extracted with 
TBME, the comb. org. layers dried over MgSO4, filtered and solvent removed in rv. 
The isolated 9.09 g crude 51 were adsorbed to SiO2 and chromatographically purified 
on SiO2 (H:AcOEt 2:1 to 1:1). 4.78 g pure Boc-DAP(NTs)-Ser(OAc)-OMe (51) (9.53 
mmol, 68%) were isolated. 
 
Rf(H/AcOEt 1:1): 0.35 
 
1H-NMR (300 MHz, CDCl3): 7.75 (d, 3J = 8.3, 2 H, Ts-o-
CH); 7.37 (br. d, 3J = 6.2, 1 H, Amid-NH); 7.31 (d, 3J = 8.3, 
2 H, Ts-m-CH); 5.82 (br. t, 3J = 5.9, 1 H, Ts-NH); 5.71 (br. d, 
3J = 5.7, 1 H, Carbamat-NH); 4.73 (dt, 3J = 7.2; 3J = 3.5, 1 
H, C-terminal NCH); 4.59 (dd, 2J = 11.7, 3J = 3.2, 1 H, 
OCH2); 4.38 (dd, 2J = 11.7, 3J = 3.5, 1 H, OCH2); 4.30 – 
4.25 (m, 1 H, N-terminal NCH); 3.79 (s, 3 H, OCH3); 3.39 – 
3.31; 3.22 – 3.12 (2 m, 2 H, NCH2); 2.42 (s, 3 H, Ts-CH3); 
2.10 (s, 3 H, (CO)CH3); 1.46 (s, 9 H, OC(CH3)3).  
 
13C-NMR (75.5 MHz, CDCl3): 171.24; 170.65; 169.54 (3 s, 3 C, 2 COO, 1 CONH); 
155.75 (s, 1 C, Carbamat-CO); 143.70 (s, Ts-CMe); 136.59 (s, 1 C, Ts-S-C); 129.85 
(d, 2 C, Ts-o-CH); 127.10 (d, 2 C, Ts-m-CH); 80.77 (s, 1 C, OCMe3); 63.03 (t, 1 C, 
OCH2); 53.74; 53.04 (2 d, 2 C, 2 NCH); 52.34 (q, 1 C, OCH3); 44.49 (t, 1 C, NCH2); 
28.28 (q, 3 C, OC(CH3)3); 21.52 (q, 1 C, Ts-CH3); 20.72 (q, 1 C, (CO)CH3). 
 
MS (ESI, MEOH/CH2Cl2 3:1 + NaI): 524.3 (100, [M + Na]+); 468.2 (10, [M – CMe3 + H 
+ Na]+); 424.3 (6, [M – CO2CMe3 + H + Na]+). 
 
8.1.2.5 Synthesis of 52 
 
   0.32 g of 51 (0.65 mmol) were dissolved in 25 ml toluene and 0.13 g of Lawesson 
reagent (0.32 mmol, 0.5 equiv.) were added. The solution was heated under reflux 
and N2 for two hours. Reaction was monitored by TLC (H:AcOEt 1:1)2. The solution 
was diluted with TBME, washed once with 0.1 M citric acid, once with sat. NaHCO3 
and twice with brine. All aq. layers were back extracted with TBME, the comb. org. 
layers were dried over MgSO4, filtered and the solvent was removed in rv. 0.38 g of 
the crude product were isolated as a yellowish, smelling oil. The substance was 
adsorbed at SiO2 and chromatographically purified on SiO2 (H:AcOEt 3:1). 0.27 g of 
Boc-ThioDAP(NTs)-Ser(OAc)-OMe (52) (mainly the open form, max. 0.52 mmol, 
80%) could be isolated and were directly used for ring-closure and oxidation reaction. 
 
Rf(H/AcOEt 2:1): 0.4; Rf(H/AcOEt 1:1): 0.75 
 
1H-NMR (300 MHz, CDCl3): 8.90 (br. d, 3J = 4.6, 1 H, 
Thioamid-NH); 7.75 (d, 3J = 8.1, 2 H, Ts-o-CH); 7.32 (d, 3J = 
8.1, 2 H, Ts-m-CH); 5.84 (br. s, 1 H, Carbamat-NH); 5.59 
(br. t, 3J = 7.3, 1 H, Ts-NH); 5.22 (dt, 3J = 6.9; 3J = 3.1, 1 H, 
C-terminal NCH); 5.01 (dd, 2J = 11.7, 3J = 3.1, 1 H, OCH2); 
4.61 – 4.56 (m, 1 H, N-terminal NCH); 4.40 (dd, 2J = 11.7, 
                                            
2
 Longer reaction time favours the formation of the in principle desired oxazoline 52, the subsequent 
reaction does not depend on the nature of 52 and yield seems to be better if the ring is not already 
formed. 
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3J = 2.7, 1 H, OCH2); 3.85 (s, 3 H, OCH3); 3.59 – 3.51; 3.25 – 3.16 (2 m, 2 H, NCH2); 
2.43 (s, 3 H, Ts-CH3); 2.15 (s, 3 H, (CO)CH3); 1.45 (s, 9 H, OC(CH3)3). 
 
8.1.2.6 Synthesis of Boc-TDAP(NTs)-OMe (44) 
 
   269 mg of 52 (0.520 mmol) were dissolved in 20 ml CH2Cl2, 275 µl of DBU (1.82 
mmol, 3.5 equiv.) and 62 µl of BrCCl3 (0.624 mmol, 1.2 equiv.) were added and the 
solution was stirred at rt under N2 for 3 h (monitored on TLC, H:AcOEt 1:1). The 
brown solution was then diluted with TBME, washed twice with 0.1 M citric acid, once 
with sat. NaHCO3 and once with brine. All aq. layers were back extracted with TBME, 
the comb. org. layers were dried over MgSO4, filtered and solvent was removed in rv. 
194 mg of the crude product were isolated. 
The oil was adsorbed at SiO2 and chromatographically purified on SiO2 (H:AcOEt 
2:1). 181 mg (0.397 mmol, 61% in relation to 51) of the pure methyl 2-{(1S)-1-[(tert-
butoxycarbonyl)amino]-2-(tosylamino)ethyl}-1,3-thiazole-4-carboxylate (Boc-TDAP 
(NTs)-OMe, 44) could be isolated. 
 
Rf(H/AcOEt 1:1): 0.35 
 
1H-NMR (300 MHz, CDCl3): 8.08 (s, 1 H, Thiazole-CH); 7.72 
(d, 3J = 8.1, 2 H, Ts-o-CH); 7.29 (d, 3J = 8.1, 2 H, Ts-m-CH); 
5.94 (br. d, 3J = 6.7, 1 H, Carbamat-NH); 5.69 (br. t, 3J = 6.8, 
1 H, Ts-NH); 5.08 (dt, 3J = 7.9, 3J = 4.4, 1 H, NCH); 3.90 (s, 
3 H, OCH3); 3.56 – 3.44 (m, 2 H, CH2); 2.42 (s, 3 H, Ts-
CH3); 1.46 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 171.86 (s, 1 C, Thiazol-CNS); 161.53 (s, 1 C, COOMe); 
155.36 (s, 1 C, Carbamat-CO); 146.62 (s, Thiazole-C-COOMe); 143.71 (s, 1 C, Ts-C-
Me); 136.64 (s, 1 C, Ts-S-C); 129.85 (d, 2 C, Ts-o-CH); 128.34 (d, 1 C, Thiazole-CH); 
127.08 (d, 2 C, Ts-m-CH); 80.75 (s, 1 C, OCMe3); 52.43 (q, 1 C, OCH3); 52.39 (d, 1 
C, NCH); 46.17 (t, 1 C, NCH2); 28.30 (q, 3 C, =C(CH3)3); 21.52 (q, 1 C, Ts-CH3). 
 
MS (ESI, MeOH + NaI): 478.1 (100, [M + Na]+); 422.1 (27, [M – CMe3 +H + Na]+); 
378.1 (17, [M – CO2CMe3 + H + Na]+). 
 
8.1.3 Synthesis of tetramer Boc-[TDAP(NTs)]4-OMe (53) 
 
8.1.3.1 Synthesis of 54 
 
   157 mg of 44 (345 µmol) were dissolved in 10 ml MeOH (purum) and 43.5 mg LiOH 
(1.82 mmol, 5 equiv.), dissolved in 10 ml H2O, were added. The progress of ester 
hydrolysis was monitored on TLC (H:AcOEt 1:1). The solution was then acidified with 
0.1 M aq. citric acid to pH 3 – 4 (formation of a white precipitate) and extracted twice 
with TBME. The org. layers were washed with brine, combined, dried over MgSO4, 
filtered and dried in rv and hv. The acid 54 was isolated as colourless foam and 
directly used for peptide bond formation.   
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8.1.3.2 Synthesis of 55 
 
   171 mg 44 (375 µmol) were dissolved in 2 ml CH2Cl2 (purum). A mixture of 2 ml 
CH2Cl2 and 2 ml TFA were added and the solution was stirred at rt for ~3 h under N2, 
till TLC (H:AcOEt 1:1, staining with ninhydrin), showed no more 44. The solvent was 
removed by rv freezing it out in a cooling trap. The oily residue was dissolved in 
MeOH, mixed with Amberlyst-A26 in its Cl--form for 5 h, filtered and dried again in rv. 
The isolated ammonium salt 55 was directly used for peptide bond formation. 
 
8.1.3.3 Synthesis of Boc-[TDAP(NTs)]2-OMe (56) 
 
   152 mg of 54 (345 µmol) were dissolved in 10 ml distilled CH2Cl2, 240 µl of Et3N 
(1.73 mmol, 5 equiv.), 112 mg of TBTU (345 µmol, 1 equiv.) and a solution of the 170 
mg of 55 (362 µmol, 1 equiv.) in 10 ml distilled CH2Cl2 was added. Reaction was 
monitored on TLC (H:AcOEt 1:3). Reaction was stirred under N2 overnight. A part of 
the solvent was removed by rv, the remaining solution diluted with TBME, washed 
twice with aq. 0.1 M citric acid, once with sat. NaHCO3 and once with brine. All aq. 
layers were back extracted with TBME, the comb. org. layers dried over MgSO4, 
filtered and dried in rv. The crude 56 was adsorbed at SiO2 and chromatographically 
purified on SiO2 (H:AcOEt 2:1 to 1:2). 261 mg pure Boc-[TDAP(NTs)]2-OMe (56, 335 
µmol, 97%) were isolated. 
 
Rf(H/AcOEt 1:2): 0.15; Rf(H/AcOEt 1:3): 0.4  
 
1H-NMR (300 MHz, CDCl3): 9.10 (br. d, 3J = 5.1, 
1 H, Amide-NH); 8.05 (s, N-terminal Thiazole-
CH); 7.86 (br. s, C-terminal Thiazole-CH); 7.72 
– 7.64 (m, 4 H, Ts-o-CH); 7.25 – 7.19 (m, 4 H, 
Ts-m-CH); 6.50; 6.43 (2 br. s, 2 H, Ts-NH); 6.16 
(br. d, 3J = 6.9, 1 H, Carbamate-NH); 5.45 (br. d, 
3J = 5.2, 1 H, NCH); 4.81 (br. s, 1 H, NCH); 3.82 
(s, 3 H, OCH3); 3.76 – 3.57; 3.25 – 2.97 (2 m, 4 H, 2 NCH2); 2.42; 2.40 (2 s, 6 H, 2 
Ts-CH3); 1.44 (s, 9 H, OC(CH3)3).  
 
13C-NMR (75.5 MHz, CDCl3): 171.57; 171.25 (2 s, 2 C, Thiazole-NCS); 161.71; 
161.64 (2 s, 2 C, COOMe, CONH); 155.31 (s, 1 C, Carbamate-CO); 148.27; 146.24 
(2 s, 2 C, Thiazole-C4); 143.69; 143.36 (2 s, 2 C, Ts-C-Me); 136.98; 136.56 (2 s, 2 C, 
Ts-C-S); 129.79; 129.68 (2 d, 4 C, Ts-o-C); 128.37 (d, 1 C, N-term. Thiazole-CH); 
127.09; 127.00 (2 d, 4 C, Ts-m-CH); 125.40 (d, 1 C, C-term. Thiazole-CH); 80.46 (s, 
1 C, OCMe3); 52.54 (q, 1 C, OCH3); 52.43; 52.22 (2 d, 2 C, NCH); 45.55; 45.03 (2 t, 2 
C, NCH2); 28.33 (q, 3 C, OC(CH3)3); 21.50 (q, 2 C, Ts-CH3). 
 
MS (ESI, MeOH + NaI): 801.3 (100, [M + Na]+). 
 
8.1.3.4 Synthesis of 141 
 
   250 mg of 56 (321 µmol) were dissolved in 15 ml MeOH (puriss. p.a.). 47 mg of 
LiOH (2.0 mmol, 6 equiv.), dissolved in 5 ml H2O, were added. The progress of the 
reaction was monitored on TLC (H:AcOEt 1:10 after little workup). A part of the 
solvent was removed in rv, the remaining oily solution was diluted with AcOEt, 
washed with 0.1 M aq. citric acid and 0.1 M citric acid in brine. The aq. layers were 
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back extracted with AcOEt, the comb. org. layers dried over MgSO4, filtered and the 
solvent removed in rv and hv. The crude 141 was directly used for peptide bond 
formation. 
 
8.1.3.5 Synthesis of 142 
 
   250 mg of 56 (321 µmol) were dissolved in 5 ml 
CH2Cl2 (puriss. p.a.). 15 ml of TFA were added 
and the solution was stirred at rt for ~6 h under 
N2. Deprotection was monitored on TLC 
(H:AcOEt 1:10). The solvent was removed under 
reduced pressure freezing it out in a cooling trap. 
The oily residue was dissolved in MeOH, mixed 
with Amberlyst-A26 in its Cl--form and stirred 
overnight, filtered and dried again in rv and hv. The 
crude 142, isolated as colourless foam, was directly 
used for peptide bond formation. 
 
8.1.3.6 Synthesis of Boc-[TDAP(NTs)]4-OMe 
(53) 
 
   321 µmol of 141 (1 equiv.) were dissolved in 20 ml dry DMF (solv. syst.) and 106 µl 
of NMM (963 µmol, 3 equiv.) were added.  
   231 µmol of 142 (1 equiv.) were dissolved in 20 ml dry DMF (solv. syst.) and 106 µl 
of NMM (963 µmol, 3 equiv.) were added.  
   251 mg of PyBOP (482 µmol, 1.5 equiv.) were added to the solution of 141. One 
minute later the solution of 142 was added to the solution of 141. The mixture was 
stirred under N2 at rt overnight. Reaction was monitored on TLC (H:AcOEt 1:10).  
The solvent was then partially removed in rv, the remaining oily substance diluted 
with AcOEt, washed once with 0.1 M citric acid, once with sat. NaHCO3 and once 
with brine. All aq. layers were back extracted with AcOEt, the comb. org. layers were 
dried over MgSO4, filtered and solvent was removed in rv. The isolated crude 53 was 
adsorbed at SiO2 and chromatographically purified on SiO2 (H:AcOEt 1:5 to 1:8). 335 
mg pure Boc-[TDAP(NTs)]4-OMe (53, 235 µmol, 73%) were isolated as a colourless 
foam. 
 
Rf(H/AcOEt 1:10): 0.3 
IR (KBr): 3324s; 2928m; 
1718s; 1663s; 1598m; 
1538s; 1495s; 1453m; 
1368m; 1327s; 1247s; 
1158s; 1093s; 1018w; 
815m; 760m; 706m; 
663m; 551s. 
 
1H-NMR (300 MHz, DMSO): 9.01 – 8.93 (m, 3 H, Amide-NH); 8.45; 8.27; 8.25; 8.24 
(4 s, Thiazole-CH); 7.97 – 7.94 (m, 3 H, Ts-NH); 7.77 (t, 3J = 6.1, 1 H, Ts-NH); 7.69 – 
7.64 (m, 8 H, Ts-o-CH); 7.60 (d, 3J = 7.6, 1 H, Carbamate-NH); 7.36 – 7.26 (m, 8 H, 
Ts-m-CH); 5.45 – 5.41 (m, 3 H, NCH); 4.91 (br. s, 1 H, NCH); 3.83 (s, 3 H, OCH3); 
3.67 – 3.58; 3.55 – 3.38; 3.27 – 3.16 (3 m, 8 H, 4 NCH2); 2.36; 2.33; 2.31; 2.30 (4 s, 
12 H, 4 Ts-CH3); 1.41 (s, 9 H, OC(CH3)3).  
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13C-NMR (100 MHz, DMSO): 172.32; 170.87; 170.73 (3 s, 4 C, Thiazole-NCS); 
161.08; 160.58; 160.46 (3 s, 4 C, COOMe, 3 CONH); 155.09 (s, 1 C, Carbamat-CO); 
148.76; 148.63; 148.60; 145.37 (4 s, 4 C, Thiazole-C4); 142.76; 142.66; 142.63 (3 s, 
4 C, Ts-C-Me); 137.60; 137.31 (2 s, 4 C, Ts-C-S); 129.61; 129.54 (2 d, 8 C, Ts-o-
CH); 126.50; 126.42 (2 d, 8 C, Ts-m-CH); 125.52; 125.33 (2 d, 4 C, Thiazole-CH); 
78.91 (s, 1 C, OCMe3); 52.95 (d, 1 C, NCH); 51.99 (q, 1 C, OCH3); 51.67; 51.51 (2 d, 
3 C, NCH); 45.49; 45.17; 44.95 (3 t, 4 C, NCH2); 28.11 (q, 3 C, OC(CH3)3); 20.94; 
20.90 (2 q, 4 C, Ts-CH3). 
 
MS (ESI, MeOH + NaI): 1447.4 (100, [M + Na]+); 1347.1 (6, [M – CO2CMe3 + H + 
Na]+). 
 
8.1.4 Macrolactamization to 58 
 
8.1.4.1 Synthesis of 143 
 
   328 mg of 53 (230 µmol) were dissolved in 40 ml hot MeOH (puriss. p.a.) and 33 
mg of LiOH (1.4 mmol, 6 equiv.), dissolved in 20 ml H2O, were added (c = 4 mM). 
The reaction was monitored on TLC (H:AcOEt 1:10) or better with HPLC. A part of 
the solvent was removed in rv, the remaining suspension was diluted with AcOEt, 
washed with 0.1 M citric acid and 0.1 M citric acid in brine. The org. layers were dried 
over MgSO4, filtered and the solvent was removed in rv. The crude material 143 was 
isolated as a colourless solid and directly submitted to deprotection on the N-
terminus. 
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8.1.4.2 Synthesis of 57 
 
   Material 143 was dissolved in a mixture of 10 ml CH2Cl2 (puriss. p.a.) and TFA. The 
solution was stirred at rt under N2. Reaction was monitored by HPLC. Completion 
was observed after about 5 h. The solvent was removed under reduced pressure, 
freezing it out in a cooling trap. The oily residue was dissolved in MeOH and some of 
the anion exchange resin Amberlyst-A26 in its Cl--form was added. The mixture was 
stirred overnight, the resin was then filtered off and the solvent removed in rv an hv. 
The crude product 106, a yellowish foam, was directly used for macrolactamisation. 
 
8.1.4.3 Synthesis of 58 
 
   230 µmol of 57 were dissolved in 150 ml DMF (solv. syst., c = 1.5 mM). 0.25 ml of 
NMM (2.3 mmol, 10 equiv.) and 599 mg of PyBOP (1.15 mmol, 5 equiv.) were added 
and the solution was stirred at rt under N2 overnight. Reaction was monitored on TLC 
(CHCl3:MeOH 10:1) or better with HPLC. The solvent was partially removed, the 
remaining oil diluted with AcOEt, washed with 0.1 M citric acid and brine. All aq. 
layers were back extracted with AcOEt, the comb. org. layers were dried over 
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MgSO4, filtered and the solvent removed in rv. The crude material was adsorbed at 
SiO2 and chromatographically purified on SiO2 (AcOEt:MeOH 15:1) .  
126 mg of the pure and colourless solid (3S,11S,19S,27S) 3,11,19,27-
tetra[(tosylamino)methyl]-1,9,17,25-tetroxo-2,10,18,26-tetraza[3.4](2,4)1,3-
thiazolophan (58) (97 µmol, 42%) were isolated.  
 
135 mg of a slightly less polar substance also showing nicely the right mass signal 
but a 1H-NMR spectrum with some additional signals in the aromatic region were 
isolated. It seems to be a mixture of diastereoisomers. 
 
Melting temperature: solidified foam, 132.2 – 132.6°C 
Rf(AcOEt/MeOH 10:1): 0.35 
IR (KBr): 3851w; 3747w; 3710w; 3448s; 2926m; 2864m; 1659s; 1542s; 1496s; 
1454m; 1442m; 1384m; 1323s; 1256m; 1202w; 1158s; 1093s; 1071m; 1051m; 
1039m; 1017m; 919w; 811m; 756m; 660s; 562s; 552s. 
 
1H-NMR (300 MHz, DMSO): 8.43 (br. d, 3J = 
8.0, 4 H, Amide-NH); 8.29 (s, 4 H, Thiazole-
CH); 7.86 (br. t, 3J = 6.1, 4 H, Ts-NH); 7.67 
(d, 3J = 8.2, 8 H, Ts-o-CH); 7.29 (d, 3J = 8.2, 
8 H, Ts-m-CH); 5.41 – 5.39 (m, 4 H, NCH); 
3.51 – 3.33 (m, 8 H, 4 NCH2); 2.33 (s, 12 H, 
4 Ts-CH3).  
 
13C-NMR (100 MHz, DMSO): 167.20 (s, 4 C, 
Thiazole-CNS); 159.72 (s, 4 C, Amide-CO); 
147.65 (s, 4 C, Thiazole-C4); 142.97 (s, 4 C, 
Ts-C-Me); 137.36 (s, 4 C, Ts-C-S); 129.75 
(d, 8 C, Ts-o-CH); 126.46 (d, 8 C, Ts-m-
CH); 126.24 (d, 4 C, Thiazole-CH); 49.61 (d, 
4 C, NCH); 44.84 (t, 4 C, NCH2); 21.00 (q, 4 
C, Ts-CH3). 
 
MS (ESI, MeOH + NH4-Acetate): 1315.3 (100, [M + Na]+); 1293.3 (45, [M + H]+); 
1222.4 (33, [M – NH2Ts + H]+); 951.3 (12, [M – 2 NH2Ts + H]+); 839.3 (7); 575.2 (10). 
 
8.1.5 Investigations towards the synthesis of imidazole units 
 
8.1.5.1 Reactions using model compounds 
 
8.1.5.1.1 Reactions using 63 
 
a. Synthesis of aldehyde 67 
   1.02 g of 63 (4.00 mmol) were suspended in 50 ml CH2Cl2 (puriss. p.a.) and cooled 
down to 0°C. 2.01 g of 97% Dess-Martin reagent (4.6 0 mmol, 1.15 equiv.) were 
added and the suspension was stirred overnight under N2 slowly warming up to rt. 
Completion of the reaction was monitored on TLC (H:AcOEt 2:1). CH2Cl2 was 
removed by rv, the remaining oil diluted with AcOEt, washed once with 0.1 M citric 
acid, twice with sat. NaHCO3 and once with brine. All aq. layers were back extracted 
with AcOEt, the comb. org. layers dried over MgSO4, filtered and dried in rv. The 
1.254 g crude material were recrystallized from H:AcOEt 5:8. 616 mg (2.43 mmol, 
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61%) of the pure product N-(1-oxo-3-phenylpropan-2-yl)benzamide (67) could be 
isolated. 
 
Rf(H/AcOEt 1:1): 0.8; Rf(H/AcOEt 1:1): 0.4  
 
1H-NMR (300 MHz, CDCl3): 9.72 (s, 1 H, CHO); 7.74 – 7.71 (m, 
2 H, arom. CH); 7.54 – 7.17 (m, 8 H, arom. CH); 6.75 (br. d, 1 
H, NH); 4.91 (app. q, 3J = 6.4, 1 H, NCH); 3.33 (dd, 2J = 14.0, 3J 
= 6.0, 1 H, CH2Ph); 3.26 (dd, 2J = 14.0, 3J = 6.7, 1 H, CH2Ph).  
 
13C-NMR (75.5 MHz, CDCl3): 198.77 (d, 1 C, CHO); 167.33 (s, 1 C, CONH); 135.60; 
133.65 (2 s, 2 C, arom. C); 131.95; 129.40; 128.86; 128.69; 127.26; 127.06 (6 d, 10 
C, arom. CH); 60.16 (d, 1 C, NCH); 35.19 (t, 1 C, CH2Ph). 
 
MS (ESI, CH2Cl2/MeOH 1:3 + NaI): 308.2 (100, [M + MeOH + Na]+); 276.1 (6, [M + 
Na]+). 
 
b. Reductive amination of 67 using tosylamine 
   127 mg of 67 (501 µmol) were dissolved in 15 ml MeOH (puriss. p.a.) and 86 mg of 
TsNH2 (502 µmol, 1 equiv.) were added and stirred at rt under N2. After 45 min, the 
solution was cooled down to 0°C and 35 mg of NaBCNH 3 (557 µmol, 1.1 equiv.) were 
added. The suspension was slowly let warm up to rt. TLC (H:AcOEt 2:1) shows a 
mixture of two substances with more or less the same Rf. Another equiv. of the 
reagents was added (86 mg TsNH2 and 35 mg NaBCNH3). The solution was heated 
up to 50°C for 30 min, solvent was then removed by rv, the remaining oil diluted with 
AcOEt, washed once with sat. NaHCO3 and twice with brine. The comb. aq. layers 
were dried over MgSO4, filtered and dried in rv. 302 mg of a mixture were isolated. 
Product 69 was detected in ESI-MS. 
 
MS (ESI, CH2Cl2/MeOH 1:4): 684.4 (11); 531.4 (53); 461.2 (56); 
431.3 (100, [M + Na]+); 429.2 (30); 308.1 (40); 278.2 (13, [M33 + 
Na]+); 276.2 (12). 
 
8.1.5.1.2 Reactions using 64 
 
a. Synthesis of the β-chloroamide 73 by chlorination of 64 
Method A: Using SOCl2 
   62 mg of 64 (0.28 mmol) were dissolved in 2 ml SOCl2 and 2 µl DMF were 
added[189, 236]. The solution was heated up to reflux overnight. Solvent was then 
removed under reduced pressure freezing it out in a cooling trap. The remaining 
material was directly used for the next step. 
 
Method B: Using LiCl and DAST 
   100 mg of 64 (448 µmol) were dissolved in 4 ml of a 0.5 M LiCl solution in DMF (86 
mg LiCl (2.03 mmol) dried at 100°C in hv for 2 h, 4  ml dry DMF (solv. syst.), c64 = 0.1 
M) and cooled down to 0°C in an ice bath. 88 µl of DAST (0.67 mmol, 1.5 equiv.) 
were added. The solution was let warm up to rt while stirring. The progress of the 
reaction was monitored on TLC (H:AcOEt 1:1). The solution was then diluted with 
AcOEt, washed with 0.1 M citric acid in brine, sat. NaHCO3 and brine. All aq. layers 
were back extracted with AcOEt, comb. org. layers dried over MgSO4, filtered and 
solvent removed in rv. The crude product was chromatographically purified on SiO2 
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(H:AcOEt 4:1 to 2:1). 82 mg of the pure methyl 2-(benzoylamino)-3-chloropropanoate 
73 (0.34 mmol, 76%) were isolated as a colourless oil. 
 
Rf(H/AcOEt 1:1): 0.32, Rf(H/AcOEt 3:1): 0.14 
 
1H-NMR (300 MHz, CDCl3): 7.86 – 7.83 (m, 2 H, arom. o-CH); 
7.58 – 7.45 (m, 3 H, arom. m-/p-CH); 7.02 (d, 3J = 6.0, 1 H, NH); 
5.21 (dt, 3J = 7.3, 3J = 3.0, 1 H, NCH); 4.10 (dd, 2J = 11.4, 3J = 
2.8, 1 H, CH2Cl); 4.04 (dd, 2J = 11.4, 3J = 3.1, 1 H, CH2Cl); 3.87 
(s, 3 H, OCH3).  
 
13C-NMR (75.5 MHz, CDCl3): 169.40 (s, 1 C, COOMe); 167.03 (s, 1 C, CON); 133.40 
(s, 1 C, arom. C); 132.09; 128.69; 127.17 (3 d, 5 C, arom. CH); 53.52 (d, 1 C, NCH); 
53.13 (q, 1 C, OCH3); 45.15(t, 1 C, CH2Cl). 
 
MS (ESI, MeOH + NaI): 316.1 (9); 264.0 (100, [M + Na]+); 246.0 (6); 227.9 (12, [M – 
HCl + Na]+). 
 
b. Substitiution of chloride by an amine 
b1. Using methylamine 
   15 mg of 73 (62 µmol) were dissolved in 1 ml DMF and 0.15 ml of the 8 M MeNH2-
solution were added (1.2 mmol, 20 equiv.). The solution was stirred at rt under N2. 
Progress was monitored on TLC (H:AcOEt 1:1, then CHCl3:MeOH 5:1). The solvent 
was removed and the product was purified on prep. TLC (CHCl3:MeOH 5:1). 5 mg 
methyl 2-(benzoylamino)-3-(methylamino)propanoate (76) (21 µmol, 34%) were 
isolated. 
 
Rf(CHCl3/MeOH 5:1): 0.23 
 
1H-NMR (300 MHz, CDCl3): 7.90 – 7.88 (m, 2 H, arom. CH); 7.58 
– 7.45 (m, 3 H, arom. CH); 4.87 (t, 3J = 5.9, 1 H, NCH); 3.80 (s, 3 
H, OCH3); 3.10 (dd, 3J = 5.6, 3J = 1.8, 2 H, CH2); 2.47 (s, 3 H, 
NCH3). 
 
b2. Using isopropylamine 
   40 mg of 73 (0.17 mmol) were dissolved in 8 ml DMF (solv. syst.) under N2 and 
cooled down to 0°C. 150 ml of isopropylamine (1.47 mmol, 10 equiv.) were added 
and the solution was let warm up to rt while stirring. The progress of the reaction was 
monitored on TLC (CHCl3:MeOH 5:1). The solvent was removed in rv, the remaining 
material dissolved in AcOEt, washed once with sat. NaHCO3, the aq. layer was back 
extracted, comb. org. layers dried over MgSO4, filtered and solvent removed in rv. 36 
mg of the quite pure methyl 2-(benzoylamino)-3-(isopropylamino)propanoate (77) 
(136 µmol, 82%) were isolated. 
 
Rf(CHCl3/MeOH 5:1): 0.42 
 
1H-NMR (300 MHz, CDCl3): 7.84 – 7.82 (m, 2 H, arom. o-CH); 
7.52 – 7.41 (m, 3 H, arom. p/m-CH); 7.28 (br. d, 3J = 5.8, 1 H, 
Amid-NH); 4.81 (dt, 3J(NH) = 7.3, 3J = 4.4, 1 H, NCHCO); 3.78 (s, 
3 H, OCH3); 3.18 (dd, 2J = 12.6, 3J = 4.4, 1 H, CH2); 3.03 (dd, 2J = 
12.6, 3J = 4.7, 1 H, CH2); 2.81 (sept, 3J = 6.2, 1 H, CHMe2); 1.37 
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(br. s, 1 H, NH); 1.05; 1.04 (2 d, 3J = 6.2, 6 H, C(CH3)2). 
 
13C-NMR (75.5 MHz, CDCl3): 172.12 (s, 1 C, COO); 167.06 (s, 1 C, CON); 133.86 (s, 
1 C, arom. C); 131.64 (d, 1 C, arom. p-CH); 128.49 (d, 2 C, arom. o-CH); 127.08 (d, 
2 C, arom. m-CH); 52.77 (d, 1 C, amid-NCH); 52.42 (q, 1 C, OCH3); 48.46 (d, 1 C, 
NCHMe2); 47.62 (t, 1 C, NCH2); 22.95; 22.89 (2 q, 2 C, 2 CH3). 
 
MS (ESI, MeOH +NaI): 287.1 (100, [M + Na]+); 265.1 (11, [M + H]+). 
 
c. Synthesis of oxazole 144 by dehydration  
   15 mg of 77 (57 µmol) were dissolved in 2 ml MeCN in a dry flask with dry reflux 
condenser under N2. 50 mg of P2O5 (352 µmol, 6 equiv.) were added and the 
suspension was heated to 60°C for 2 h. The progress  of the reaction was monitored 
on TLC (CHCl3:MeOH 5:1). The solution was then diluted with AcOEt, washed with 
sat. NaHCO3 and brine, the aq. layers were back extracted, the comb. org. layers 
dried over MgSO4, filtered and the solvent removed in rv. 13 mg of the quite pure 
oxazole 4-isopropylamino-5-methoxy-2-phenyl-1,3-oxazole (144) (53 µmol, 93%) 
were isolated. 
 
Rf(CHCl3/MeOH 5:1): 0.33 
 
1H-NMR (300 MHz, CDCl3): 7.93 – 7.90 (m, 2 H, arom. CH); 
7.45 – 7.38 (m, 3 H, arom. CH); 4.04 (s, 3 H, OCH3); 3.69 (s, 2 
H, NCH2); 2.91 (sept, 3J = 6.3, 1 H, CHMe2); 2.35 (br. s, 1 H, 
NH); 1.13 (d, 3J = 6.3, 6 H, C(CH3)2). 
 
13C-NMR (75.5 MHz, CDCl3): 155.47; 152.36 (2 s, 2 C, Thiazole-C2 / -C5); 129.61; 
128.65 (2 d, 3 C, arom. CH); 127.65 (s, 1 C, arom. C); 125.45 (d, 2 C, arom. CH); 
114.90 (s, 1 C, Thiazole-C4); 60.84 (q, 1 C, OCH3); 47.77 (d, 1 C, NCH); 40.91 (t, 1 
C, NCH2); 22.50 (q, 2 C, i-Pr-CH3).  
 
MS (ESI, MeOH + 0.1% HCOOH): 269.0 (5, [M + Na]+); 247.0 (51, [M + H]+); 187.9 
(64); 159.9 (100); 130.0 (7); 103.0 (46). 
 
8.1.5.1.3 Reactions using 66 
 
a. Synthesis of 87 
   1.00 g of 1,2-bis-(diphenylphosphino)ethan (2.51 mmol) were dissolved in a 
separating funnel in 100 ml CH2Cl2 (tech.). 10 ml aqueous 35% H2O2 solution was 
added and the mixture was shaken till no more gas evolution was observed[202]. The 
process was monitored on TLC (CH2Cl2). The org. layer was collected, washed twice 
with H2O and the aqueous layers were back extracted. The remaining H2O2 was 
destroyed with catalytic MnO2, the comb. org. layers dried over MgSO4, filtered and 
solvent removed in rv. The crude product was recrystallized from toluene to furnish 
1.04 g (2.41 mmol, 96%) of the pure 1,1'-(1,2-ethanediyl)bis[1,1-diphenylphosphine 
oxide] (87). 
 
1H-NMR (300 MHz, CDCl3): 7.73 – 7.67 (m, 8 H, arom. CH); 
7.54 – 7.28 (m, 12 H, arom. CH); 2.52 (d, 3JP-H = 2.6, 4 H, 
CH2). 
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MS (ESI, MeOH + NaI): 453.2 (100, [M + Na]+).  
 
b. Kelly reaction for synthesis of imidazoline 85 
   84 mg of 87 (0.20 mmol, 1.5 equiv.) were dissolved in 3 ml dry CH2Cl2 (puriss. p.a. 
o.m.s.), cooled down to 0°C under N 2 and 30 µl of Tf2O (0.18 mmol, 1.5 equiv.) were 
added. Immediately a precipitate of the cyclic phosphoanhydride formed[182, 197, 202]. 
15 min later 50 mg of 66 (0.13 mmol) were added3. After 15 min everything had 
dissolved again indicating good conversion. The solution was stirred overnight. 
Completion of the conversion was monitored on TLC (H:AcOEt 1:3). The solution 
was diluted with CH2Cl2, washed once with sat. NaHCO3 and once with brine. Aq. 
layers were back extracted with CH2Cl2, comb. org. layers dried over MgSO4, filtered 
and the solvent removed in rv. 135 mg of a mixture with 87 and methyl S-2-(1,3-
thiazol-5-yl)-1-tosyl-1H-imidazoline-4-carboxylate (85) were isolated and directly 
used for the oxidation step. 
 
Rf(H/AcOEt 1:3): 0.1 
 
1H-NMR (300 MHz, CDCl3): 8.83 (d, 4J = 2.0, 1 H, NC2HS); 
8.04 (d, 4J = 2.0, 1 H, NC4HC); 7.70 (d, 3J = 8.2, 2 H, arom. o-
CH); 7.31 (d, 3J = 8.2, arom. m-CH); 4.65 (dd, 3J = 8.9, 3J = 
10.3, 1 H, NCH); 4.27 – 4.24 (m, 2 H, CH2); 3.72 (s, 3 H, 
OCH3); 2.43 (s, 3 H, Ts-CH3). 
 
MS (ESI, MeOH + NaI): 579.2 (27, [2 MPh3PO + Na]+); 406.1 (12, [M176 + Na]+); 388.1 
(100, [M + Na]+); 366.1 (6, [M + H]+); 301.1 (68, [MPh3PO + Na]+); 279.2 (12, [MPh3PO + 
H]+). 
 
c. Synthesis of the imidazole 145 
   135 mg of a mixture of 85 (max. 130 µmol) and 87 were dissolved in 5 ml CH2Cl2 
under N2 and cooled down to -10°C. 40 µl of DBU (0.26 mmol, 2 equiv.) and 20 µl of 
BrCCl3 (0.20 mmol, 1.5 equiv.) were added. The solution was slowly let warm up to rt 
while stirring. After 90 min TLC (H:AcOEt 1:2) monitored complete conversion. The 
solution was diluted with CH2Cl2, washed with 0.1 M citric acid, sat. NaHCO3 and 
brine, all aq. layers were back extracted with CH2Cl2, comb. org. layers dried over 
MgSO4, filtered and the solvent removed in rv. The 95 mg of crude product were 
further purified over SiO2 (H:AcOEt 1:1). 31 mg of the pure methyl 2-(1,3-thiazol-5-
yl)-1-tosyl-1H-imidazole-4-carboxylate (145) (85 µmol, 66% in two steps) could be 
isolated. 
 
Rf(H/AcOEt 1:2): 0.4 
 
1H-NMR (300 MHz, CDCl3): 8.81 (d, 4J = 2.3, 1 H, Thiazole-
C2H); 8.29 (s, 1 H, Imidazole-C5H); 7.97 (d, 4J = 2.3, 1 H, 
Thiazole-C5H); 7.93 (d, 3J = 8.3, 2 H, Ts-o-CH); 7.34 (d, 3J = 
8.3, Ts-m-CH); 3.92 (s, 3 H, OCH3); 2.44 (s, 3 H, Ts-CH3). 
 
                                            
3
 The reaction was also performed following the original Kelly protocol[182, 197] using 3 equiv. Ph3PO and 
1.5 equiv. Tf2O as described for the examples with 56 or 53 in section 8.1.5.1.4. 
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13C-NMR (75.5 MHz, CDCl3): 162.17 (s, 1 C, COOMe); 152.05 (d, 1 C, Thiazole-
C2H); 146.64; 144.39; 142.45; 134.20; 132.63 (5 s, Ts-i/p-C, Thiazole-C4, Imidazole-
C2/C4); 129.92 (d, 2 C, Ts-m-CH); 128.83 (d, 2 C, Ts-o-CH); 126.46 (d, 1 C, 
Imidazole-C5H); 122.68 (d, 1 C, Thiazole-C5H); 52.21 (q, 1 C, OCH3); 21.81 (q, 1 C, 
Ts-CH3). 
 
MS (ESI, MeOH + NaI): 386.1 (100, [M + Na]+); 364.2 (7, [M + H]+). 
 
d. Synthesis of the thioamide 84  
   40 mg of 66 (0.10 mmol) were dissolved in 2 ml pyridine (puriss. p.a. o.m.s.). 46 
mg of P2S5 (0.21 mmol, 2 equiv.) were added and the solution was heated up to 
reflux (oil bath at 150°C). After 2 h TLC (H:AcOEt 1:3) showed complete conversion. 
Solvent was removed under reduced pressure freezing it out in a cooling trap. The 
material was adsorbed at SiO2 and the substance chromatographically purified on 
SiO2 (H:AcOEt 2:1 to 1:1). 32 mg of the pure methyl 3-(tosylamino)-2-[(1,3-thiazol-5-
yl)thiocarbonyl]propanate (84) (80 µmol, 77%) were isolated. 
 
Rf(H/AcOEt 1:3): 0.6 
 
1H-NMR (300 MHz, CDCl3): 9.87 (d, 3J = 7.2, 1 H, Thioamide-NH); 
8.77 (d, 4J = 2.1, 1 H, Thiazol-C2H); 8.38 (d, 4J = 2.1, 1 H, Thiazol-
C4H); 7.70 (d, 3J = 8.2, 2 H, 2 arom. o-CH); 7.23 (d, 3J = 8.2, 2 H, 
2 arom. m-CH); 5.39 (dt, 3JNH = 7.6, 3JCH = 4.4, 1 H, CH); 5.31 (t, 
3J = 6.8, 1 H, Ts-NH); 3.80 (s, 3 H, OCH3); 3.72 (ddd, 2J = 13.9, 
3JNH = 6.5, 3JCH = 4.3, 1 H, CH2); 3.59 (ddd, 2J = 13.9, 3JNH = 7.1, 
3JCH = 4.5, 1 H, CH2); 2.38 (s, 3 H, Tosyl-CH3).  
 
13C-NMR (75.5 MHz, CDCl3): 187.55 (s, 1 C, CSNH); 169.61 (s, 1 C, COOMe); 
154.79 (s, 1 C, Thiazol-C5); 152.75 (d, 1 C, Thiazol-C2H); 143.89 (s, 1 arom. i-C); 
136.75 (s, 1 arom. p-C); 129.97; 129.90; 127.31; 126.66 (4 d, 4 arom. CH); 126.27 
(d, 1 C, Thiazol-C4H); 57.16 (q, 1 C, OCH3); 53.40 (d, 1 C, NCH); 43.65 (t, 1 C, 
NCH2); 21.73 (q, 1 C, Tosyl-CH3). 
 
MS (ESI, MeOH + NaI): 422.0 (100, [M + Na]+). 
 
e. Sulphur abstraction and formation of imidazoline 85 
   9 mg of 84 (0.02 mmol) were dissolved in 1 ml pyridine (puriss. p.a. o.m.s.). 6 mg 
of orange HgO (0.03 mmol, 1.2 equiv.) and 4 µl of Et3N (0.03 mmol, 1.2 equiv.) were 
added[196] and the suspension was heated up to 100°C for 2 h.  TLC (H:AcOEt 1:3) 
showed clean conversion. The suspension was diluted with AcOEt, washed twice 
with 0.1 M citric acid, once with sat. NaHCO3 and once with brine. All aq. layers were 
back extracted with AcOEt, comb. org. layers dried over MgSO4, filtered and solvent 
removed in rv. 8 mg of the quite clean product 85 (0.02 mmol, 96%) were isolated. 
 
f. Secundary protection of the β-tosylaminoamide 
   100 mg of 66 (261 µmol) were dissolved in 2 ml MeCN. 63 mg of Boc2O (0.29 
mmol, 1.1 equiv. and 5 mg of DMAP (0.04 mmol, cat. 0.1 equiv.) were added. The 
solution was stirred at rt under N2. After 4 h TLC (1:3) confirmed complete conversion 
to a single product. The solution was diluted with AcOEt, washed with 0.1 M citric 
acid, sat. NaHCO3 and brine. All aq. layers were back extracted with AcOEt, comb. 
org. layers were dried over MgSO4, filtered and solvent removed in rv. 126 mg of the 
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pure methyl 3-[(t-butyloxycarbonyl)tosylamino]-2-[(1,3-thiazol-5-yl) 
carbonyl]propanate (82) (261 µmol, 100%) could be isolated. 
 
Rf(H/AcOEt 1:3): 0.55 
 
1H-NMR (300 MHz, CDCl3): 8.78 (d, 4J = 2.0, 1 H, Thiazole-
C2H); 8.20 (br. d, 3J = 5.5, 1 H, NH); 8.19 (d, 4J = 2.0, 1 H, 
Thiazole-C5H); 7.78 (d, 3J = 8.3, 2 H, Ts-o-CH); 7.23 (d, 3J = 
8.3, 2 H, Ts-m-CH); 5.17 (dt, 3JCH2 = 7.8, 3JNH = 6.3, 1 H, 
NCH); 4.33 (dd, 2J = 1.8, 3JCH = 7.8, 2 H, CH2); 3.80 (s, 3 H, 
OCH3); 2.40 (s, 3 H, Ts-CH3); 1.34 (s, 9 H, OC(CH3)3). 
 
MS (ESI, MeOH + NaI): 606.2 (6, [M – H + Boc + Na]+); 506.2 (100, [M + Na]+); 406.1 
(92, [M – Boc + H + Na]+). 
 
8.1.5.1.4 Reactions using building blocks 56 and 53 
 
a. Synthesis of 81 
   In 1 ml dry (freshly distilled over CaH2) CH2Cl2 214 mg of Ph3PO (770 µmol, 6 
equiv) were dissolved and cooled down to 0°C in an ice bath. 64 µl of Tf2O (385 
µmol, 3 equiv.) were added and the solution was stirred under Ar for 10 min. 0.10 g 
of 56 (0.13 mmol, having two equiv reacting centers in the molecule) were added and 
the solution was further stirred under Ar, letting it warm up to rt. The reaction was 
monitored on TLC (H:AcOEt 1:10). The solution was then diluted with CH2Cl2, 
washed with dilute NaHCO3, the aq. layer back extracted with CH2Cl2, the comb. org. 
layers dried over MgSO4, filtered and solvent removed in rv. The crude material were 
dissolved in CH2Cl2, adsorbed on SiO2 and chromatographically purified on SiO2 with 
H:AcOEt 1:5. 51 mg (74 µmol, 58%) of the colourless solid 81 were isolated. 
 
Rf(H/AcOEt 1:10): 0.2  
 
1H-NMR (300 MHz, DMSO): 8.71 (br. s, 1 H, 
NH); 8.26 (t, 3J = 6.4, 1 H, NCH); 8.11; 7.87 
(2 s, 2 H, Thiazole-CH); 7.82 (d, 3J = 8.1, 2 H, 
Ts-CH); 7.63 (d, 3J = 8.0, 2 H, Ts-CH); 7.40 
(d, 3J = 8.2, 2 H, Ts-CH); 7.30 (2 d, 3J = 8.3, 2 
H, Ts-CH); 5.10 (dd, 2J = 4.1, 3J = 9.1, 1 H); 
4.31 (t, 3J = 9.1, 1 H); 4.07 (d, 3J = 6.3, 2 H, CH2); 3.91 (dd, 3J = 4.1, 2J = 9.4, 1 H); 
3.62 (s, 3 H, OCH3); 2.40; 2.33 (2 s, 6 H, Ts-CH3). 
 
MS (ESI, CHCl3/MeOH 3:1 + Na): 709.2 (100, [M + Na]+); 301.1 (74, [MPh3PO + Na]+). 
 
b. Synthesis of 88 
   In a dry 5 ml flask 141 mg of Ph3PO (507 µmol, 12 equiv.) were dissolved in 1 ml 
dry CH2Cl2 (puriss. p.a.) under N2 and the solution was cooled down to 0°C. 42 µl of 
Tf2O (255 µmol, 6 equiv.) were added. After 10 min a precipitate has formed. 60 mg 
of 53 (42 µmol) were added and after 5 min all substances have dissolved again. The 
solution was let warm up to rt while stirring. Reaction was monitored on TLC 
(H:AcOEt 1:10). After 2.5 h the solution was diluted with AcOEt, washed with 0.1 M 
citric acid and once with brine. All aq. layers were back extracted with AcOEt, comb. 
org. layers dried over MgSO4, filtered and the solvent removed in rv. The crude 
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material was further purified chromatographically on SiO2 (H:AcOEt 1:10 to pure 
AcOEt). 17 mg of the not completely pure product 88 (around 13 µmol, 31%) were 
isolated. 
 
Rf(H/AcOEt 1:10): 
0.15 
 
MS (ESI, 
MeOH/DMSO 9:1 + 
NaI): 1337.2 (30, [M + 
H2O + Na]+); 1319.2 (100, [M + Na]+); 1303.2 (20). 
 
8.1.5.2 Reactions on macrocycle 58 
 
8.1.5.2.1 Synthesis of tetrathioamide macrocycle 86 
 
   90 mg of 58 (70 µmol) were dissolved in 12 ml dry pyridine (puriss. p.a.) and 309 
mg of P2S5 (1.39 mmol, 4 x 5 equiv.) were added. The suspension was heated up to 
reflux (oil bath 150°C) for 5 h under N 2. The progress of the reaction was monitored 
on TLC (CHCl3:MeOH 6:1). The solvent was then removed under reduced pressure 
freezing it out in a cooling trap, the remaining material was suspended in a mixture of 
CHCl3 and MeOH, the solid component was filtered off, the dissolved one adsorbed 
at SiO2. Filtration over SiO2 (CH2Cl2:MeOH 25:1) yielded 24 mg of the quite pure 
(3S,11S,19S,27S) 3,11,19,27-tetra[(tosylamino)methyl]-1,9,17,25-tetrathio-2,10,18, 
26-tetraza[3.4](2,4)1,3-thiazolophan (86) (18 µmol, 26%). 
 
Rf(H/AcOEt 1:3): 0.6 
 
MS (ESI, MeOH + NaI): 1529.0 (5); 1379.1 
(100, [M + Na]+); 1196.1 (11). 
 
 
 
 
 
N
H
NO
SO2
S
N
N
N
S
N
SO2
N
N
S
N
SO2
N
N
S
N
SO2
O
O
88
86
S
N
S
N
S
N
S
N
HNNH
HNNH
S
S
S
S
HN
H
NNH
N
H
SO2
O2
S
S
O2
O2S
Synthetic Procedures and Analytic Data  Chapter II – 8.  
 
 - 126 / 181 - 
8.2 Target 2: [0.8](2,4)1,3-Thiazolophan (34) 
 
8.2.1 Synthesis of Boc-TSer(OBn)-OMe (rac-89) 
 
8.2.1.1 Synthesis of 39 
 
   See section 8.1.1.2. 
 
8.2.1.2 Synthesis of 91 
 
   2.93 g of 39 (9.94 mmol) were dissolved in ca. 100 ml CH2Cl2 (purum) under Ar. 
3.01 g of CaCO3 (30.1 mmol, 3 equiv.), 2.10 g of Et3OBF4 (11.0 mmol, 1.1 equiv.) 
were added and the suspension was stirred at rt. The reaction was monitored by TLC 
(H:AcOEt 1:1). After 9 h the solution containing intermediate 40 was filtered over 2 
cm SiO2 and diluted with CH2Cl2 to 200 ml. 
   1.89 g of cysteine hydrochloride methyl ester (11.0 mmol, 1.1 equiv.) were 
suspended in ca. 100 ml CH2Cl2 (puriss. p.a.) and 1.4 ml of Et3N (10 mmol, 1 equiv.) 
were added. The 200 ml solution containing 40 was added during 10 min and the 
suspension was stirred at rt overnight. The progress of the reaction was monitored 
on TLC (H:AcOEt 1:1). Suspension was then filtered to remove the precipitated 
NH4Cl and the solvent was removed in rv. The remaining oil was dissolved in TBME, 
washed twice with 0.1 M citric acid and once with brine. All aq. layers were back 
extracted with TBME and the comb. org. layers dried over MgSO4, filtered and 
solvent removed in rv. 3.20 g of the crude product 91 were isolated and 
chromatographically purified over SiO2 (H:AcOEt 4:1 to 2:1). 2.54 g (6.44 mmol, 
68%) of the pure methyl 2-{2-(benzyloxy)-1-[(tert-butoxycarbonyl)amino]ethyl}-
thiazoline-4-carboxylate (91) were isolated as colourless oil. 
 
Rf(Hexane/AcOEt 2:1): 0.26  
IR (film on NaCl): 3360m; 3063w; 3030w; 2977m; 2952m; 2932m; 2867m; 1742s; 
1716s; 1618m; 1496s; 1454s; 1437m; 1392m; 1366s; 1247s; 1201s; 1168s; 1104s; 
1047m; 1026s; 933w; 864w; 779w; 739m; 698m; 604w.  
 
1H-NMR (300 MHz, CDCl3): 7.34 – 7.26 (m, 5 H, arom. CH); 
5.52 (d, 3J = 6.8, 1 H, NHC); 5.11 (dd, 3Jcis = 9.5, 3Jtrans = 
1.8, 1 H, NCH); 4.72 (br. s, 1 H, Thiazoline-CH); 4.54 (s, 2 
H, CH2Ph); 3.85 (br. s, 1 H, trans-H, CH2); 3.79 (s, 3 H, 
OMe); 3.75 (dd, 3Jcis = 9.5, 2J = 4.3, 1 H, cis-H, CH2); 3.63 – 
3.47 (m, 2 H, Thiazoline-CH2); 1.45 (s, 9 H, t-Bu).  
 
13C-NMR (75.5 MHz, CDCl3): 176.41 (s, 1 C, Thiazoline-CNS); 171.03 (s, 1 C, 
COOMe); 155.14 (s, 1 C, Carbamat-CO); 137.69 (s, 1 C, arom. C); 128.39; 127.76; 
127.61 (3 d, 5 C, arom. CH); 80.08 (s, 1 C, OCMe3); 78.30 (d, 1 C, Thiazoline-CH); 
73.28; 70.98 (2 t, 2 C, 2 OCH2); 53.46 (d, 1 C, NCH); 52.77 (q, 1 C, OCH3); 35.23 (t, 
1 C, Thiazoline-CH2); 28.32 (q, 3 C, C(CH3)3). 
 
MS (ESI, MeOH/CHCl3 1:1 + NaI): 433.1 (4, [M + K]+); 417.2 (50, [M + Na]+); 395.2 
(100, [M + H]+); 339.2 (20, [M – CMe3 + 2 H]+); 287.1 (5, [M – O-Bn + 2 H]+); 231.0 
(4, [M – CMe3 – O-Bn + 3 H]+). 
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8.2.1.3 Synthesis of Boc-TSer(OBn)-OMe (89) 
 
   2.42 g of 91 (6.13 mmol) were dissolved in 100 ml CH2Cl2 (purum) and cooled 
down to 0°C. 1.86 ml of DBU (12.3 mmol, 2 equiv.) a nd 0.63 ml of BrCCl3 (6.39 
mmol, 1.05 equiv.) were added[182, 203] and the solution was stirred for 30 min at 0°C, 
then ice bath was removed. The reaction was monitored by TLC (H:AcOEt 2:1). After 
one hour the solvent was removed, the remaining oil dissolved in AcOEt, washed 
twice with 0.1 M citric acid, once with sat. NaHCO3 and once with brine. All aq. layers 
were back extracted with AcOEt, the comb. org. layers dried over MgSO4, filtered and 
dried in rv. 2.64 g of the crude 89 were purified over SiO2 (H:AcOEt 5:1 to 3:1). 2. 36 
g (6.03 mmol, 98%) of the pure methyl 2-{(rac)-2-(benzyloxy)-1-[(tert-
butoxycarbonyl)amino]ethyl}-1,3-thiazole-4-carboxylate (Boc-TSer(OBn)-OMe, 89) 
were isolated. 
 
Rf(H/AcOEt 2:1): 0.2 
IR (KBr): 3451m; 3238s; 3127m; 3061m; 2976m; 2927m; 2855m; 1741s; 1696s; 
1553s; 1498m; 1479m; 1453m; 1430m; 1415m; 1386m; 1364s; 1346m; 1296s; 
1274m; 1216s; 1171s; 1121s; 1101s; 1070m; 1048m; 1023m; 994m; 979m; 915w; 
903w; 891w; 869m; 831w; 820w; 809w; 785m; 761m; 735s; 713w; 697m; 666w; 
653w; 641w; 630w; 615m. 
 
1H-NMR (300 MHz, CDCl3): 8.12 (s, 1 H, Thiazole-H); 7.34 – 
7.19 (m, 5 H, arom. CH); 5.67 (br. s, 1 H, NH)); 5.20 (br. s, 1 
H, NCH); 4.52; 4.47 (2 d, 2J = 11.9, 2 H, OCH2Ph); 4.02 (br. 
s, 1 H, CH2); 3.94 (s, 3 H, OCH3); 3.86 (dd, 2J = 9.5, 3J = 
4.5, 1 H, CH2); 1.45 (s, 9 H, C(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 172.89 (s, 1 C, Thiazole NCS); 161.78 (s, 1 C, 
COOMe); 155.15 (s, 1 C, Carbamat-CO); 146.82 (s, 1 C, Thiazole-C); 137.34 (s, 1 C, 
arom. C); 128.38; 127.80; 127.69; 127.58 (d, 6 C, 5 arom. CH, Thiazole-CH); 80.38 
(s, OCMe3); 73.32; 71.39 (2 t, 2 C, CH2OCH2); 53.16 (d, 1 C, CH); 52.34 (q, 1 C, 
OCH3); 28.23 (q, 3 C, OC(CH3)3). 
 
MS (ESI, MeOH): 431.2 (5, [M + K]+); 415.3 (100, [M + Na]+); 359.2 (7, [M – C(CH3)3 
+ 2 H]+); 337.2 (14, [M – C(CH3)3 + H + Na]+); 293.2 (9, [M – COOC(CH3)3 + 2 H]+). 
 
X-ray crystallography: A nice crystal of 89, sufficient for x-ray analysis, could be 
obtained by slow evaporation of a mixture of CH2Cl2 and AcOEt. 
 
8.2.2 Synthesis of L-Boc-TSer(OAll)-OMe (90) 
 
8.2.2.1 Synthesis of 46 
 
   10.01 g of H-Ser-OMe.HCl (64.3 mmol) were suspended in ~150 ml freshly distilled 
CH2Cl2 in a fire dried flask under N2 and stirred mechanically. 20 ml of Et3N (0.14 
mol, 2.2 equiv) were added and the suspension was cooled down to 0°C in an ice 
bath. After around 30 min 15.50 g Boc2O (71.02 mmol, 1.1 equiv.) were added and 
the suspension was further stirred for at least 3 h or overnight[237]. The reaction was 
monitored by TLC (H:AcOEt 2:1) staining with ninhydrin. The suspension was then 
diluted with CH2Cl2, washed three times with 1 M NaHSO4, once with sat. NaHCO3 
and once with brine. All aq. layers were back extracted with CH2Cl2 and the comb. 
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org. layers dried over MgSO4, filtered and solvent removed in rv. 14.31 g (65.3 mmol, 
101%) pure L-Boc-Ser-OMe (46) were isolated. 
 
Rf(H/AcOEt 3:1): 0.06 
 
1H-NMR (300 MHz, CDCl3): 5.49 (br. s, 1 H, NH); 4.40 (br. s, 1 H, 
CH); 3.94 (dd, 2J = 10.1, 3J = 3.7, 2 H, CH2); 3.79 (s, 3 H, OCH3); 
1.45 (s, 9 H, C(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 171.20 (s, 1 C, COOCH3); 155.65 (s, 1 C, COON); 
80.26 (s, 1 C, OCMe3), 63.47 (t, 1 C, CH2), 55.60 (d, 1 C, CH); 52.56 (q, 1 C, OCH3); 
28.18 (q, 3 C, C(CH3)3). 
 
MS (MeOH + NaI): 461.0 (5); 342.1 (17, [M – H + COOCMe3 + Na]+); 298.1 (7); 
286.0 (15, [M + COOCMe3 – CMe3 + Na]+); 242.0 (100, [M + Na]+); 185.9 (26, [M – 
CMe3 + H + Na]+). 
 
8.2.2.2 Synthesis of 47 
 
   14.87 g of 46 (67.9 mmol) were dissolved in ~150 ml CH2Cl2 (purum) and cooled 
down to 0°C in an ice bath. 18.9 ml of Et 3N (136 mmol, 2 equiv.), 250 mg of DMAP 
(2.05 mmol, 3 mol%) and 9.6 ml of Ac2O (102 mmol, 1.5 equiv.) were added. The 
colourless solution was stirred under N2. After 15 min ice bath was removed and the 
solution was warmed up to rt. The reaction was monitored on TLC (H:AcOEt 2:1, 
staining with ninhydrin). After 90 min reaction was finished. The solution was diluted 
with CH2Cl2, washed once with 1 M NaHSO4, once with 0.1 M citric acid, once with 
sat. NaHCO3 and once with brine. All aqueous layers were back extracted with 
CH2Cl2, the comb. org. layers were dried over MgSO4, filtered and the solvent 
removed in rv. The 16.61 g of the slightly yellow oil 47 were distilled in “Kugelrohr 
oven” (first fraction (impurity): 15 mbar, 140-150°C, second (product): 15 mbar, 
~160°C) and 14.89 g (56.97 mmol, 84%) of the pure L -Boc-Ser(OAc)-OMe (47) were 
collected as a colourless oil. 
 
Rf(H/AcOEt 2:1): 0.30; Rf(H/AcOEt 3:1): 0.17 
 
1H-NMR (300 MHz, CDCl3): 5.30 (br. d, J = 4.6, 1 H, NH); 4.59 – 
4.56 (m, 1 H, CH); 4.44 (br. dd, 2J = 11.1, 3J = 3.7, 1 H, CH2); 4.33 
(dd, 2J = 11.1, 3J = 3.6, 1 H, CH2); 3.77 (s, 3 H, (CO)OCH3); 2.06 
(s, 3 H, (CO)CH3); 1.46 (s, 9 H, C(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 170.49; 170.30 (2 s, 2 C, 2 COO); 155.18 (s, 1 C, 
O(CO)NH); 80.36 (s, 1 C, OCMe3); 64.27 (t, 1 C, CH2O); 52.94 (d, 1 C, CH); 52.73 
(q, 1 C, (CO)OCH3); 28.30 (q, 1 C, OC(CH3)3); 20.67 (q, 1 C, (CO)CH3). 
 
MS (ESI, MeOH+ NaI): 284.1 (100, [M + Na]+), 228.0 (27, [M – C(CH3)3 + H + Na]+). 
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8.2.2.3 Synthesis of 92 
 
   8.50 g of Boc-Ser-OH (41.4 mmol) were dissolved in 60 ml dry DMF (solvent 
system). In another flask 4.14 g of the 60% NaH on paraffin (104 mmol, 2.5 equiv.) 
were mixed with 30 ml dry DMF (solvent system) and cooled down to 0°C. The 
solution of Boc-Ser-OH was slowly added through a dropping funnel. A vigorous 
evolution of H2 was observed. After complete addition, 3.5 ml of allylbromide (41 
mmol, 1 equiv.) were added. The solution was slowly let warm up to rt and stirred 
overnight[238]. The remaining NaH was then quenched by addition of some H2O, a 
part of the solvent was removed by rv, the remaining oily substance diluted with H2O 
and washed twice with hexane. The org. layers were back extracted with little 1 M 
NaOH, the comb. aq. layers acidified with 6 M HCl to pH 3 – 4 and extracted three 
times with AcOEt. The comb. AcOEt layers were washed once with 0.1 M aq. citric 
acid and once with 0.1 M citric acid in brine, dried over MgSO4, filtered and the 
solvent removed in rv. 9.44 g pure L-Boc-Ser(OAll)-OH (92) (38.5 mmol, 93%) were 
isolated. 
 
1H-NMR (300 MHz, CDCl3): 5.93 – 5.80 (m, 1 H, Allyl-CH); 5.40 
(br. d, 3J = 8.4, 1 H, NH); 5.30 – 5.19 (m, 2 H, Allyl-C=CH2); 
4.46 – 4.44 (m, 1 H, NCH); 4.02 (dt, 3J = 5.3, 4J = 1.0, 2 H, Allyl-
OCH2); 3.91 ( b. dd, 2J = 9.5, 3J = 3.4, 1 H, OCH2); 3.67 (dd, 2J 
=9.5, 3J = 3.9, 1 H, OCH2); 1.46 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 174.04 (s, 1 C, COOH); 155.72 (s, 1 C, Carbamat-CO); 
134.09 (d, 1 C, Allyl-CH); 117.50 (t, 1 C, Allyl-C=CH2); 80.11 (s, 1 C, OCMe3); 72.35; 
69.80 (2 t, 2 C, CH2OCH2); 53.86 (d, 1 C, NCH); 28.33 (q, 3 C, OC(CH3)3). 
 
8.2.2.4 Synthesis of 50 
 
   0.52 g of 47 (2.0 mmol) were dissolved in 5 ml dry CH2Cl2 (freshly distilled over 
CaH2). A mixture of 2.5 ml CH2Cl2 and 2.5 ml TFA was added and the solution was 
stirred at rt for 3 h under N2. Reaction was monitored on TLC (H:AcOEt 2:1, staining 
with ninhydrin). Solvent was then removed by rv, freezing it out in a cooling trap. The 
oily residue was dissolved in MeOH, mixed with Amberlyst in its Cl--form during 2 h, 
filtered and dried again in rv and hv. Amine 50 was directly used for peptide coupling. 
 
8.2.2.5 Synthesis of 93 
 
   2.40 g of 92 (9.77 mmol) were dissolved in 100 ml CH2Cl2. 2.2 ml of N-
methylmorpholine (19.5 mmol, 2 equiv.) and 3.12 g of TBTU (9.72 mmol, 1 equiv.) 
were added. 1 equiv. 50 (9.72 mmol, prepared as described above), dissolved in 100 
ml CH2Cl2 and 2.2 ml of NMM (19.5 mmol, 2 equiv.) were added. The mixture was 
stirred at rt under N2 for 5 h. The reaction was monitored on TLC (H:AcOEt 2:1). A 
part of the solvent was removed, the rest diluted with TBME, washed three times with 
aq. 0.1 M citric acid, once with sat. NaHCO3 and once with brine. All aq. layers were 
back extracted with TBME, the comb. org. layers dried over MgSO4, filtered and dried 
in rv. The isolated 4.11 g crude 93 were chromatographically purified on SiO2 
(hexane:AcOEt 2:1). 2.55 g pure Boc-Ser(OAll)-Ser(OAc)-OMe 93 (6.58 mmol, 67%) 
were isolated. 
 
Rf(H/AcOEt 2:1): 0.35 
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1H-NMR (300 MHz, CDCl3): 7.34 (br. s, 1 H, Amide-NH); 
5.96 – 5.83 (m, 1 H, Allyl-CH), 5.42 (br. s, 1 H, Carbamat-
NH); 5.32 – 5.18 (m, 2 H, Allyl-C=CH2); 4.86 – 4.81 (m, 1 H, 
N-terminal NCH); 4.46 (dd, 2J = 11.1, 3J = 3.8, 1 H, 
AcOCH2); 4.35 (dd, 2J = 11.4, 3J = 3.4, 1 H, AcOCH2); 4.29 
(br. s, 1 H, C-terminal NCH); 4.05 (br. d, 3J = 5.3, 2 H, Allyl-
OCH2); 3.86 (dd, 2J = 9.2, 3J = 3.8, 1 H, CH2OAll); 3.78 (s, 3 
H, OCH3); 3.54 (dd, 2J = 9.2, 3J= 7.4, 1 H, CH2OAll); 2.05 (s, 
3 H, (CO)CH3); 1.47 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 170.42; 170.26; 169.52 (3 s, 3 C, 3 COO); 155.92 (s, 1 
C, Carbamat-CO); 133.91 (d, 1 C, Allyl-CH); 117.46; 117.42 (2 t, 1 C, Allyl-CH2); 
80.25 (s, 1 C, OCMe3); 72.21; 72.16; 69.53; 69.32; 63.67; 63.54 (6 t, 3 C, 3 OCH2); 
53.67; 52.80 (2 d, 2 C, 2 NCH); 51.71 (q, 1 C, OCH3); 28.23 (q, 3 C, OC(CH3)3); 
20.60 (q, 1 C, (CO)CH3). 
The occurrence of doubled signals indicates the existence of diastereoisomers. 
Apparently at least one of the steregenic centers has racemised during the synthesis.  
 
MS (ESI, MeOH/CHCl3 1:1 + NaI): 451.2 (5); 411.2 (100, [M + Na]+). 
 
8.2.2.6 Synthesis of 94a and 94b (mixture) 
 
   2.54 g of 93 (6.55 mmol) were dissolved in 25 ml toluene (purum) and heated to 
125°C (reflux) under N 2. 1.32 g of Lawesson reagent (3.27 mmol, 0.5 equiv.) were 
added and the solution was stirred for two hours. Reaction was monitored on TLC 
(H:AcOEt 2:1)4. The solution was diluted with TBME, washed twice with 0.1 M aq. 
citric acid, twice with sat. NaHCO3 and once with brine. All aq. layers were back 
extracted with TBME, the comb. org. layers were dried over MgSO4, filtered and 
solvent was removed in rv. 3.33 g of the crude product was isolated as a yellowish, 
smelling oil. The oily substance was purified chromatographically on SiO2 (H:AcOEt 
3:1). 2.61 g of Boc-ThiaSer(OAll)-Ser(OAc)-OMe 94a (6.44 mmol, 98%) could be 
isolated. 
 
8.2.2.7 Synthesis of L-Boc-TSer(OAll)-OMe (90) 
 
   2.61 g of 94 (6.44 mmol) were dissolved in 100 ml CH2Cl2, 3.4 ml of DBU (23 
mmol, 3.5 equiv.) and 0.76 ml of BrCCl3 (7.7 mmol, 1.2 equiv.) were added and the 
solution was stirred at rt under N2 for 3 h. The reaction was monitored on TLC 
(H:AcOEt 2:1). A part of the solution was removed by rv, the remaining brown oil 
diluted with TBME, washed twice with 0.1 M citric acid, once with sat. NaHCO3 and 
once with brine. All aq. layers were back extracted with TBME, the comb. org. layers 
were dried over Na2SO4, filtered and solvent was removed in rv. 1.90 g (5.54 mmol, 
86%) of the crude product were isolated and chromatographically purified on SiO2 
(H:AcOEt 4:1). 1.61 g (4.70 mmol, 73%) of the pure methyl 2-{2S-2-(benzyloxy)-1-
[(tert-butoxycarbonyl)amino]ethyl}-thiazole-4-carboxylate (L-Boc-TSer(OAll)-OMe, 90) 
could be isolated. Oil 90 solidified after some days. 
 
Rf(H/AcOEt 2:1): 0.45 
                                            
4
 longer reaction time favours the evolution of the in principle desired oxazolidine 94b, the following 
oxidation reaction does not depend on nature of 94 and therefore normally mixtures of 94a and 94b 
were isolated and oxidized as such 
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1H-NMR (300 MHz, CDCl3): 8.12 (s, 1 H, Thiazole-CH); 5.88 
– 5.75 (m, 1 H, Allyl-CH); 5.68 (br. s, 1 H, NH); 5.24 – 5.13 
(m, 3 H, Allyl-C=CH2, NCH); 4.00 – 3.95 (m, 3 H, Allyl-O-
CH2, 1xOCH2); 3.94 (s, 3 H, OCH3); 3.81 (dd, 2J = 9.5, 3J = 
4.5, 1 H, OCH2); 1.46 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 172.94 (s, 1 C, Thiazole-CNS); 161.86 (s, 1 C, 
COOMe); 155.16 (s, 1 C, Carbamat-CO); 146.85 (s, 1 C, Thiazole-C); 133.90 (d, 1 C, 
Allyl-CH); 127.78 (d, 1 C, Thiazole-CH); 117.50 (t, 1 C, Allyl-C=CH2); 80.45 (s, 1 C, 
OCMe3)); 72.25; 71.35 (2 t, 2 C, CH2OCH2); 53.14 (d, 1 C, NCH); 52.43 (q, 1 C, 
OCH3); 28.30 (q, 3 C, OC(CH3)3). 
 
MS (ESI, MeOH/CHCl3 1:1 + NaI): 365.2 (100, [M + Na]+); 309.1 (6, [M – C(CH3)3 + H 
+ Na]+). 
 
8.2.3 Synthesis of tetramer Boc-[TSer(OBn)]4-OMe (95) 
 
8.2.3.1 Synthesis of 96 
 
   9.98 g of 89 (25.5 mmol) were dissolved in 100 ml MeOH at rt under N2. 3.67 g of 
LiOH (153 mmol, 6 equiv.) were dissolved in 50 ml H2O and added to the solution of 
89. The reaction was monitored on TLC (H:AcOEt 2:1). After completion a part of the 
solvent was removed in rv. The remaining solution was acidified with 1 M NaHSO4, 
whereas a colourless precipitate formed which was twice extracted with AcOEt. The 
org. layers were washed with 0.1 M citric acid in brine, then combined, dried over 
MgSO4, filtered and dried in rv and hv. The isolated acid 96 was directly used for 
peptide bond formation. 
 
1H-NMR (300 MHz, CDCl3): 9.80 (br. s, 1 H, OH); 8.23 (s, 1 
H, Thiazole-H); 7.34 – 7.21 (m, 5 H, arom. CH); 5.76 (br. d, 1 
H, NH); 5.24 (br. s, 1 H, NCH); 4.54; 4.49 (2 d, 2J = 12.2, 2 
H, OCH2Ph); 4.04 (br. s, 1 H, CH2); 3.86 (dd, 2J = 9.1, 3J = 
4.1, 1 H, CH2); 1.46 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 172.98 (s, 1 C, Thiazole NCS); 164.14 (s, 1 C, COOH); 
155.27 (s, 1 C, Carbamat-CO); 146.35 (s, 1 C, Thiazole-C); 137.29 (s, 1 C, arom. C); 
128.95; 127.46; 127.92; 127.69 (d, 6 C, Thiazole-CH, 5 arom. CH); 80.61 (s, 
OCMe3); 73.40; 71.28 (2 t, 2 C, CH2OCH2); 53.06 (d, 1 C, CH); 28.28 (q, 3 C, 
OC(CH3)3). 
 
MS (ESI, MeOH): 401.3 (100, [M + Na]+); 345.2 (15, [M – CMe3 + H + Na]+); 323.2 
(31, [M – CMe3 + 2 H]+); 320.2 (8); 301.3 (5, [M – CO2CMe3 + H + Na]+); 279.2 (20, 
[M – CO2CMe3 + 2 H]+); 150.1 (14). 
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8.2.3.2 Synthesis of 97 
 
   9.96 g of 89 (25.5 mmol) were dissolved in 45 ml CH2Cl2 at rt under N2 and 15 ml 
TFA were added. The reaction was monitored on TLC (H:AcOEt 2:1). The solvent 
was then removed under reduced pressure freezing it out in a cooling trap and the 
remaining oil dried in hv, then dissolved again in MeOH and stirred at rt under N2 for 
16 h over Amberlyst-A26 in it’s Cl--form. The solid was then removed by filtration and 
the solvent in rv and hv. The isolated 97 was directly used for peptide bond 
formation.  
 
MS (ESI, CH2Cl2/MeCN 1:3 + NaI): 315.1 (10, [M + Na]+); 293.2 
(100, [M + H]+). 
 
8.2.3.3 Synthesis of Boc-[TSer(OBn)]2-OMe (98) 
 
   25.45 mmol of 96 (directly form deprotection) were dissolved 
in 150 ml CH2Cl2 and 7.0 ml of NMM (62 mmol, 2.5 equiv.).  
   25.45 mmol of 97 (directly from deprotection) were dissolved in 150 ml CH2Cl2 and 
7.0 ml of NMM (62 mmol, 2.5 equiv.). 
   8.17 g of TBTU (25.4 mmol, 1 equiv.) and the solution of 97 were added to the 
solution of 96. The mixture was stirred at rt under N2. The reaction was monitored on 
TLC (H:AcOEt 1:1). After 16 h a part of the solvent was removed by rv, the remaining 
oil diluted with AcOEt, washed with 1 M NaHSO4, 0.1 M citric acid, sat. NaHCO3 and 
brine. All aq. layers were back extracted with AcOEt, the comb. org. layers dried over 
MgSO4, filtered and solvent removed in rv and hv. 16.83 g of the crude product were 
obtained and chromatographically purified on SiO2 (H:AcOEt 2:1, to 3:2 and 1:1). 
11.60 g Boc-[TSer(OBn)]2-OMe 98 (17.79 mmol, 70%) were isolated. 
 
Rf(H/AcOEt 1:1): 0.3 
[α]D20 (CHCl3): + 2.1 
IR (KBr): 3408s; 3114m; 3030m; 2927m; 2865m; 1717s; 1670s; 1536s; 1496s; 
1454s; 1384m; 1366s; 1324m; 1264s; 1214s; 1167s; 1100s; 1022s; 913w; 862w; 
826w; 805w; 752s; 698s; 607m; 518w; 499w; 
489w; 479w; 469w; 461w. 
 
1H-NMR (400 MHz, DMSO): Mixture of 
diastereoisomers: 9.19 – 8.89 (m, 1 H, Amid-
NH); 8.79; 8.51; 8.49; 8.48; 8.32 (5 s, 2 H, 
Thiazole-CH); 7.86 – 7.84 (m, 1 H, Carbamat-
NH); 7.34 – 7.26 (m, 10 H, arom. CH); 5.69 – 
5.70 (m, 1 H, NCH); 5.16 – 5.14 (m, 1 H, NCH); 4.61 – 4.52 (m, 4 H, OCH2Ph); 4.10 
– 3.95 (m, 3 H, 2 CH2); 3.84 (s, 3 H, OCH3); 3.84 – 3.81 (m, 1 H, CH2); 1.42 (s, 9 H, 
OC(CH3)3). 
 
1H-NMR (300 MHz, CDCl3): Mixture of diastereoisomers: 8.25 (br. d, 3J = 8.1, Amide-
NH); 8.12; 8.11; 8.09 (3 s, 2 H, Thiazole-CH); 7.33 – 7.19 (m, 10 H, arom. CH); 5.72 
– 5.66 (m, 2 H, 2 NCH); 5.18 (br. s, 1 H, Carbamate-NH); 4.56 – 4.45 (m, 4 H, 2 
OCH2Ph); 4.18 – 4.10 (m, 1 H, CH2); 3.99 – 3.95 (m, 2 H, CH2); 3.93; 3.93 (2 s, 3 H, 
OCH3); 3.88 (br. dd, 2J = 9.4, 3J = 4.3, CH2); 1.46 (s, 9 H, OC(CH3)3). 
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13C-NMR (75.5 MHz, CDCl3): 172.15; 171.16 (2 s, 2 C, 2 Thiazole-CNS); 161.76; 
160.95 (2 s, 2 C, COOMe, CONH); 155.21 (s, 1 C, Carbamate-CO); 149.02; 146.85 
(2 s, 2 C, Thiazole-C); 137.44; 137.37 (2 s, 2 C, 2 arom. C); 128.46; 128.42; 127.89; 
127.84; 127.81; 127.67; 127.62; 127.58 (8 d, 12 C, 10 arom. CH, 2 Thiazole CH); 
80.58 (s, 1 C, OCMe3); 73.46; 73.41; 73.35; 73.31; 71.34; 70.90 (6 t, 4 C, 2 
CH2OCH2); 53.09; 52.40 (2 d, 2 C, 2 NCH); 51.54 (q, 1 C, OCH3); 28.32 (q, 3 C, 
OC(CH3)3).  
 
MS (ESI, MeOH): 691.3 (24, [M + K]+); 675.4 (100, [M + Na]+); 653.4 (5, [M + H]+); 
597.3 (11, [M + - CMe3 + 2 H]+); 553.3 (8, [M + - CO2CMe3 + 2 H]+). 
MS (ESI, CH2Cl2/MeCN 1:3 + NaI): 675.4 (100, [M + Na]+). 
 
8.2.3.4 Synthesis of 146 
 
   0.42 g 98 (0.64 mmol) were dissolved in 20 ml MeOH and 89 mg of LiOH (3.7 
mmol, 6 equiv.), dissolved in 10 ml H2O, were added. The reaction was monitored on 
TLC (H:AcOEt 1:1). After 6 h a part of the solvent was removed by rv. The remaining 
solution was acidified with 0.1 M citric acid, whereas a colourless precipitate formed 
which was twice extracted with AcOEt. The org. layers were washed with 0.1 M citric 
acid in brine, combined, dried over MgSO4, filtered and solvent removed in rv and hv. 
The so isolated 146 was directly used for peptide bond formation. 
 
8.2.3.5 Synthesis of 147 
 
   0.40 g 98 (0.61 mmol) were dissolved in 15 ml 
CH2Cl2 under N2 and 15 ml TFA were added. 
Reaction was monitored on TLC (H:AcOEt 1:1). 
The solvent was then removed under reduced 
pressure freezing it out in a cooling trap and the remaining oil dried in hv. It was then 
dissolved in MeOH and stirred at rt under N2 for 16 h over Amberlyst-A26 in it’s Cl--
form, then filtered, dried in rv and hv. The obtained 147 was directly used for peptide 
bond formation. 
 
8.2.3.6 Synthesis of Boc-[TSer(OBn)]4-OMe 
(95) 
 
   0.64 mmol of 146 (1 equiv.), directly after 
deprotection as described above, were dissolved in 
25 ml DMF and 200 µl of NMM (1.82 mmol, 3 
equiv.) were added. pH was tested to be basic. 
   0.607 mmol of 147 (1 equiv.), directly after deprotection as described above, were 
dissolved in 25 ml DMF and 200 µl of NMM (1.82 mmol, 3 equiv.) were added. pH 
was tested to be basic. 
   470 mg of PyBOP (903 µmol, 1.5 equiv.) and the solution of 147 were added to the 
solution of 146. The suspension was stirred at rt under N2. The formation of product 
95 was monitored on TLC (H:AcOEt 1:3). When no more change was observed (after 
~16 h) a part of the solvent was removed by rv, the remaining one diluted with 
AcOEt, washed twice with 0.1 M citric acid, sat. NaHCO3 and brine. All aq. layers 
were back extracted with AcOEt, the comb. org. layers dried over MgSO4, filtered and 
dried in rv and hv. 1.01 g of the crude product were obtained, adsorbed at SiO2 and 
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purified over SiO2 (H:AcOEt 1:1 to 2:3 and 1:2). 0.52 g (0.45 mmol, 74%) Boc-
[TSer(OBn)]4-OMe (95) were isolated. 
 
Rf(H/AcOEt 1:3): 0.55; Rf(H/AcOEt 1:2): 0.35 
IR (KBr): 3926w; 3760m; 3361s; 3236s; 3121w; 3031w; 2921w; 2863w; 2029m; 
1775m; 1714s; 1635s; 1615s; 1572m; 1534s; 1490s; 1454m; 1391w; 1365m; 1245s; 
1215s; 1167s; 1100s; 1028s; 914w; 845w; 814w; 781w; 753m; 698m; 642s; 508m.  
 
1H-NMR (300 MHz, 
DMSO): Mixture of 
diastereoisomers: 8.97 
– 8.90 (m, 3 H, Amide-
NH); 8.48; 8.47; 8.35; 
8.35; 8.33 (5 s, 4 H, 
Thiazole-CH); 7.35 – 7.22 (m, 20 H, arom. CH); 5.70 – 5.60 (m, 4 H, NCH); 5.15 (br. 
d, 3J = 4.5, 1 H, Carbamat-NH); 4.58 – 4.54 (m, 8 H, 4 OCH2Ph); 4.16 – 3.93 (m, 7 H, 
4 CH2); 3.86 – 3.80 (m, 1 H, CH2); 3.84 (s, 3 H, OCH3); 1.42 (s, 9 H, OC(CH3)3). 
 
13C-NMR (100 MHz, DMSO): 171.14; 171.10; 170.92 (3 s, 4 C, 4 Thiazole NCS); 
161.19; 160.63; 160.60; 160.49 (4 s, 4 C, COOMe, 3 Amide-CO); 155.47 (s, 1 C, 
Carbamate-CO); 148.64; 145.49 (2 s, 4 C, Thiazole-C); 138.04; 137.91 (2 s, 4 C, 
arom. C); 129.51; 129.16; 128.29; 128.23; 127.57; 127.55; 127.52; 125.45; 125.31 (9 
d, 24 C, 20 arom. CH, 4 Thiazole-CH); 78.87 (s, 1 C, OCMe3); 72.23; 72.17; 71.14; 
70.56; 70.41 (5 t, 8 C, 4 CH2OCH2); 53.08 (d, 1 C, NCH); 52.03 (q, 1 C, OCH3); 
51.42; 51.38; 51.20 (3 d, 3 C, 3 NCH); 28.18 (q, 3 C, OC(CH3)3). 
 
MS (ESI, MeOH + NaI): 1195.6 (100, [M + Na]+). 
 
8.2.4 Macrolactamization to 60 
 
8.2.4.1 Synthesis of 100 
 
   0.17 g of 95 (0.15 mmol) were dissolved in 6 ml MeOH at rt. 18 mg of LiOH (0.77 
mmol, 5 equiv.) were dissolved in 2 ml H2O and added to the solution of 95. A part of 
the starting material precipitated again. The reaction was monitored on TLC 
(H:AcOEt 1:3) and in HPLC (reversed phase). After completion a part of the solvent 
was removed by rv. The remaining solution was acidified with 1 M NaHSO4, whereas 
a colourless precipitate forms which is twice extracted with AcOEt. The org. layers 
were washed with 0.1 M citric acid in brine, combined, dried over MgSO4, filtered and 
dried in rv and hv. The so isolated 100 was directly submitted to deprotection on the 
N-terminus. 
 
8.2.4.2 Synthesis of 101 
 
   0.15 mmol of 100 were dissolved in 6 ml CH2Cl2 under N2 at rt and 6 ml TFA were 
added. Reaction was monitored in HPLC (reversed phase). The solvent was 
removed under reduced pressure freezing it out in a cooling trap and the remaining 
oil was dried in hv. It was then dissolved in MeOH and stirred at rt under N2 for 16 h 
over Amberlyst-A26 in it’s Cl--form, then filtered, dried in rv and hv. 0.16 g 101 were 
isolated and directly used for macrolactamisation. 
 
O
O
N
H
O
S
N
O
N
H
O
S
N
O
N
H
O
S
N
O
N
H
O
S
N
O
O
95
Chapter II – 8.  Synthetic Procedures and Analytic Data 
  
 - 135 / 181 - 
8.2.4.2 Synthesis of 60 
 
   0.28 mmol of 101 were dissolved in 175 ml DMF (dry, solvent system, 
concentration of 1.5 mM), 300 µl of NMM (2.70 mmol, 10 equiv.) were added, the pH 
tested to be basic and 714 mg of PyBOP (1.37 mmol, 5 equiv.) were added. The 
solution was stirred at rt under N2. The evolution of product 60 was monitored on TLC 
(H:AcOEt 1:3) and HPLC (reversed phase). When no more change was observed a 
part of the solvent was removed by rv, the remaining oil diluted with AcOEt, washed 
twice with 0.1 M citric acid, sat. NaHCO3 and brine. All aq. layers were back 
extracted with AcOEt, the comb. org. layers dried over MgSO4, filtered and dried in rv 
and hv. The crude product was adsorbed at SiO2 and chromatographically purified on 
SiO2 (H:AcOEt 1:1 to 1:2 and 1:2). 154 mg (148 µmol, 54%) 3,11,19,27-
tetra[(benzyloxy)mehtyl]-1,9,17,25-tetroxo-2,10,18,26-tetraza[3.4](2,4)1,3-
thiazolophan (60) could be isolated. 
 
Melting temperature: solidified foam, 124.3 – 126.9°C 
Rf(H/AcOEt 1:5): 0.4 
IR (KBr): 3934w; 3892w; 3876w; 3859w; 3844w; 3826w; 3808w; 3761w; 3717m; 
3695m; 3681m; 3655m; 3413s; 3236s; 3031w; 2921w; 2860w; 2030m; 1640s; 
1615s; 1538s; 1493s; 1453m; 1363m; 1247s; 1155s; 1106s; 1028m; 913w; 847m; 
750m; 698m; 627s; 491m. 
 
1H-NMR (300 MHz, DMSO + 1 Tr MeOD): 
Mixture of diastereoisomers: 8.40; 8.38; 8.36; 
8.35; 8.34; 8.29; 8.26 (7 s, 4 H, Thiazole-CH); 
7.30 – 7.14 (m, 20 H, arom. CH); 5.71 – 5.53 (m, 
4 H, NCH); 4.57 – 4.45 (m, 8 H, 4 OCH2Ph); 
4.06 – 3.82 (m, 8 H, 4 CH2). 
 
13C-NMR (75.5 MHz, CDCl3): 168.60; 168.10; 
168.05; 167.91; 167.89; 167.80; 167.65 (7 s, 4 
C, 4 Thiazole-NCS); 160.06; 160.02; 159.91; 
159.86; 159.72; 159.67 (6 s, 4 C, 4 Amide-CO); 
148.35; 148.30; 148.08; 148.05; 147.89; 147.65; 
147.42 (7 s, 4 C, 4 Thiazole-C); 138.00; 137.89; 
137.80; 137.72; 137.66; 137.63; 137.58 (7 s, 4 
C, 4 arom. C); 128.24; 128.20; 128.14; 128.04; 127.67; 127.59; 127.56; 127.49; 
127.44; 127.35; 127.30; 127.26; 126.65; 126.52; 125.80; 125.50; 125.02 (17 d, 24 C, 
20 arom. CH, 4 Thiazole-CH); 72.33; 72.25; 72.14; 72.04; 71.98 (2 t, 4 C, 4 
OCH2Ph); 70.78; 70.70; 70.54; 70.05; 69.72; 69.55 (6 t, 4 C, 4 CH2); 51.23; 50.79; 
50.43; 49.92; 49.41; 49.27; 48.51 (7 d, 4 C, 4 NCH). 
 
MS (ESI, MeOH + NaI): 1213.1 (5); 1063.4 (100, [M + Na]+). 
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8.2.5 Investigations towards the synthesis of thiazole units 
 
8.2.5.1 Reactions using model compounds 
 
8.2.5.1.1 Reactions using 63 
 
a. Benzylation of 63 to synthesize 102 
   0.50 g of 63 (1.97 mmol) were suspended in 20 ml dry DME (solvent system) and 
178 mg of NaH (55-65% on parafin, ~4.5 mmol, 2.2 equiv.) were added under N2. 
250 µl of benzylchloride (2.17 mmol, 1 equiv.) were added. After four hours, the 
suspension was heated up to 100°C. Completion of th e reaction could be monitored 
on TLC (H:AcOEt 1:1). The solution was then diluted with TBME, washed once with 1 
M NaHSO4, once with 0.1 M citric acid, once with sat. NaHCO3 and once with brine. 
All aq. layers were back extracted with TBME, the comb. org. layers dried over 
MgSO4, filtered and solvent removed in rv and v. The product was filtered over SiO2, 
first washing out the parafin with H:AcOEt 4:1, then product 102 with H:AcOEt 1:1. 
The product was recrystallized from hot H:AcOEt 3:1. 252 mg (730 µmol, 37%) of the 
pure colourless crystalline N-(1-benzyloxy-3-phenylpropan-2-yl)benzamide (102) 
were isolated.  
 
Rf(H/AcOEt 5:1): 0.10 
 
1H-NMR (300 MHz, CDCl3): 7.71 – 7.69; 7.51 – 7.16 (2 m, 15 
arom. CH); 6.49 (br. d, 3J = 8.2, 1 H, NH); 4.52 (d, 3J = 2.3, 2 H, 
OCH2Ph); 4.51 – 4.45 (m, 1 H, NCH); 3.5 (d, 3J = 3.6, 2 H, 
OCHC); 3.05 (dd, 2J = 13.4, 3J = 6.1, 1 H, CCH2Ph); 2.97 (dd, 2J 
= 13.4, 3J = 8.5, 1 H, CCH2Ph). 
 
13C-NMR (75.5 MHz, CDCl3): 167.00 (s, 1 C, CONH); 138.16; 
138.13; 134.87 (3 s, 3 C, arom. C); 131.55; 129.61; 128.66; 128.63; 128.05; 128.03; 
127.06; 126.64 (8 d, 15 C, arom. CH); 73.48 (t, 1 C, OCH2Ph); 69.79  (t, 1 C, 
OCH2C); 50.91 (d, 1 C, NCH); 37.67 (t, CCH2Ph).  
 
MS (ESI, MeOH / CH2Cl2 3:1 + NaI): 368.2 (100, [M + Na]+). 
 
b. Debenzylation of 102 to synthesize 63 
   20 mg of 102 (58 µmol) were dissolved in 2 ml CH2Cl2 (puriss.), 47 ml of anisole 
(430 µmol, 7.5 equiv.) and 47 µg of AlCl3 (anhydrous, 50 µmol, 6 equiv.) were added. 
The mixture was stirred overnight under N2 at rt. The conversion was monitored on 
TLC (H:AcOEt 1:1). The solution was diluted with AcOEt, washed twice with 0.1 M 
citric acid, once with sat. NaHCO3 and once with brine. All aq. layers were back 
extracted, comb. org. layers dried over MgSO4, filtered and solvent removed in rv and 
hv. 9.0 mg 63 (35 mmol, 60%) were isolated. 
 
c. Synthesis of 148 by acetylation 
   255 mg of 63 (1.00 mmol) were dissolved in 2.5 ml pyridine and cooled down to 
0°C. 0.24 ml of Ac 2O (2.5 mmol, 2.5 equiv.) were added and the mixture was stirred 
under N2 for 5 h, slowly warming up to rt. The reaction was monitored on TLC 
(H:AcOEt 1:1). The rest of Ac2O was quenched with MeOH and 1 M aq. HCl. A 
colourless precipitate formed, which was extracted with TBME. The org. layers were 
washed three times with 1 M HCl, once with H2O and once with brine. The comb. org. 
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layers were dried over MgSO4, filtered and dried in rv. 284 mg (955 µmol, 96%) of 
the pure N-(1-acetoxy-3-phenylpropan-2-yl)benzamide (148) were isolated as a 
colourless solid. 
 
Rf(H/AcOEt 1:1): 0.7 
 
1H-NMR (300 MHz, CDCl3): 7.73 – 7.21 (m, 10 H, arom. CH); 
6.38 (br. d, 3J = 7.9, 1 H, NH); 4.64 – 4.60 (m, 1 H, NCH); 4.34 
(dd, 2J = 11.5, 3J = 5.9, 1 H, OCH2); 4.14 (dd, 2J = 11.5, 3J = 
4.2, 1 H, OCH2); 3.06 (dd, 2J = 13.7, 3J = 5.9, 1 H, CH2Ph); 2.90 
(dd, 2J = 13.7, 3J = 7.9, 1 H, CH2Ph); 2.09 (s, 3 H, (CO)CH3). 
 
13C-NMR (75.5 MHz, CDCl3): 171.31 (s, 1 C, COO); 166.93 (s, 1 C, CONH); 136.85; 
134.26 (2 s, 2 C, arom. C); 131.46; 129.20; 128.59; 128.51; 126.75 (5 d, 10 C, arom. 
CH); 64.74 (t, 1 C, OCH2); 50.24 (d, 1 C, NCH); 37.42 (t, 1 C, CH2Ph); 20.74 (q, 1 C, 
CH3). 
 
MS (CHCl3 / MeOH 4:6 + NaI): 320.1 (100, [M + Na]+); 260.0 (3, [M – AcOH + Na]+); 
238.0 (3, [M – AcOH + H]+). 
 
d. Synthesis of 149 by thionation 
   151 mg of 148 (508 µmol) were dissolved in 10 ml dry toluene (puriss. p.a.) in a dry 
flask. 123 mg of Lawesson reagent (304 mmol, 0.6 equiv.) were added and the 
mixture was heated to reflux for 150 min. The progress of the reaction was monitored 
on TLC (H:AcOEt 5:1). Toluene was then removed by rv and the remaining oily 
material chromatographically purified on SiO2 (H:AcOEt 8:1 to 5:1). 149 mg of the 3-
phenyl-2-(thiobenzoylamino)prop-1-yl acetate (149) (475 µmol, 94%) were isolated. 
 
Rf(H/AcOEt 5:1): 0.45 
 
1H-NMR (300 MHz, CDCl3): 7.97 (br. d, 3J = 6.4, 1 H, NH); 7.73 
– 7.24 (m, 10 H, arom. CH); 5.20 – 5.15 (m, 1 H, NCH); 4.33 
(dd, 2J = 11.9, 3J = 5.4, 1 H, OCH2); 4.26 (dd, 2J = 11.9, 3J = 
3.7, 1 H, OCH2); 3.28 (dd, 2J = 13.6, 3J = 5.2, 1 H, CH2Ph); 2.94 
(dd, 2J = 13.6, 3J = 8.8, 1 H, CH2Ph); 2.12 (s, 3 H, (CO)CH3). 
 
13C-NMR (75.5 MHz, CDCl3): 198.87 (s, 1 C, CSNH); 171.56 (s, 1 C, COO); 141.59; 
136.48 (2 s, 2 C, arom. C); 131.07; 129.17; 128.68; 128.44; 126.93; 126.56 (6 d, 10 
C, arom. CH); 63.97 (t, 1 C, OCH2); 56.40 (d, 1 C, NCH); 35.66 (t, 1 C, CH2Ph); 
20.75 (q, 1 C, CH3). 
 
MS (ESI, MeOH): 336.2 (5, [M + Na]+); 314.2 (13, [M + H]+); 272.1 (5); 254.1 (100, [M 
– CH3CO2H + H]+). 
 
e. Oxazolin opening using H2S to synthesize β-hydroxythioamide 110 
   1.4 ml of Et3N (10 mmol, 10 equiv.), 1.20 g of Na2S.9H2O (5.00 mmol, 5 equiv.) and 
0.6 ml AcOH (10 mmol, 10 equiv.) were added to 5 ml cold MeOH under N2 flow. 225 
mg of 72 (948 µmol) were dissolved in another 5 ml MeOH and dropped into the 
solution of H2S. The mixture turned slightly yellow and was slowly let warm up to rt 
while stirring. The reaction was monitored on TLC (H:AcOEt 5:1). After 24 h no 
change was observed and 5 ml of Et3N were added. 4 d later the solution was diluted 
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with TBME, washed three times with sat. NaHCO3, once with 0.1 M citric acid, once 
with H2O and once with brine. All aq. layers were back extracted with TBME, the 
comb. org. layers dried over MgSO4, filtered and solvent removed by rv. 235 mg of 
the crude mixture were isolated and chromatographically purified on SiO2. 59% of the 
starting material 72 and 92 mg of pure 110 (0.34 mmol, 36%), identified by 13C-NMR 
with the characteristic thioamide-C at 198.92 ppm, were isolated.5 
 
8.2.5.1.2 Reactions using 106 
 
a. Synthesis of 107 by acetylation 
   1.00 g of 106 (2.43 mmol) were dissolved in 10 ml pyridine (puriss. p.a.) under N2. 
The solution was cooled down to 0°C and 570 µl of Ac2O (6.03 mmol, 2.5 equiv.) 
were added. The solution was stirred overnight, slowly warming up to rt. TLC 
(H:AcOEt 1:1) showed quantitative conversion. The solution was diluted with 100 ml 
1 M HCl, a colourless solid precipitated which was extracted with TBME. The org. 
layer was washed again twice with 1 M HCl, once with sat. NaHCO3 and once with 
brine. All aq. layers were back extracted with TBME. Comb. org. layers were dried 
over MgSO4, filtered and dried in rv. 984 mg crude product were recrystallized from 
EtOH. 715 mg (1.57 mmol, 65%) pure Boc-Cys(SBn)-Ser(OAc)-OMe (107) were 
isolated as a colourless solid. 
 
Rf(H/AcOEt 1:2): 0.20  
 
1H-NMR (300 MHz, CDCl3): 7.36 – 7.24 (m, 5 H, arom. CH); 
7.11 (br. d, 3J = 7.6, 1 H, Amide-NH); 5.29 (br. s, 1 H, 
Carbamat-NH); 4.80 (dt, 3J = 8.1, 3J = 3.8, 1 H, N-terminal 
NCH); 4.45 (dd, 2J = 11.4, 3J = 4.1, 1 H, OCH2); 4.36 (dd, 2J 
= 11.4, 3J = 3.3, 1 H, OCH2); 4.28 (br. d, 3J = 6.1, 1 H, C-
terminal NCH); 3.77 (s, 5 H, OCH3 & SCH2Ph); 2.88 (dd, 2J 
= 14.0, 3J = 5.9, 1 H, SCH2); 2.77 (dd, 2J = 14.0, 3J = 6.5, 1 
H, SCH2); 2.30 (s, 3 H, (CO)CH3); 1.46 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 170.57; 170.35; 169.30 (3 s, 3 C, 2 COO, 1 CONH); 
155.16 (s, 1 C, Carbamat OCONH); 137.69 (s, 1 C, arom. C); 128.90; 128.50 (2 d, 4 
C, arom. o-, m-CH); 127.15 (d, 1 C, arom. p-CH); 80.37 (s, 1 C, OCMe3); 63.43 (t, 1 
C, OCH2); 53.66; 52.74 (2 d, 2 C, NCH); 51.80 (q, 1 C, OCH3); 36.41; 33.52 (2 t, 2 C, 
CH2SCH2); 28.16 (q, 3 C, OC(CH3)3); 20.50 (q, 1 C, (CO)CH3). 
 
MS (ESI, CH2Cl2:MeOH 1:3 + NaI): 931.5 (10, [2 M + Na]+); 709.4 (6); 493.3 (17, [M 
+ K]+); 477.3 (100, [M + Na]+); 382.2 (10, [M – OCMe3]+); 355.2 (33, [M – CO2CMe3 + 
2 H]+); 338.2 (10). 
 
b. Synthesis of 108 by thionation 
   454 mg of 107 (1.00 mmol) were dissolved in 5 ml boiling toluene and 201 mg of 
Lawesson reagent (0.50 mmol, 0.5 equiv.) were added and the solution was refluxed 
for 2 h. The progress of the reaction was monitored on TLC (H:AcOEt 3:1), two 
products were formed. Toluene was partially removed, the remaining oil diluted with 
AcOEt, washed once with 0.1 M citric acid, once with sat. NaHCO3 and once with 
brine. All aq. layers were back extracted with AcOEt, comb. org. layers dried over 
                                            
5
 See more efficient procedure in section 8.2.5.1.3 a. 
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MgSO4, filtered and dried in rv. The 642 mg of the crude product were adsorbed at 
SiO2 and chromatographically purified on SiO2 (H:AcOEt 5:1 to 2:1). 9 mg of the pure 
thioamide 108a (0.02 mmol, 2%), 362 mg of the mixture and 186 mg of thiazoline 
108b (395 µmol, 40%) were isolated. 
 
108a: Rf(H/AcOEt 3:1): 0.7; Rf(H/AcOEt 4:1): 0.45 
108b: Rf(H/AcOEt 3:1): 0.5; Rf(H/AcOEt 4:1): 0.25  
 
108a: 1H-NMR (300 MHz, CDCl3): 8.70 (br. d, 3J = 6.8, 1 H, 
Thioamide-NH); 7.36 – 7.25 (m, 5 H, arom. CH); 5.37 (br. s, 
1 H, Carbamat-NH); 5.34 (dt, 3J = 7.2, 3J = 3.5, 1 H, N-
terminal NCH); 4.59 (dd, 2J = 11.7, 3J = 3.3, 1 H, OCH2); 
4.52 (dd, 2J = 11.7, 3J = 3.5, 1 H, OCH2); 4.51 (dd, 3J = 
13.3, 3J = 6.5, 1 H, C-terminal NCH); 3.80 (s, 3 H, OCH3); 
3.76 (s, 2 H, SCH2Ph); 2.94 (d, 2J = 6.2, 2 H, SCH2); 2.03 
(s, 3 H, (CO)CH3); 1.46 (s, 9 H, OC(CH3)3). 
 
MS (ESI, CH2Cl2:MeOH 1:3 + NaI): 509.2 (29, [Ma + K]+); 493.2 (100, [Ma + Na]+). 
 
c. Synthesis of thiazole 109  
   167 mg of 108b6 (407 µmol) were dissolved in 3 ml CH2Cl2 under N2 at rt. 123 µl of 
DBU (814 µmol, 2 equiv.) and 42 µl of BrCCl3 (427 µmol, 1.05 equiv.) were added. 
The solution was stirred for 1 h and turned dark. The completion of the reaction was 
monitored on TLC (H:AcOEt 4:1). The solution was diluted with TBME, washed twice 
with 0.1 M citric acid, once with sat. NaHCO3 and once with brine. All aq. layers were 
back extracted with TBME, the comb. org. layers dried over MgSO4, filtered and 
solvent removed in rv. 137 mg of the crude product were chromatographically 
purified on SiO2 (H:AcOEt 4:1, 3:1, 2:1). 112 mg pure methyl 2-{2S-2-
(benzylsulphanyl)-1-[(tert-butoxycarbonyl)amino]ethyl}-thiazole-4-carboxylate (L-Boc-
TCys(SBn)-Ome, 109) (274 µmol, 69%) were isolated as a slightly yellow oil. 
 
Rf(H/AcOEt 4:1): 0.35 
 
1H-NMR (300 MHz, CDCl3): 8.12 (s, 1 H, Thioazole-CH); 
7.33 – 7.23 (m, 5 H, arom. CH); 5.53 (br. s, 1 H, Carbamat-
NH); 5.20 (br d, 3J = 6.8, 1 H, NCH); 3.94 (s, 3 H, OCH3); 
3.59 (s, 2 H, SCH2Ph); 3.14 (dd, 2J = 13.9, 3J = 5.9, 1 H, 
SCH2); 3.02 (dd, 2J = 13.9, 3J = 6.0, 1 H, SCH2); 1.45 (s, 9 
H, OC(CH3)3). 
 
MS (ESI, CH2Cl2:MeOH 1:3 + NaI): 447.1 (4, [M + K]+); 431.1 (100, [M + Na]+). 
 
8.2.5.1.3 Reactions using 64 
 
a. Oxazolin opening using H2S to synthesize β-hydroxythioamide 111 
   50 mg of 75 (244 µmol) were dissolved in 2 ml MeOH and 2 ml of Et3N. During 20 
min H2S was bubbled through the solution at rt[210, 211]. Gas flow was then stopped 
and the solution was stirred at rt for 2 h. The progress of the reaction was monitored 
                                            
6
 It is also possible to use a mixture of 108a and 108b, the conversion to 109 is performing equally 
good. 
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on TLC (H:AcOEt 2:1). Solution was diluted with AcOEt, washed with 0.1 M citric 
acid, sat. NaHCO3 and brine. Aq. layers were back extracted with AcOEt, comb. org. 
layers dried over MgSO4, filtered and solvent removed in rv. 66 mg of the crude 
methyl 2-(thiobenzoylamino)-3-hydroxypropanoate (111) was obtained and directly 
converted into 113 usind DAST cyclisation and DBU, BrCCl3 oxidation. 
 
Rf(H/AcOEt 3:1): 0.45 
 
b. Synthesis of thiazoline 112 using 111  
   66 mg of crude material 111 (containing max. 244 µmol) were 
dissolved in 4 ml CH2Cl2 (puriss. p.a.) and cooled down to -10°C under N 2. 38 µl of 
DAST (0.29 mmol, 1.2 equiv.) were added. Reaction was monitored on TLC 
(H:AcOEt 3:1). After two hours another 9 µl of DAST (0.07 mmol, 0.3 equiv.) were 
added. 20 min later no more 111 was detected. The solution was diluted with CH2Cl2, 
washed with sat. NaHCO3 and brine, aq. layers were back extracted, comb. org. 
layers dried over MgSO4, filtered and solvent removed in rv. 57 mg of the crude 
methyl (4S)-2-phenyl-1,3-thiazoline-4-carboxylate (112) could be isolated and directly 
used for oxidation.  
 
c. Synthesis of thiazoline 112 using 64 
   41 mg of 64 (0.18 mmol) were dissolved in 2.5 ml dry pyridine and 82 mg of P2S5 
(0.37 mmol, 2 equiv.) were added[212]. The mixture was heated to reflux (oil bath 
150°C). According to TLC (H:AcOEt 1:1) conversion w as complete after 2 h. Solvent 
was removed under reduced pressure freezing it out in a cooling trap. The remaining 
oil was chromatographically purified on SiO2 (H:AcOEt 2:1) and 28 mg of the pure 
methyl (4S)-2-phenyl-1,3-thiazoline-4-carboxylate (112) (0.13 mmol, 69%) were 
isolated as a yellow oil. 
 
Rf(H/AcOEt 3:1): 0.55 
 
1H-NMR (300 MHz, CDCl3): 7.88 – 7.85 (m, 2 H, 2 arom. CH 
meta); 7.50 – 7.37 (m, 3 H, 3 arom. CH ortho, para); 5.29 (t, 3J = 
9.1, 1 H, N-CH); 3.83 (s, 3 H, OCH3); 3.69 (dd, 2J = 26.1, 3J = 
11.2, 1 H, SCH2); 3.66 (dd, 2J = 26.6, 3J = 11.2, 1 H, SCH2). 
 
13C-NMR (75.5 MHz, CDCl3): 171.53; 171.18 (2 s, COOMe & CNS); 132.87 (s, 1 
arom. C); 131.88 (d, 2 arom. CH(meta)); 128.82; 128.69 (2 d, 3 arom. CH(ortho, 
para)); 78.69 (d, 1 C, N-CH); 52.97 (q, 1 C, O-CH3); 35.57 (t, 1 C, S-CH2). 
 
MS (MeOH + NaI): 243.9 (100, [M + Na]+); 222.0 (5, [M + H]+). 
 
d. Synthesis of thiazole 113 by oxidation 
   53 mg of 112 (0.25 mmol) were dissolved in 4 ml CH2Cl2 (puriss. p.a.) and cooled 
in an ice bath to 0°C. 74 µl of DBU (0.49 mmol, 2 equiv.) and 29 µl of BrCCl3 (0.29 
mmol, 1.2 equiv.) were added. Solution was let warm up to rt while stirring under N2. 
After 2 h TLC (H:AcOEt 3:1) showed complete conversion. The solution was diluted 
with CH2Cl2, washed with 0.1 M citric acid, sat. NaHCO3 and brine. Aq. layers were 
back extracted with CH2Cl2, comb. org. layers dried over MgSO4, filtered and solvent 
removed in rv. The crude 113 was chromatographically purified on SiO2 (H:AcOEt 
5:1) and 37 mg of the pure methyl (4S)-2-phenyl-1,3-thiazole-4-carboxylate (113) 
(0.17 mmol, 69%) were isolated as a slightly yellow solid. 
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Rf(H/AcOEt 3:1): 0.55 
 
1H-NMR (300 MHz, CDCl3): 8.18 (s, 1 H, Thiazole-CH); 8.03 – 
7.99 (m, 2 H, 2 arom. m-CH); 7.50 – 7.37 (m, 3 H, 3 arom. o-/p-
CH); 3.99 (s, 3 H, OCH3). 
 
13C-NMR (75.5 MHz, CDCl3): 169.03 (s, 1 C, COO); 161.95 (s, 1 C, Thiazole-C2); 
147.68 (s, 1 C, Thiazole-C4); 132.72 (s, 1 C, arom. C); 130.76; 129.00; 127.36; 
126.98 (4 d, 6 C, 5 arom. CH, Thiazole-C5H); 52.52 (q, 1 C, OCH3). 
 
MS (MeOH + NaI): 241.9 (100, [M + Na]+). 
 
8.2.5.1.4  Reactions using 99 
 
a. Debenzylation to give β-hydroxyamide 104 
   117 mg of 99 (263 µmol) were dissolved in 10 ml CH2Cl2 (puriss. p.a. o.m.s.) and 
cooled down to 0°C. 0.5 ml of Tf 2O (3 mmol, 11 equiv.) and 376 µl of BF3.Et2O (2.63 
mmol, 10 equiv.) were added and the solution was slowly let warm up to rt while 
stirring under N2 overnight. Reaction was monitored on TLC (H:AcOEt 1:3). The 
suspension was diluted with AcOEt, washed once with 0.1 M citric acid, once with 
sat. NaHCO3 and once with brine. All aq. layers were back extracted with AcOEt, 
comb. org. layers dried over MgSO4, filtered and solvent removed in rv. The crude 
material was adsorbed at SiO2 and chromatographically purified on SiO2. 40 mg of 
the starting material 99 (90 µmol, 34%) and 56 mg of methyl 2-{1-[(2-acetyl-1,3-
thiazole-4-yl)carbonylamino]-2-hydroxyethyl}-1,3-thiazole-4-carboxylate (104) (0.16 
mmol, 60%) were isolated. 
 
Rf(H/AcOEt 1:3): 0.2  
 
1H-NMR (300 MHz, CDCl3): 8.46 (s, 1 H, Thiazole-CH); 
8.36 (br. d, 3J = 8.2, 1 H, NH); 8.16 (s, 1 H, Thiazole-
CH); 5.58 (dt, 3J = 8.2, 3J = 4.0, 1 H, NCH); 4.47 (dd, 2J 
= 11.4, 3J = 3.8, 1 H, OCH2); 4.13 (dd, 2J = 11.9, 3J = 
4.2, 1 H, OCH2); 3.94 (s, 3 H, OCH3); 2.74 (s, 3 H, (CO)CH3). 
 
MS (ESI, MeOH): 378.1 (100, [M + Na]+). 
 
8.2.5.2 Reactions on the macrocycle 
 
8.2.5.2.1 Debenzylation to give tetraacetoxy macrocycle 105 
 
   397 mg of 60 (381 µmol) were dissolved in a mixture of 40 ml CH2Cl2 (puriss. p.a.) 
and 40 ml of Ac2O. 2.4 ml of BF3.Et2O (~7 M, 17 mmol, 4 x 10 equiv.) were added 
and the solution was stirred under N2 at rt overnight. The progress of the reaction 
was monitored on TLC (CHCl3:MeOH 12:1). The solvent was then removed in rv, the 
remaining crude material adsorbed at SiO2 and chromatographically purified on SiO2 
using CH2Cl2:MeOH 40:1 as solvent. 233 mg 3,11,19,27-tetra[(acetoxy)methyl]-
1,9,17,25-tetroxo-2,10,18,26-tetraza[3.4](2,4)1,3-thiazolophan (105) (274 mmol, 72%) 
were isolated. 
 
Melting temperature: 261.3 – 269.3°C (amorphous solid) 
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Rf(H/AcOEt 1:5): 0.25 
IR (KBr): 3928w; 3860w; 3375s; 3236s; 2927w; 2854w; 2030m; 1744m; 1638s; 
1616s; 1543m; 1492m; 1365w; 1224m; 1157m; 1050m; 806w; 767w; 631s; 500m.  
 
1H-NMR (300 MHz, DMSO): mixture of 
diastereoisomers: 8.93 – 8.67 (m, 4 H, NH); 8.45; 8.43; 
8.42; 8.40; 8.38; 8.33 (6 s, 4 H, Thiazole-CH); 5.75 – 
5.61 (m, 4 H, NCH); 4.87 – 4.41 (m, 8 H, CH2); 2.01; 
2.00; 1.99; 1.95; 1.95; 1.92; 1.88 (7 s, 12 H, (CO)CH3). 
 
13C-NMR (100 MHz, DMSO): mixture of 
diastereoisomers: 170.26; 170.23; 170.13; 170.16 (4 s, 4 
C, COO); 167.03; 167.00; 166.81; 166.79; 166.78 (5 s, 4 
C, CONH); 160.23; 160.12; 159.93; 159.79 (4 s, 4 C, 
Thiazole-C2); 148.44; 148.18; 147.97; 147.92; 147.69 (5 
s, 4 C, Thiazole-C4); 126.91; 126.88; 126.46; 126.25; 125.86 (5 d, 4 C, Thiazole-
C5H); 64.44; 64.27; 64.11; 63.76; 63.42 (5 t, 4 C, CH2); 50.37; 49.39; 49.33; 49.07; 
48.38 (5 d, 4 C, NCH); 20.57 (q, 4 C, CH3).  
 
MS (ESI, MeOH:CHCl3 1:1 + NaI): 919.3 (6, [M – COCH3 + C7H7 + Na]+); 871.3 (100, 
[M + Na]+); 685.5 (13, [M – CH3CO2H – 3 CH3CO + 3 H + Na]+); 663.5 (5, [M – 
CH3CO2H – 3 CH3CO + 4 H]+); 413.4 (8); 304.3 (15). 
 
8.2.5.2.2 Hydrolysis of 105 to tetraalcohol 59 
 
   200 mg of 105 (236 µmol) were suspended in 20 ml MeCN, 20 ml MeOH and 5 ml 
H2O and heated up to 45°C. 52 mg of LiOH (2.2 mmol, 1 0 equiv.) were dissolved in 
15 ml H2O. This solution was added over 5 min to the hot suspension of 105. The 
suspension was further stirred for 3 min, during which time all material dissolved. 
Then 2.2 ml 1 M HCl were added and the pH was adjusted to about 7 by adding 
some more drops of 1 M HCl. The solvent was removed in rv, the remaining material 
adsorbed at SiO2 and the product chromatographically purified on SiO2 (CHCl3: 
MeOH 10:1 to 5:1). 143 mg of the colourless solid 59 (210 µmol, 89%) were isolated. 
 
8.2.5.2.3 Debenzylation to tetraalcohol 59 
 
   504 mg of 60 (484 µmol) were dissolved in 50 ml ClCH2CH2Cl. 1.7 ml of Tf2O (19 
mmol, 4 x 10 equiv.) and 2.2 ml BF3.Et2O (7 M, 15 mmol, 4 x 8 equiv.) were added. 
The reaction was monitored on TLC (CHCl3:MeOH 5:1) and 
stopped after 4 h by cooling down to 0°C in an ice bath, 
adding little ice water, diluting after 5 min with MeOH to get 
one layer and adjusting to neutral pH with sat. Na2CO3. The 
solvent was then removed in rv, the remaining solid 
suspended in a 1:1 mixture of CHCl3 and MeOH, filtered and 
adsorbed to SiO2. After column chromatography 
(H:AcOEt:MeOH 1:5:1) 152 mg 3,11,19,27-
tetra(hydroxymehtyl)-1,9,17,25-tetroxo-2,10,18,26-
tetraza[3.4] (2,4)1,3-thiazolophan (59) (223 mmol, 46%) 
were isolated. 
 
Rf(CHCl3/MeOH 5:1): 0.23 
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1H-NMR (300 MHz, DMSO): mixture of diastereoisomers: 8.73 – 8.40 (m, 4 H, NH); 
8.34; 8.33; 8.32; 8.31; 8.30; 8.29; 8.26 (7 s, 4 H, thiazole-CH); 5.48 – 5.29 (m, 4 H, 
NCH); 4.11 – 3.72 (m, 8 H, CH2). 
 
MS (ESI, MeOH + NaI): 703.2 (100, [M + Na]+). 
 
8.2.5.2.4 Optimized procedure for thionation of 105 
 
   8 mg of 105 (9 µmol) were suspended in 2 ml dry DME (solv. system). A spatula of 
LiOTf and one of Lawesson reagent were added and the suspension was stirred 
under reflux for 7 h. It was then diluted with AcOEt, washed with 0.1 M citric acid, sat. 
NaHCO3 and brine. An ESI MS of the crude material revealed some of the thioamide 
product. 
 
MS (ESI, CHCl3/MeOH 3:1 + NaI): 933.2 (10, [M + Na]+); 871.3 (100, [M105 + Na]+). 
 
8.2.5.2.5 Optimized procedure for the formation of 115 from 59 
 
   50 mg of 59 (73 µmol) were dissolved in 6 ml dry pyridine and 135 mg of P2S5 (607 
µmol, 4 x 2 equiv.) were added. The suspension, which solubilized at higher 
temperatures, was heated to 150°C under N 2 and stirred at this temperature for 5 h. 
The pyridine was removed then under reduced pressure freezing it out in a cooling 
trap, the remaining material was suspended using sonication in a mixture of AcOEt, 
CHCl3 and MeOH and filtered. The solvent was removed in rv and the residue again 
dissolved in CHCl3 and MeOH, adsorbed at SiO2 and chromatographically purified on 
SiO2 (CH2Cl2:MeOH 25:2). 10 mg of fractions containing to a big extent the desired 
[0.4]{(2,4)1,3-thiazolo[0](2,4)1,3-thiazolino}phan (115) were isolated. 
 
Rf(CHCl3/MeOH 5:1): 0.5 
 
1H-NMR (400 MHz, CDCl3/MeOD): Mixture of 
diastereoisomers: 8.08; 8.04; 8.03; 7.97; 7.95; 7.92 (6 s, 4 H, 
Thiazole-CH); 6.14 – 6.03 (m, 4 H, NCH); 4.24 – 4.22; 3.68 – 
3.64 (2 m, 8 H, CH2). 
 
MS (ESI, MeOH + NaI): 664.9 (67, [M + Na]+); 673.0 (5, [M + 
H]+); 413.3 (14); 310.1 (9); 280.1 (100). 
 
8.2.5.2.6 Optimized procedure to generate traces of 34 
 
   11 mg of a mixture containing the tetrathiazoline 115 were dissolved in 2 ml dry 
DMF (solv. system) under Ar and cooled down to -5°C  in an ice/brine bath. 63 µl of 
BrCCl3 (638 µmol, 4 x 10 equiv.) were added. 30 µl of DBU 
(198 µmol, 4 x 3 equiv.) were diluted in 0.5 ml dry DMF and 
added during 10 min dropwise to the reaction. The solution 
was stirred under Ar for 4 h. There was no change of colour. 
Solvent was then removed in rv and a tiny amount of a 
substance with UV absorbtion at 220 and 280 nm isolated in 
HPLC. ESI MS showed the mass of [0.8](2,4)1,3-thiazolophan 
(8TP, 34). 
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MS (ESI, DMSO:MeOH 1:10 + NaI): Among a forest of other signals: 986.6 (46, [M + 
Na]+); 685.5 (100), signal intensity: 2.2x104. 
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8.3 Target 3: [0.4]{(2,4)1,3-Thiazolo[0](2,4)1,3-oxazolo}phan (32) 
 
8.3.1 Investigations towards the synthesis of oxazole units 
 
8.3.1.1 Reactions using model compounds 
 
8.3.1.1.1 Reactions using 63 
 
a. Synthesis of oxazoline 72 
 
a.1 Using DAST 
   325 mg of 63 (1.27 mmol) were suspended in 40 ml of dry CH2Cl2 (puriss.) and 
cooled down to -80°C (frozen acetone) under N 2. 209 µl of DAST (1.60 mmol, 1.25 
equiv.) were added and the solution was slowly let warm up to rt. Reaction was 
monitored on TLC (H:AcOEt 5:1). The solution was diluted with CH2Cl2, washed with 
sat. NaHCO3 and brine. The aq. layers were back extracted with CH2Cl2, the com. 
org. layers dried over MgSO4, filtered and solvent removed in rv. 302 mg 2-phenyl-4-
(phenylmehtyl)-1,3-oxazoline (72) (1.27 mmol, 100%) were isolated. 
 
a.2 Using TsCl 
   255 mg of 63 (1.00 mmol) were suspended in 10 ml CH2Cl2 (puriss.) and cooled 
down to 0°C under N 2. 250 mg of DMAP (2.05 mmol, 2 equiv.) and 238 mg TsCl 
(1.25 mmol, 1.25 equiv.) were added. After three hours everything had dissolved 
and. The reaction was monitored on TLC (H:AcOEt 7:1). The solution was diluted 
with TBME (precipitation), washed twice with 0.1 M citric acid, twice with sat. 
NaHCO3 and once with brine. All aq. layers were back extracted with TBME, the 
comb. org. layers dried over MgSO4, filtered and dried in rv and hv. The crude 
product was chromatoraphically purified on SiO2 (H:AcOEt 10:1 to 7:1). 184 mg 2-
phenyl-4-(phenylmehtyl)-1,3-oxazoline (72) (0.775 mmol, 78%) were isolated. 
 
Rf(H/AcOEt 5:1): 0.55 
 
1H-NMR (300 MHz, CDCl3): 7.97 – 7.93 (m, 2 arom. H); 7.50 – 
7.37 (m, 3 arom. H); 7.33 – 7.19 (m, 5 arom. H); 4.63 – 4.53 (m, 
1 H, NCH); 4.35 (dd, 2J = 8.4, 3J = 8.5, 1 H, OCH2); 4.14 (dd, 2J 
= 8.4, 3J = 7.4, 1 H, OCH2); 3.24 (dd, 2J = 13.7, 3J = 5.1, 1 H, CH2Ph); 2.73 (dd, 2J = 
13.7, 3J = 8.8, 1 H, CH2Ph). 
 
13C-NMR (75.5 MHz, CDCl3): 164.07 (s, 1 C, CNO); 138.12 (s, 1 C, arom. C); 131.41; 
129.36; 128.65; 128.40; 128.37 (5 d, 9 C, arom. CH); 127.93 (s, 1 C, arom. CR); 
126.60 (d, 1 C, arom. CH); 71.97 (t, 1 C, OCH2); 68.00 (d, 1 C, NCH); 41.95 (t, 1 C, 
CH2Ph). 
 
MS (ESI, MeOH): 296.1 (7); 260.1 (43, [M + Na]+); 238.1 (100, [M + H]+) 
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8.3.1.1.2 Reactions with 65 
 
a. Synthesis of the dehydro product 150 using TsCl  
   0.496 g of 65 (1.25 mmol) were dissolved in 10 ml CH2Cl2 (puriss. p.a.), 0.311 g of 
DMAP (2.55 mmol, 2 equiv.) and 0.257 g of TsCl (1.35 mmol, 1.05 equiv.) were 
added under N2 and the solution was stirred at rt overnight. The reaction was 
monitored on TLC (H:AcOEt 1:1 or 5:1). The solvent was then removed by rv, the 
remaining oily mixture diluted with TBME, washed twice with 0.1 M citric acid, once 
with sat. NaHCO3 and once with brine. All aq. layers were back extracted with TBME, 
the comb. org. layers dried over MgSO4, filtered and dried in rv and hv. 438 mg (1.16 
mmol, 93%) of Boc-Cys(SBn)-dehydroSer-OMe (150) were isolated. 
 
Rf(H/AcOEt 5:1): 0.5 
 
1H-NMR (300 MHz, MeOD): 7.33 – 7.23 (m, 5 H, arom. CH); 
6.44; 5.88 (2 s, 2 H, =CH2); 4.57; 4.52 (2 d, 2J = 12.1, 2 H, 
OCH2Ph); 4.34 (br. s, 1 H, NCH); 3.80 (s, 3 H, OCH3); 3.77 
– 3.68 (m, 2 H, OCH2); 1.45 (s, 9 H, OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 171.56 (s, 1 C, COOMe); 
165.36 (s, 1 C, CONH); 156.31 (s, 1 C, Carbamate-CO); 139.14 (s, 1 C, C=CH2); 
132.89 (s, 1 C, arom. C); 129.42; 128.89; 128.81 (3 d, 5 C, arom. CH); 110.16 (t, 1 C, 
C=CH2); 81.21 (s, 1 C, OCMe3); 74.27; 70.61 (2 t, 2 C, PhCH2OCH2); 56.74 (d, 1 C, 
NCH); 53.38 (q, 1 C, OCH3); 28.67 (q, 3 C, OC(CH3)3). 
 
MS (ESI, CH2Cl2 / MeOH 1:3 + NaI): 401.3 (100, [M + Na]+). 
 
8.3.1.1.3 Reactions using 106 
 
a. Synthesis of the dehydro product 151 using TsCl 
   619 mg of 106 (1.50 mmol) were dissolved in 20 ml CH2Cl2 (puriss. p.a.) under N2. 
367 mg of DMAP (3.00 mmol, 2 equiv.) and 300 mg of TsCl (1.58 mmol, 1.05 equiv.) 
were added. The solution was stirred at rt. for 5 h. TLC (H:AcOEt 5:1) showed 
completion. A part of the CH2Cl2 was removed, the rest diluted with TBME, washed 
twice with 0.1 M citric acid, once with sat. NaHCO3 and once with brine. All aq. layers 
were back extracted with TBME, comb. org. layers dried over MgSO4, filtered and 
dried in rv. 582 mg of Boc-Ser(OBn)-dehydroSer-OMe (151) (1.48 mmol, 98%) were 
isolated. 
 
Rf(H/AcOEt 5:1): 0.55 
 
1H-NMR (300 MHz, CDCl3): 8.58 (br. s, 1 H, NH); 7.34 – 
7.23 (m, 5 H, arom. CH); 6.61 (s, 1 H, =CH2); 5.92 (d, 2J = 
1.4, 1 H, =CH2); 5.30 (br. s, 1 H, NH); 4.32 (br. s, 1 H, 
NCH); 3.80 (s, 3 H, OCH3); 3.73 (s, 2 H, SCH2Ph); 2.92; 
2.80 (2 dd, 2J = 14.1, 3J = 6.1, 2 H, SCH2); 1.47 (s, 9 H, 
OC(CH3)3). 
 
13C-NMR (75.5 MHz, CDCl3): 169.45 (s, 1 C, COOMe); 164.01 (s, 1 C, CONH); 
155.22 (s, 1 C, Carbamate-CO); 137.57 (s, 1 C, C=CH2); 130.63 (s, 1 C, arom. C); 
128.88; 128.54; 126.95 (3 d, 5 C, arom. CH); 109.44 (t, 1 C, C=CH2); 80.64 (s, 1 C, 
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OCMe3); 54.49 (d, 1 C, NCH); 52.84 (q, 1 C, OCH3); 36.41; 33.21 (2 t, 2 C, 
PhCH2SCH2); 28.14 (q, 3 C, OC(CH3)3). 
 
8.3.1.1.4 Reactions using 64 
 
a. Synthesis of oxazoline 75 
 
a1. Using DAST 
   505 mg of 64 (2.24 mmol) were dissolved under N2 in 20 ml dry CH2Cl2 (puriss. p.a. 
over m.s.) and cooled down to 0°C in an ice bath. 3 52 µl of DAST (2.69 mmol, 1.2 
equiv.) were added and the solution was slowly let warm up to rt while stirring under 
N2. Reaction was monitored on TLC (H:AcOEt 1:1). After 2 h the solution was diluted 
with CH2Cl2, washed with 0.1 M citric acid, sat. NaHCO3 and brine. All aq. layers 
were back extracted with CH2Cl2, the comb. org. layers dried over MgSO4, filtered 
and solvent removed in rv. 464 mg of the crude product were chromatographically 
purified (H:AcOEt 3:1) and 443 mg of the pure methyl (4S)-2-penyl-1,3-oxazoline-4-
carboxylate (75) (2.16 mmol, 96%) were isolated as a colourless oil. 
 
a2. Using TsCl 
   400 mg of 64 (1.79 mmol) were dissolved in 10 ml dry CH2Cl2 (puriss. p.a. over 
m.s.) and cooled down to 0°C in an ice bath under N 2. 219 mg of DMAP (1.79 mmol, 
1 equiv.) and 378 mg of TsCl (1.98 mmol, 1.1 equiv.) were added and the solution 
was stirred at 0°C, slowly warming up to rt. Reacti on was monitored on TLC 
(H:AcOEt 1:1). After 5 h another 171 mg of TsCl (896 µmol, 0.5 equiv.) and 22 mg of 
DMAP (179 µmol, 0.1 equiv.) were added. When no more change could be observed 
on TLC, solution was diluted with CH2Cl2, washed with 0.1 M citric acid, sat. NaHCO3 
and brine. All aq. layers were back extracted with CH2Cl2, the comb. org. layers dried 
over MgSO4, filtered and solvent removed in rv. 679 mg of the crude material were 
chromatographically purified (H:AcOEt 2:1 to 1:2). 128 mg of the pure methyl (4S)-2-
penyl-1,3-oxazoline-4-carboxylate (75) (624 µmol, 35%, colourless oil) and 151 mg of 
64 (676 µmol, 38%) were isolated. 
 
Rf(H/AcOEt 2:1): 0.25 
 
1H-NMR (300 MHz, CDCl3): 8.00 – 7.97 (m, 2 H, arom. o-CH); 
7.50 – 7.38 (m, 3 H, arom. m-/p-CH); 4.96 (dd, 3J = 10.6, 3J = 7.9, 
1 H, NCH); 4.70 (dd, 2J = 8.7, 3J = 7.9, 1 H, OCH2); 4.59 (dd, 2J = 
8.7, 3J = 10.6, 1 H, OCH2); 3.82 (s, 3 H, OCH3). 
 
13C-NMR (75.5 MHz, CDCl3): 171.64 (s, 1 C, COOMe); 166.28 (s, 1 C, CON); 131.87 
(d, 1 C, arom. p-CH); 128.58; 128.35 (2 d, 4 C, arom. o-/m-CH); 126.91 (s, 1 C, 
arom. C); 69.53 (t, 1 C, OCH2); 68.60 (d, 1 C, NCH); 52.72 (q, 1 C, OCH3). 
 
MS (ESI-MS, MeOH + NaI): 433.1 (5, [2 M75 + Na]+); 228.0 (100, [M + Na]+); 206.1 
(17, [M + H]+). 
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b. Synthesis of oxazole 120 
 
b1. Starting from oxazoline 75 
   100 mg of 75 (487 µmol) were dissolved in 5 ml CH2Cl2 (puriss. p.a.)7 and cooled 
down to 0°C in an ice bath. 176 µl of DBU (975 µmol, 2 equiv.) and 53 µl of BrCCl3 
(536 µmol, 1.1 equiv.) were added. The solution was let warm up to rt while stirring 
under N2. After 16 h TLC (H:AcOEt 2:1) showed conversion to the product. Solution 
was diluted with AcOEt, washed twice with 0.1 M citric acid, once with sat. NaHCO3 
and once with brine. All aq. layers were back extracted with AcOEt, comb. org. layers 
were dried over MgSO4, filtered and the solvent was removed by rv and v. 85 mg 
methyl 2-penyl-1,3-oxazole-4-carboxylate (120) (0.42 mmol, 86%) were isolated as a 
colourless oil. 
 
b2. Starting from the β-hydroxyamide 64 
   40 mg of 64 (0.18 mmol) were dissolved in 2 ml DMF (solvent system)8, cooled 
down to -10°C in an ice/brine bath and 35 µl of DAST (0.23 mmol, 1.5 equiv.) were 
added under N2. It was let warm up to rt while stirring. After 90 min TLC (H:AcOEt 
1:1) showed complete conversion to the oxazoline 75. Solution was cooled down to 
0°C again, 108 µl of DBU (713 µmol, 4 equiv.) and 27 µl of BrCCl3 (0.27 mmol, 1.5 
equiv.) were added. After 45 min no more 75 can be detected in TLC, quite clean 
conversion to methyl 2-penyl-1,3-oxazole-4-carboxylate (120) but a little bit of the 
elimination product 71 is found. 
 
Rf(H/AcOEt 2:1): 0.5 
 
1H-NMR (300 MHz, CDCl3): 8.30 (s, 1 H, Oxazole-CH); 8.13 – 
8.10 (m, 2 H, arom. CH); 7.50 – 7.47 (m, 3 H, arom. CH); 3.96 (s, 
3 H, OCH3). 
 
13C-NMR (75.5 MHz, CDCl3): 162.47; 161.74 (2 s, COO & CNO); 143.78 (d, 1 C, 
Oxazole-CH); 134.35 (s, 1 C, Oxazole-C); 131.18 (d, 1 C, arom. p-CH); 128.80 (d, 2 
C, arom. o-CH); 126.84 (d, 2 C, arom. m-CH); 126.32 (s, 1 C, arom. C); 52.23 (q, 1 
C, OCH3).  
 
MS (ESI-MS, MeOH + NaI): 429.0 (6, [2 M + Na]+); 226.0 (100, [M + Na]+). 
 
c. Synthesis of dehydro product 71 
   600 mg of 64 (2.69 mmol) were dissolved in 60 ml THF (puriss. p.a.)9 under N2. 
811 µl of DPPA (3.76 mmol, 1.4 equiv.) were added, the solution was stirred for 10 
min and then cooled down to 0°C. 570 µl of DBU (3.76 mmol, 1.4 equiv.) were 
added[188]. The solution was warmed up to rt while stirring. The reaction was 
monitored on TLC (H:AcOEt 1:1). After 15 hours the solution was diluted with AcOEt, 
washed with 0.1 M citric acid, sat. NaHCO3 and birne. All aq. layers were back 
extracted with AcOEt, comb. org. layers dried over MgSO4, filtered and solvent 
removed in rv and v. The crude product was chromatographically purified on SiO2 
                                            
7
 The reaction was also performed in DMF, pyridine and the ionic liquid 1-ethyl-3-methylimidazolium 
trifluoromethanesulfonate. TLC control showed comparable good conversions. 
8
 Reaction was also successfully performed in CH2Cl2 or CHCl3, in pyridine more of dehydro product 
71 was found.  
9
 Reaction was successfully also performed in MeCN and DMF. 
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(H:AcOEt 3:1). 507 mg of the pure methyl 2-benzoylaminoprop-2-enoate 71 (2.47 
mmol, 79%) were isolated as colourless oil. 
 
Rf(H/AcOEt 1:1): 0.5 
 
1H-NMR (300 MHz, CDCl3): 8.54 (br. s, 1 H, NH); 7.85 – 7.83 (m, 
2 H, 2 arom. H (o)); 7.55 – 7.46 (m, 3 H, 3 arom. H (m, p)); 6.80 
(s, 1 H, CH2(cis); 6.00 (d, 2J = 0.9, 1 H, CH2(trans)); 3.89 (s, 3 H, 
OMe). 
 
13C-NMR (75.5 MHz, CDCl3): 165.81 (s, 1 C, Ester); 164.82 (s, 1 C, Amide); 134.28 
(s, 1 C, arom. C); 132.09 (d, 1 C, arom. p-CH); 131.03 (s, 1 C, NCCH2); 128.82 (d, 2 
C, arom. o-CH); 126.97 (d, 2 C, arom. m-CH2); 108.94 (t, 1 C, CH2); 53.13 (q, 1 C, 
OCH3). 
 
MS (+ESI-MS, MeOH + NaI): 227.9 (100, [M+Na]+). 
 
d. Synthesis of bromoadduct 119 
   205 mg of 71 (1.00 mmol) were dissolved in 20 ml CH2Cl2 (puriss. p.a. o. m. s.). 2.5 
ml MeOH (puriss. p.a.) and some pulverized molecular sieve A4 were added and the 
suspension was cooled to 0°C in an ice bath. After 15 min 187 mg of NBS (1.05 
mmol, 1.05 equiv.) were added and the suspension was slowly let warm up to rt[157]. 
TLC (H:AcOEt 1:1) showed after 3 h complete consumption of 71. The suspension 
was then washed twice with sat. Na2S2O3 and once with brine. The aq. layers were 
back extracted with CH2Cl2, comb. org. layers dried over MgSO4, filtered and the 
solvent removed in rv. The product was purified by recrystallisation from H/AcOEt. 
116 mg of the pure methyl 2-(benzoylamino)-3-hydroxy-2-methoxypropanoate (119) 
(367 µmol, 37%) could be isolated as colourless crystals. 
 
Rf(H/AcOEt 1:1): 0.75; Rf(H/AcOEt 5:1): 0.14  
 
1H-NMR (300 MHz, CDCl3): 7.88 – 7.85; 7.60 – 7.46 (2 m, 5 H, 
arom. CH); 4.71 (d, 2J = 10.3, 1 H, CH2Br); 3.94 (s, 3 H, OCH3); 
3.85 (d, 2J = 10.3, 1 H, CH2Br); 3.32 (s, 3 H, OCH3). 
 
MS (ESI, MeOH + NaI): 408.3 (8); 340.1 (100, [M + Na]+); 338.1 (90, [M + Na]+); 
258.1 (23, [M – HBr + Na]+); 236.1 (17, [M – HBr + H]+); 222.1 (8, [M – HBr – CH2 + 
H]+); 204.1 (16, [M – HBr – MeOH + H]+); 105.1 (10). 
 
e. Protection of β-hydroxyamides with trialkylsilyl groups 
 
e1. Synthesis of trimehtylsilanol 152 
   100 mg of 64 (448 µmol) were dissolved in 3 ml CH2Cl2 (puriss. p.a.) and cooled 
down to 0°C in an ice bath. 0.1 ml of TMSCl (0.8 mm ol, 1.8 equiv.) and 160 µl of Et3N 
(1.15 mmol, 2.5 equiv.) were added. The solution was let warm up to rt while stirring 
under N2 overnight. The solution was then diluted with AcOEt, washed with 0.1 M 
citric acid, sat. NaHCO3 and brine. All aq. layers were back extracted with AcOEt and 
the comb. org. layers dried over MgSO4. The salt was removed by filtration and the 
solvent by rv. 116 mg of methyl (2S)-2-(benzoylamino)-3-
(trimethylsilyloxy)propanoate (152) were isolated (392 µmol, 88%). 
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1H-NMR (300 MHz, CDCl3): 7.95 – 7.93; 7.66 – 7.54 (2 m, 5 H, 
arom. CH); 7.09 (br. d, 3J = 7.8, 1 H, NH); 4.98 (dt, 3J = 8.1, 3J = 
2.9, 1 H, NCH); 4.24 (dd, 2J = 10.5, 3J = 2.7, 1 H, CH2); 4.05 (dd, 
2J = 10.5, 3J = 3.2, 1 H, CH2); 3.90 (s, 3 H, OCH3); 0.20 (s, 9 H, 
OSi(CH3)3). 
 
MS (ESI, MeOH + NaI): 360.4 (6); 318.2 (100, [M + Na]+); 246.1 
(9, [M – SiMe3 + H + Na]+). 
 
e2. Synthesis of the triethylsilanol 132 
   204 mg of 64 (914 µmol) were dissolved in 16 ml dry pyridine, 0.75 ml of TES-Cl 
(4.5 mmol, 5 equiv.) were added and the solution was heated up to 60°C for 1 h [239]. 
The solvent was then removed under reduced pressure, freezing it out in a cooling 
trap. The remaining oil was diluted in AcOEt, washed twice with 0.1 M citric acid, 
once with sat. NaHCO3 and once with brine. All aq. layers were back extracted with 
AcOEt, comb. org. layers were dried over MgSO4, filtered and solvent removed in rv. 
The crude product was chromatographically purified on SiO2 (hexane, then H:AcOEt 
2:1). 275 mg methyl (2S)-2-(benzoylamino)-3-(triethylsilyloxy)propanoate (132) (815 
µmol, 89%) were isolated as a colourless oil. 
 
Rf(H/AcOEt 1:1): 0.57; Rf(H/AcOEt 2:1): 0.28 
 
1H-NMR (300 MHz, CDCl3): 7.84 – 7.81 (m, 2 H, arom. o-CH); 
7.53 – 7.43 (m, 3 H, arom. m/p-CH); 7.00 (br. d, 3J = 7.8, 1 H, 
NH); 4.88 (dt, 3J = 8.3, 3J = 2.7, 1 H, NCH); 4.17 (dd, 2J = 10.1, 3J 
= 2.7, 1 H, OCH2); 3.97 (dd, 2J = 10.1, 3J = 3.1, 1 H, OCH2); 3.79 
(s, 3 H, OCH3); 0.93 (t, 3J = 7.9, 9 H, 3 TES-CH3 ); 0.58 (q, 3J = 
7.9, 6 H, 3 TES-CH2). 
 
f. Conversion of silanol 132 into oxazoline 75 
   40 mg of 132 (0.12 mmol) were dissolved in 1 ml CH2CH2 (techn.) at rt under N2. 
15 µl of DAST (0.11 mmol, 1 equiv.) were added[231, 232]. According to TLC (H:AcOEt 
2:1) 50% were converted to 75 after 5 h, reaction overnight gave clean and 
quantitative conversion to 75. Product was not isolated. 
 
g. Conversion of silanol 132 into oxazole 120   
   40 mg of 132 (0.12 mmol) were dissolved in 1 ml CH2CH210 (techn.) at rt under N2. 
15 µl of DAST (0.11 mmol, 1 equiv.) were added. After 20 min reaction to the 
oxazoline 75 was completed according to TLC (H:AcOEt 2:1). Solution was cooled 
down to 0°C, 54 µl of DBU (0.36 mmol, 3 equiv.) and 12 µl of BrCCl3 (0.12 mmol, 1 
equiv.) were added. Another 30 min later clean and qunatitative conversion to 120 is 
completed. Product was not isolated. 
 
8.3.1.1.5 Reactions using 116 
 
a. Synthesis of 127 by debenzylation and tosylation 
   269 mg of 116 (840 µmol) were dissolved in 20 ml CH2Cl2 (puriss. p.a.) and 1.4 g of 
Ts2O (4.3 mmol, 5 equiv.) and 1.2 ml of BF3.Et2O (~7 M, 8.4 mmol, 10 equiv.) were 
                                            
10
 Reaction is also possible in CHCl3 but is less clean. Under the addition of K2CO3 in granular or 
powdered form at 0°C formation of little dehydro pr oduct could be observed. 
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added and the solution was stirred under N2 overnight at 50°C. The conversion was 
monitored on TLC (H:AcOEt 1:1). The solution was then diluted with AcOEt, washed 
with 0.1 M citric acid, sat. NaHCO3 and brine. All aq. layers were back extracted with 
AcOEt, comb. org. layers dried over MgSO4, filtered and solvent removed in rv. The 
crude product was adsorbed to SiO2 and chromatographically purified on SiO2 
(H:AcOEt 3:1 to 1:1). 122 mg of a mixture of products, containing also 127, the 
elimination product 129 and the alcohol 128, could be isolated. 
 
8.3.1.1.6 Reactions using 99 
 
a. Debenzylation and tosylation 
   100 mg of 99 (224 µmol) were dissolved in 4 ml CH2Cl2 (puriss. p.a.) at rt under N2. 
322 µl of BF3.Et2O (2.20 mmol, 10 equiv.) and 740 mg of Ts2O (2.30 mmol, 10 
equiv.) were added. After 6 h stirring at rt almost no conversion could be observed by 
TLC (H:AcOEt 1:1). The solution was heated up to reflux for 20 h, then diluted with 
AcOEt, washed with 0.1 M citric acid, sat. NaHCO3 and brine. All aq. layers were 
back extracted with AcOEt, the comb. org. layers were dried over MgSO4, filtered and 
the solvent removed in rv. The crude material was adsorbed at SiO2 and the mixture 
of products chromatographically purified on SiO2. 18 mg of the quite pure methyl 2-
{1-[(2-acetyl-1,3-thiazole-4-yl)carbonylamino]-2-(tosyloxy)ethyl}-1,3-thiazole-4-
carboxylate (130) (35 µmol, 16%) and 25 mg of the almost clean alcohol 104 (70 
µmol, 31%) were isolated. An unquantified amount oxazoline 118 was also found. 
 
Rf(H/AcOEt 1:3): 0.5   
 
1H-NMR (300 MHz, CDCl3): 8.44 (s, 1 H, Thiazole-CH); 
8.27 (br. d, 3J = 8.2, 1 H, NH); 8.14 (s, 1 H, Thiazole-
CH); 7.72 (d, 3J = 7.9, 2 H, Ts-o-CH); 7.30 (d, 3J = 7.9, 2 
H, Ts-m-CH); 5.78 (dt, 3J = 8.2, 3J = 4.8, 1 H, NCH); 
4.72 (dd, 2J = 10.5, 3J = 5.6, 1 H, OCH2); 4.58 (dd, 2J = 
10.5, 3J = 4.5, 1 H, OCH2); 3.95 (s, 3 H, OCH3); 2.79 (s, 
3 H, (CO)CH3); 2.43 (s, 3 H, Ts-CH3). 
 
MS (ESI, MeOH + NaI): 532.0 (100, [M + Na]+); 510.0 (12, [M + H]+); 425.4 (5); 406.1 
(6); 378.1 (27, [M – SO2C7H7 + H + Na]+ = [M104 + Na]+); 360.4 (6, [M – C7H7SO3H + 
H + Na]+ = [M118 / 117 + Na]+); 356.1 (11, [M – SO2C7H7 + 2 H]+ = [M104 + H]+); 338.1 
(61, [M – C7H7SO3H + 2 H]+ = [M118 / 117 + H]+). 
 
b. Synthesis of oxazoline 118 starting with β-hydroxyamide 104 
   15 mg of 104 (42 µmol) were suspended in 4 ml CH2Cl2 (puriss. p.a. o.m.s.). 6 mg 
of DMAP (49 µmol, 1.2 equiv.) and 18 mg of TsCl (94 µmol, 2.2 equiv.) were added. 
The suspension was stirred at rt under N2 overnight. TLC (H:AcOEt 1:3) showed 
around 50% conversion. Another 10 mg of TsCl (52 µmol, 1.2 equiv.) and 6 mg of 
DMAP (49 µmol, 1.2 equiv.) were added and the solution was heated to 40°C for 20 
h. The suspension was then diluted with AcOEt, washed once with 0.1 M citric acid, 
once with sat. NaHCO3 and once with brine. All aq. layers were back extracted with 
AcOEt, comb. org. layers dried over MgSO4, filtered and solvent removed in rv. The 
crude material was chromatographically purified on SiO2 (H:AcOEt 1:1). 5 mg of the 
pure methyl 2-[2-(2-acetyl-1,3-thiazol-4-yl)-1,3-oxazolin-4-yl]-1,3-thiazole-4-
carboxylate 118 (15 µmol, 35%) were isolated. 
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MS (ESI, MeOH + NaI): 576.1 (16); 554.2 (18); 532.0 
(100, [M + TsOH + Na]+ = [M130 + Na]+); 510.1 (10, [M + 
TsOH + H]+ = [M130 + H]+); 486.1 (8); 468.1 (11); 446.2 
(9); 378.1 (31, [M + H2O + Na]+ = [M104 + Na]+); 360.1 
(100, [M + Na]+); 338.2 (47, [M + H]+). 
 
c. Synthesis of dehydro product 117 
   60 mg 99 (0.14 mmol) were dissolved in 3 ml CH2Cl2 (puriss. p.a.), 300 µl 
(CF3CO)2O (10 vol%) and 192 µl BF3.Et2O (1.3 mmol, 10 equiv.) were added and the 
solution was stirred at rt under N2 overnight. TLC (H:AcOEt 1:1) did not show 
complete conversion, so another 150 µl (CF3CO)2O (5 vol%) and 96 µl BF3.Et2O (0.7 
mmol, 5 equiv.) were added. The solution was stirred for another 20 h, then cooled 
down to 0°C and 1 ml of a 1 M solution of DBU in DM F (1 mmol) was added. 1 h later 
diluted in AcOEt, washed with 0.1 M citric acid, sat. NaHCO3 and brine. Aq. layers 
back extracted, org. layers dried over MgSO4, filtered and solvent removed in rv. The 
crude product was chromatographically purified on SiO2. 5 mg methyl 2-{1-[(2-acetyl-
1,3-thiazol-4-yl)-carbonylamino]ethen-1-yl}-1,3-thiazole-4-carboxylate (117) (15 µmol, 
11%) were isolated. 
 
Rf(H/AcOEt 1:1): 0.65  
 
1H-NMR (300 MHz, CDCl3): 10.52 (br. s, 1 H, NH); 8.48; 
8.17 (2 s, 2 H, Thiazole-CH); 6.67; 5.62 (2 d, 2J = 1.9, 2 
H, =CH2); 3.96 (s, 3 H, OCH3); 2.89 (s, 3 H, (CO)CH3).  
 
MS (ESI, MeOH + NaI): 411.2 (17); 360.1 (100, [M + Na]+); 338.1 (5, [M + H]+). 
 
8.3.1.2 Reactions on the macrocycle 
 
8.3.1.2.1 Most promising procedure for the formation of tetrachloride 74 
   108 mg of LiCl (previously dried at 100°C in hv during one hour) were dissolved in 
5 ml dry DMF (solv. system) under Ar. 40 mg of 59 (59 mmol) were added and the 
solution was cooled down to 0°C in an ice bath. 42 ml of DAST (320 mmol, 4 x 1.5 
equiv.) were added and the solution was let warm up to rt while stirring. The progress 
of the reaction was monitored on TLC (CHCl3:MeOH 5:1). The solvent was partially 
removed in rv, the remaining solution diluted with AcOEt, washed with 0.1 M citric 
acid, sat. NaHCO3 and brine. All aq. layers back extracted with AcOEt, comb. org. 
layers dried over MgSO4, filtered and solvent removed in rv. The 29 mg of crude 
material contained some of the product 3,11,19,27-tetra(chloromehtyl)-1,9,17,25-
tetroxo-2,10,18,26-tetraza[3.4](2,4)1,3-thiazolophan (74).  
 
8.3.1.2.2 Synthesis of tetrasilanole 133 
 
   50 mg of 59 (73 µmol) were dissolved in 4 ml dry pyridine (puriss. p.a. o.m.s.). 0.2 
ml of TES-Cl (1.2 mmol, 4 x 4 equiv.) were added. The solution was heated up to 
60°C under N 2 for two hours and the conversion was monitored on TLC (H:AcOEt 
1:4). The solution was then diluted with AcOEt, washed with 0.1 M citric acid, sat. 
NaHCO3 and brine. All aq. layers were back extracted with AcOEt, comb. org. layers 
dried over MgSO4, filtered and the solvent removed in rv. The crude material was 
chromatographically purified on SiO2. 43 mg of the pure 3,11,19,27-
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tetra[(triethylsilyloxy)mehtyl]-1,9,17,25-tetroxo-2,10,18,26-tetraza[3.4](2,4)1,3-
thiazolophan (133) (37 µmol, 50%) were isolated as a solidifying oil. 
 
Rf(H/AcOEt 1:5): 0.62 
 
1H-NMR (300 MHz, CDCl3): mixture of isomers: 8.47 – 
8.25 (m, 4 H, NH); 8.17; 8.14; 8.14 (3 s, 4 H, Thiazole-
CH); 5.77 – 5.36 (m, 4 H, NCH); 4.55 – 3.69 (m, 8 H, 
OCH2); 1.03 – 0.73 (m, 36 H, Silyl-CH3); 0.65 – 0.40 
(m, 24 H, Silyl-CH2). 
 
MS (ESI, MeOH + NaI): 1309.4 (6); 1159.6 (100, [M + 
Na]+); 1027.5 (5, [M – Et3SiOH + Na]+). 
 
8.3.1.2.3 Synthesis of tetraoxazoline 61 
 
   20 mg of 133 (18 µmol) were dissolved in 1.2 ml dry 
CH2Cl2 (puriss. p.a.). 33.3 mg of XtalFluor-E (144 µmol, 8 equiv.) were added at rt 
under Ar and stirred for 72 h. The progress of the reaction was monitored on TLC 
(CH2Cl2:MeOH 20:1). The mixture was then treated with 1.0 ml MeOH (puriss. p.a.) 
and stirred for another 10 min at rt under Ar. The crude product was adsorbed onto 
previously dried neutral Alox and chromatographically purified over neutral dry Alox 
(CH2Cl2:MeOH 99:1, both purum). 4.5 mg (7.4 µmol, 41%) of a mixture of 
diastereoisomers of [0.4]{(2,4)1,3-thiazolo[0](2,4)1,3-oxazolino}phan (DH4TOP, 61) 
was isolated.   
 
Rf(CH2Cl2/MeOH 20:1): 0.49  
 
1H-NMR (300 MHz, CDCl3): mixture of diastereoisomers: 7.97; 
7.93; 7.90; 7.86; 7.82; 7.76 (6 s, 4 H, thiazole-CH); 5.60 – 5.48 
(m, 4 H, NCH); 4.91 – 4.85; 4.73 – 4.64 (2 m, 8 H, CH2). 
 
MS (ESI, MeOH/DMSO 10:1 + NaI): 780.9 (25, [M + TES-OH 
+ H2O + Na]+); 682.2 (7); 649.0 (18); 631.0 (100, [M + Na]+); 
609.1 (20, [M + H]+).  
 
8.3.1.2.4 Formation of 0.4TOP (32) 
 
   4.5 mg 61 (7.4 µmol) were dissolved in 2.5 ml dry DMF (solvent system, c = 3 mM) 
and 8.9 µl BrCCl3 (90 µmol, 12 equiv.) were added. A first precipitate was observed. 
The suspension was cooled down to 0°C and 5.3 ml of  a 50 mM solution of DBU 
(270 µmol, 36 equiv.) in DMF were added over 10 min. The 
suspension was stirred at rt under N2 for 16 h. The suspension 
was then diluted with 25 ml H2O, the precipitate was collected 
by centrifugation, dissolved in DMSO and again precipitated 
by addition of H2O. The colourless solid was collected by 
centrifugation. The isolated material contained [0.4]{(2,4)1,3-
thiazolo[0](2,4)1,3-oxazolo}phan (4TOP, 32) according to 
MALDI-MS and 1H-NMR. 
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1H-NMR (400 MHz, DMSO): 9.17 (s, 4 H, thiazole-CH); 8.56 (s, 4 H, oxazole-CH). 
 
MS (MALDI, Matrix PAC HCCA): 834.0 (6); 706.0 (100, [M + CH2(C6H4O)]+); 674.1 
(17); 660.0 (21); 638.9 (12, [M + Na]+); 622.9 (74, [M + Na]+); 618.0 (15, [M + H2O]+); 
601.0 (18, [M + H]+). 
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Part III 
 
18O Isotopic Labeling of Amino Acids 
 
9.  Introduction 
 
   Much of our synthetic efforts towards new telomestatin analogs utilize standard 
peptide chemistry. As coupling reagents, the benzotriazole-based TBTU and PyBOP 
(Figure 9.1) were used.  
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Figure 9.1: Coupling reagents PyBOP and TBTU 
 
   These reagents are widely used, but their precise mechanism of action is still a 
matter of debate[240-243]. Two pathways for the initiation of the coupling reaction are 
theoretically possible. The acid is either (A) attacking the phosphorous or the 
uronium-carbon or (B) attacking the triazole-nitrogen. These possible mechanisms 
are presented in Scheme 9.1 with PyBOP as the coupling reagent. While much 
research has been aimed at elucidating the nature of the reactive species[242, 244, 245], 
the question of the first intermediate formed during amino acid activation has not 
previously been addressed. Specifying the carboxylic acid oxygens versus the 
PyBOP oxygen by using a doubly 18O isotopic labeled amino acids should prove a 
different distribution of 18O in the products for path A or B (Scheme 9.1).  
   Isotopically labeled amino acids have found wide application in structure 
elucidation of peptides and proteins. In addition to 17O NMR studies[246-254], 2D-IR 
techniques are emerging as important new tools for probing protein folding and 
ligand binding[255-267]. Due to its time resolution in the subpicosecond range, time 
resolved 2D-IR spectroscopy can report the rapid evolution of non-equilibrium 
conformational states to reveal folding pathways[256-267]. These techniques rely upon 
site-specific incorporation of 18O-labeled amino acids into peptides and proteins to 
serve as spectroscopic probes[260-267]. To date, only aliphatic, aromatic, and sulfur-
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from 20 – 85% for products containing a single 17O atom[251, 252]. In order to expand 
the range of amino acids labeling, we developed a new methodology using mild 
conditions compatible with different protective groups that provide efficiency for 
double isotopically labeled acids[273]1. 
 
 
 
                                            
1
 
18O labeling and PyBOP reactivity experiments were conducted with Birgit Lauber during her project 
practicum in our lab.  
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containing amino acids have been utilized in such studies because currently used 
methods for preparing 18O-labeled amino acids result in uniform 18O-labeling of side 
chain and α-carboxylic acids[268-272]. 
 
Scheme 9.1. Two possible mechanisms for PyPOP-mediated peptide bond formation 
 
   
18O-labeling is normally conducted by heating the carboxylic acid with 18OH2 in the 
presence of a strong acid to catalyze exchange (Scheme 9.2). By using an excess of 
18O water, the reported yields for isotopic enrichments are typically 75 – 85%[255, 268-
272]
. A labeling procedure for Fmoc-protected amino acids using multiple rounds of 
acid-catalyzed 18OH2 equilibration recently reported 18O enrichments of 90 – 96% for 
Phe, Ala, Gly, and Phe[255]. This method can be very efficient with respect to 18OH2 
consumption, but the protective groups typically used for functionalized side chains 
(Boc, Trt, tBu, etc.) are not stable under the strongly acidic conditions used to 
catalyze exchange. These conditions can therefore cause uniform labeling of Asp, 
Glu, Asn and Gln residues[270-272].  
 
Scheme 9.2. Typical equilibrium-based 18O labeling reaction 
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   Single-turnover 17OH2 saponification reactions of pentafluorophenyl esters have 
recently been reported[251, 252]. These reactions tolerate acid labile (tBu) protective 
groups and can selectively label α-carboxylic acids with isotopic enrichments ranging 
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10.  Results and Discussion 
 
   We report a mild and selective reaction for the isotopic labeling of amino acids, 
peptides and proteins to provide highly enriched materials for NMR, IR, and MS 
studies. Making use of a non-equilibrium multiple-turnover reaction, the carboxylic 
acid is reacted with a carbodiimide to form an O-acylisourea that is hydrolysed by 18O 
water. After one round of activation and hydrolysis, the mixed 16O/18O carboxylic acid 
will be re-activated and hydrolysed again and again (Scheme 10.1). Since 
carbodiimides react more rapidly with carboxylates than with water[274], one-pot 
reactions containing an excess of coupling reagent and 18OH2 result in multiple 
rounds of O-acylisourea formation and hydrolysis to provide isotopic enrichments of 
approximately 92 – 95 % for both oxygen atoms of the carboxylic acid (Table 10.1). 
 
Scheme 10.1. Non-equilibrium, multiple turnover 18O labeling reaction 
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   While heavy atom isotope effects are typically considered negligible for 
preparative-scale reactions, a modest kinetic bias should favor formation of the 
double–labeled 18O product. The 16O atom in the mixed carboxylic acid (Scheme 
10.1) should reacts slightly faster than 18O to form the corresponding 16O-
acylisourea[275]. The resulting effect on efficiency depends on the kinetic isotope 
effect (KIE) to the exponential power of reaction turnovers (n), i.e. (KIE)n. In theory, a 
very small KIA of 1.010 would result in cumulative KIA’s of about 11% and 270% 
after 10 and 100 turnovers, respectively. This should serve to decrease 18OH2 
consumption, especially for large-scale reactions. In the current set of examples, only 
six turnovers/equivalents of 18OH2 (if 100 % enriched) are theoretically sufficient for 
making amino acids with 98% isotopic enrichment, even without taking kinetic 
isotope effects into account. 
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Table 10.1. 18O enrichment and isolated yield 
entry         product % 
enrichment * 
isolated 
yields 
   
 
 
FmocHN
18O
18OH
OtBuO
153
 
93% 94% 
 
FmocHN
18O
18OH
154
NBoc
 
 
92% 88% 
 
FmocHN
18O
18OH
155
S-Trt
 
 
95% 95% 
 
   Our protocol for the selective labeling of α-carboxyl groups of amino acids utilizes 
commercially available, protected amino acids and coupling reagents. All starting 
materials were dried before use. To activate the carbodiimide and suppress 
racemization of the O-acylisourea intermediate, an excess of 3,5-dimethylpyridinium 
bromide (pKa ~ 5) is included as a dry proton source. We conducted isotope labeling 
experiments with three different Fmoc-protected amino acids containing a variety of 
acid-labile protective groups (Table 10.1). In a typical reaction, 50 equiv. of 18OH2 
(95% 18O), 30 equiv. of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC), and 20 equiv. of 3,5-dimethylpyridinium bromide in dry DMF were reacted 
overnight at room temperature. Reactions containing 18 equiv. of 18O and 10 equiv. 
of carbodiimide furnished products with only 55% enrichment. While other 
carbodiimides (DCC, DIC, etc.) worked well for this reaction, the water solubility of 
EDC greatly simplified purification as the resulting 16O and 18O-containing ureas were 
washed away with water. Isolated yields for 153 and 155 were nearly quantitative (94 
– 95%), while the yield for Fmoc-Trp(Boc)-18OH (154) was slightly lower (88%) due to 
the extreme acid sensitivity of the Boc-protected indole (Table 10.1). Each product 
153 – 155 was characterized by MS, IR, NMR, and polarimetry. Selective 18O 
labeling of the α-carboxylic acids was observed by 13C-NMR by using mixtures of 
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starting materials and isolated products. Consistent with previous reports of other 
acids[268, 276], the 18O-labeled α-carbon of products 153 – 155 were shifted upfield by 
~ 0.05 ppm as compared to 16O-containing starting materials. Selective labeling was 
also indicated by mass spectrometry as exactly two 18O atoms were incorporated into 
each product. Quantitative ESI mass spectrometry of 153 – 155 revealed total 
isotopic enrichments of 92 – 95% (Table 10.1). This enrichment is very similar to the 
purity of the 18OH2 (95% 18O) added to each reaction. Based on these results, we 
estimate that five or more cycles of activation and hydrolysis occurred during each 
reaction. Similar results were also obtained for relatively simple amino acids like 
Fmoc-Gly-18OH. To the best of our knowledge, these are the first reported examples 
of kinetically-enhanced multiple turnover reactions used for preparative isotopic 
labeling.  
   Together with Birgit Lauber, preliminary experiments for tracking 18O during PyBOP 
mediated amide bond formation were performed. The labelled amino acids were 
reacted in dry DMF with benzylamine using PyBOP and NMM. The mixture was then 
fractionated and the tripyrrolidinephosphinoxide was analysed with ESI-MS. Different 
ratios of labelled to unlabeled phosphinoxides were observed, ranging from 2:1 to 
1:2. This result can not be reconciled with a single mechanism (Scheme 9.1). It is not 
currently known whether unrelated oxygen exchange reactions can take place under 
these reaction conditions.   
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Figure 10.1: ESI mass spectra of compounds 153 – 155. Total % isotopic enrichments were calculated 
by taking the peak intensities of the 16O/16O species as 0 %, the 16O/18O species as 50 %, and the 
18O/18O species as 100 % enrichment. 
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11.  Synthetic Procedures 
 
11.1  Materials and methods 
   
18O-labeled water was purchased as a normalized 95% 18O solution (5% 16O) from 
Armar Chemicals (Döttingen, Switzerland). 3,5-dimethylpyridine was purchased from 
Aldrich in purum quality, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC.HCl) was purchased in purum quality from Fluka. DMF 
purification grade from Aldrich was dried over a column of 5 Å molecular sieves in a 
Pure Solvent System from Innovative Technology (Newberyport, MA). All amino 
acids were obtained from Bachem AG.  
   Immediately before 18O labelling all reagents and starting materials were 
extensively dried by making sonicated suspensions in dry CH3CN and removing the 
residual water as a CH3CN azeotrope under reduced pressure. This procedure was 
repeated three times prior to labeling. Oven-dried glassware and stirrer bars were 
used and all reactions and starting materials were kept under dry N2. 
   For preparative HPLC a VARIAN Prep Star Model 218 equipped with a Waters X 
Bridge Column (19 x 50 mm, 5 µm C18 particles) was used. 1H- and 13C-NMR 
spectra were measured on Bruker ARX-300 or AV-400 spectrometers (Bruker, 
Karlsruhe, Germany). The chemical shift values are given in ppm relative to the 
residual signal from TMS (δ = 0.00) for 1H-NMR and CD3OD (δ = 49.00 ppm) for 13C-
spectra. The coupling constants J are given in Hz; resonance multiplicity is described 
as s for singlet, d for doublet, dd for doublet of doublet, t for triplet, m for multiplet; 
and br is used to indicate broad signals. All data processing was carried out with 
Topspin and Xeasy (Bruker). IR spectra were collected using a JASCO FT/IR-4100 
spectrometer equipped with an anvil sample compressor for matrix-free data 
collection. [α]D-values were measured on a Perkin-Elmer Polarimeter 241 using 
solutions of 10 – 20 mM in the indicated solvent. 
   Mass spectra were measured by the Organic Chemistry Institute of the University 
of Zürich. ESI mass spectra were performed on a Bruker ESQUIRE-LC quadrupole 
ion trap instrument (Bruker Daltonik GmbH, Bremen, Germany), equipped with a 
combined Hewlett-Packard Atmospheric Pressure Ion (API) source (Hewlett-Packard 
Co., Palo Alto, CA, USA). Ions with more than 5% intensity are given.  
 
11.2 Synthesis of Fmoc-L-Glu(OtBu)-18OH (153)  
   850 mg dry 3,5-dimethylpyridine hydrobromide (4.52 mmol, 20 equiv.) were 
suspended in 2 ml dry DMF under N2, 430 mg dry EDC.HCl (2.24 mmol, 10 equiv.) 
and 225 µl 18OH2 (95%, 11.3 mmol, 50 equiv.) were added. 100 mg dried Fmoc-L-
Glu(OtBu)-OH.H2O (225 µmol), dissolved in 3 ml dry DMF, was immediately added 
by syringe. The mixture was stirred at rt for 18 h under N2. A second portion dry 
EDC.HCl (430 mg, 2.24 mmol, 10 equiv.) was added and the mixture was stirred for 
another 8 h at rt. A third portion dry EDC.HCl (430 mg, 2.24 mmol, 10 equiv.) was 
added and stirred for another 15 hours. The reaction was diluted into AcOEt (30 ml), 
washed three times with 0.1 M citric acid (25 ml), once with 0.1 M citric acid in brine 
(25 ml). All aq. layers were back extracted once with one portion AcOEt (30 ml). 
Comb. org. layers were dried over MgSO4, filtered, and the solvent removed by rv 
and hv. The isolated material was further purified by preparative HPLC using an 
CH3CN/H2O gradient (flow rate of 6 ml/min) of 60% to 70% CH3CN (0.05% TFA) over 
10 minutes to yield 90.8 mg (212 mmol, 94%) of a colourless solid. 
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Analytical data for Fmoc-L-Glu(OtBu)-16OH.H2O (starting material): 
 
[α]D20 (MeOH): - 9.06  
IR (neat): 1720.2s, 1527.4w; 1447.3w; 1371.1w; 1331.6w; 1248.7m; 1155.2m; 
1054.9w; 947.8w; 844.7w; 747.3w. 
 
1H-NMR (300 MHz, MeOD): 7.77 (d, 3J = 7.3, 2 H, Fluorenyl-C4’/5’-H); 7.68 – 7.64 (m, 
2 H, Fluorenyl-C1’/8’-H); 7.39 – 7.27 (m, 4 H, Fluorenyl-C2’/3’/6’/7’-H); 4.35 – 4.32 (m, 2 
H, C10’-H); 4.24 – 4.09 (m, 2 H, C2-H & C9’-H); 2.34 (t, 3J = 7.2, 2 H, C4-H); 2.21 – 
2.10; 1.95 – 1.83 (2 m, 2 H, C3-H); 1.44 (s, 9 H, C(CH3)3). 
 
13C-NMR (75.5 MHz, MeOD): 175.39 (s, 1 C, C1OOH); 173.84 (s, 1 C, C5OOtBu); 
158.65 (s, 1 C, OCONH); 145.31; 145.15; 142.56 (3 s, 4 arom. C); 128.78; 128.16; 
126.27; 120.92 (4 d, 8 arom. CH); 81.83 (s, 1 C, OCMe3); 67.99 (t, 1 C, OCH2); 54.53 
(d, 1 C, NHCH); 48.37 (s, 1 C, OCH2CH); 32.70 (t, 1 C, C3H2); 28.35 (q, 3 C, 
OC(CH3)3); 27.98 (t, 1 C, C4H2). 
 
Analytical data for Fmoc-L-Glu(OtBu)-18OH (product): 
 
[α]D20 (MeOH): - 9.28 
IR (neat): 1707.7s; 1527.4w; 1447.3w; 1372.1w; 1331.6w; 1251.6m; 1155.2m; 
1053.9w; 746.3m. 
 
1H-NMR (400 MHz, MeOD): 7.79 (d, 3J = 7.5, 2 H, Fluorenyl-C4’/5’-H); 7.69 – 7.65 (m, 
2 H, Fluorenyl-C1’/8’-H); 7.40 – 7.29 (m, 4 H, Fluorenyl-C2’/3’/6’/7’-H); 4.35 (d, 2 H, 3J = 
7.3, C10’-H); 4.24 – 4.19 (m, 2 H, C2-H & C9’-H); 2.34 (t, 3J = 7.3, 2 H, C4-H); 2.20 – 
2.11; 1.94 – 1.84 (2 m, 2 H, C3-H); 1.45 (s, 9 H, C(CH3)3.  
 
13C-NMR (100 MHz, MeOD): 175.30 (s, 1 C, C1-18O18OH); 173.85 (s, 1 C, C5OOtBu); 
158.66 (s, 1 C, OCONH); 145.34; 145.18; 142.59 (3 s, 4 arom. C); 128.78; 128.17; 
126.27; 120.90 (4 d, 8 arom. CH); 81.84 (s, 1 C, OCMe3); 67.99 (t, 1 C, OCH2); 54.54 
(d, 1 C, NHCH); 48.42 (s, 1 C, OCH2CH); 32.71 (t, 1 C, C3H2); 28.34 (q, 3 C, 
OC(CH3)3); 27.99 (t, 1 C, C4H2). 
 
MS (- ESI-MS, MeOH + 0.52% NH3): 857.3 (25, [2 M2x - H]-); 428.1 (100, [M2x – H]-); 
426.1 (10, [M1x – H]-); 232.0 (70, [M2x – H – C14H12O]-); 230.0 (10, [M1x – H – 
C14H12O]-); 206.0 (79, [M2x – H – C15H10O2]-); 204.1 (11, [M1x – H – C15H10O2]-); 131.9 
(41, [M2x – H – C14H11O – C5H9O2]-); 130.0 (6, [M1x – H – C14H11O – C5H9O2]-). 
 
 
11.3 Synthesis of Fmoc-L-Trp(Boc)-18OH (154)  
   858 mg dry 3,5-dimethylpyridine hydrobromide (4.56 mmol, 20 equiv.) was 
suspended in 5 ml dry DMF under N2, and 437 mg dried EDC.HCl (2.28 mmol, 10 
equiv.) and 180 µl 18OH2 (9.0 mmol, 40 equiv.) were added. 120 mg dried Fmoc-L-
Trp(Boc)-OH (228 µmol), dissolved in 4 ml dry DMF was immediately added by 
syringe. The mixture was stirred under N2 at rt for 18 h. A second portion dried 
EDC.HCl (437 mg, 2.28 mmol, 10 equiv.) was added. The mixture was stirred 
another 8 h and the third portion dried EDC.HCl (437 mg, 2.28 mmol, 10 equiv.) was 
added. The solution was stirred for a final 15 hours. The solvent was removed by rv 
and diluted with AcOEt (30 ml) and washed three times with 0.1 M citric acid and 
once with 0.1 M citric acid in brine. All aqu. layers were extracted once with AcOEt 
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(30 ml). The comb. org. layers were dried over MgSO4, filtered, and the solvent 
removed by rv and hv. The isolated material was partially dissolved in hot toluene (10 
ml), filtered and the filtrate dried using rv and hv to furnish 106 mg (200 mmol, 88%) 
of a colourless solid. 
 
Analytical data for Fmoc-L-Trp(Boc)-16OH (starting material): 
 
[α]D20 (DMF): - 19.8 
IR (neat): 1726.0s; 1518.7w; 1450.2m; 1375.0m; 1333.5m; 1260.3m; 1159.0m; 
1085.7m; 746.3m. 
 
1H-NMR (400 MHz, MeOD): 8.08 (d, 3J = 8.0, 1 H, arom. indole-H); 7.71 (d, 3J = 7.6, 
2 H, Fluorenyl-C4’/5’-H); 7.60 (d, 3J = 7.6, 1 H, arom. indole-H); 7.51 – 7.48 (m, 3 H, 
arom. indole-H & Fluorenyl-C1’/8’-H); 7.33 – 7.16 (m, 6 H, Fluorenyl-C2’/3’/6’/7’-H & 
arom. indole-H); 4.58 (dd, 3J = 9.3, 3J = 4.5, 1 H, C2H); 4.29 – 4.25 (m, 1 H, cis- & 
trans-form of C9’H); 4.17 – 4.08 (m, 2 H, cis- & trans-form of C10’H2); 3.32 (dd, 2J = 
14.8, 3J = 4.5, 1 H, C3H2); 3.11 (dd, 2J = 14.8, 3J = 9.3, 1 H, C3H2); 1.55 (s, 9 H, 
C(CH3)3). 
 
13C-NMR (100 MHz, MeOD): 175.30 (s, 1 C, C1OOH); 158.37 (s, 1 C, OCONH); 
150.92 (s, 1 C, OCON); 145.14; 145.09; 142.46; 142.43 (4 s, 4 Fluorenyl-C); 136.81; 
131.76 (2 s, 2 arom. indole-C); 128.67; 128.08; 126.27; 126.15; 125.40; 125.04; 
123.67; 120.84; 120.81; 119.97 (10 d, 10 arom. CH); 117.69 (s, 1 arom. indole-C); 
116.14 (d, 1 arom. indole-CH); 84.67 (s, 1 C, OCMe3); 68.05 (t, 1 C, C10’H2); 55.31 
(d, 1 C, NHC2H); 48.25 (d, 1 C, C9’H); 28.71 (t, 1 C, C3H2); 28.32 (q, 3 C, OC(CH3)3).  
 
Analytical data for Fmoc-L-Trp(Boc)-18OH (product): 
 
[α]D20 (DMF): - 18.8 
IR (neat): 1724.1s; 1516.7w; 1450.2m; 1374.0m; 1332.6m; 1259.3m; 1159.0m; 
1085.7m; 1052.0m; 746.3m. 
 
1H-NMR (400 MHz, MeOD): 8.08 (d, 3J = 7.8, 1 H, arom. indole-H); 7.73 (d, 3J = 7.4, 
2 H, Fluorenyl-C4’/5’-H); 7.60 (d, 3J = 7.5, 1 H, arom. indole-H); 7.55 – 7.50 (m, 3 H, 
arom. indole-H & Fluorenyl-C1’/8’-H); 7.34 – 7.12 (m, 6 H, Fluorenyl-C2’/3’/6’/7’-H & 
arom. indole-H); 4.58 (dd, 3J = 9.3, 3J = 4.6, 1 H, C2H); 4.31 – 4.27 (m, 1 H, cis- & 
trans-form of C9’H); 4.19 – 4.12 (m, 2 H, cis- & trans-form of C10’H2); 3.31 (dd, 2J = 
14.8, 3J = 4.6, 1 H, C3H2); 3.11 (dd, 2J = 14.8, 3J = 9.3, 1 H, C3H2); 1.56 (s, 9 H, 
C(CH3)3). 
 
13C-NMR (100 MHz, MeOD): 175.10 (s, 1 C, C1-18O18OH); 158.40 (s, 1 C, OCONH); 
150.94 (s, 1 C, OCON); 145.17; 145.13; 142.49; 142.46 (4 s, 4 Fluorenyl-C); 136.84;  
131.77 (2 s, 2 arom. indole-C); 128.70; 128.68; 128.10; 126.24; 126.18; 126.08; 
125.42; 125.05; 123.68; 120.85; 120.82; 119.97 (12 d, 10 arom. CH); 117.70 (s, 1 
arom. indole-C); 116.15 (d, 1 arom. indole-CH); 84.69 (s, 1 C, OCMe3); 68.07 (t, 1 C, 
C10’H2); 55.26 (d, 1 C, NHC2H); 48.29 (d, 1 C, C9’H); 28.77 (t, 1 C, C3H2); 28.33 (q, 3 
C, OC(CH3)3). 
 
MS (- ESI-MS, MeOH): 529.1 (100, [M2x – H]-); 527.1 (18, [M1x – H]-); 426.9 (9); 391.0 
(9); 333.1 (68, [M2x – H – C14H11O]-); 331.1 (12, [M1x – H – C14H11O]-); 307.1 (72, [M2x 
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– H – C15H10O2]-); 305.1 (14, [M1x – H – C15H10O2]-); 207.0 (21, [M2x – H – C15H10O2 – 
C5H8O2]-); 190.9 (10); 110.9 (5). 
 
 
11.4 Synthesis of Fmoc-L-Cys(Trt)-18OH (155)  
   960 mg dry 3,5-dimethylpyridine hydrobromide (5.10 mmol, 20 equiv.) was 
suspended in 3 ml dry DMF under N2, and 490 mg of dry EDC.HCl (2.56 mmol, 10 
equiv.) and 256 µl 18OH2 (12.8 mmol, 50 equiv.) were added. 150 mg of dry Fmoc-L-
Cys(Trt)-OH (256 µmol) dissolved in 3 ml dry DMF was immediately added. The 
mixture was stirred under N2 at rt for 18 h. A second portion dry EDC (490 mg, 2.56 
mmol, 10 equiv.) was added. The mixture was stirred another 8 h and a third portion 
dry EDC.HCl (490 mg, 2.56 mmol, 10 equiv.) was added. The solution was stirred for 
15 hours, diluted into AcOEt (30 ml), washed twice with 0.1 M citric acid (25 ml) and 
once with 0.1 M citric acid in brine (25 ml). All aq. layers were back extracted with 
AcOEt (30 ml) and the comb. org. layers were dried over MgSO4, filtered, and the 
solvent removed by rv and hv. The isolated material was filtered over SiO2 using 
CH2Cl2/AcOEt 1:1 as the solvent and dried. The resulting solid was dissolved into 
approximately 1 ml of AcOEt and hexane was added (15 ml). The milky suspension 
was cooled to -20°, whereas an oily precipitate for med. The oily precipitate was 
isolated by decantation and dried under hv to yield 143 mg (243 mmol, 95%) of a 
colourless solid. 
 
Analytical data for Fmoc-L-Cys(Trt)-16OH (starting material): 
 
 [α]D20 (CHCl3): + 12.86 
IR (neat): 1720.2s; 1508.1m; 1442.5m; 1333.5w; 1221.7m; 1053.9m; 747.3s; 
702.9m; 622.9w. 
 
1H-NMR (400 MHz, CDCl3 + MeOD): 7.75 (dd, 3J = 7.3, 4J = 3.5, 2 H, Fluorenyl-C4’/5’-
H); 7.61 (dd, 3J = 7.1, 4J = 3.3, 2 H, Fluorenyl-C1’/8’-H); 7.41 – 7.17 (m, 19 H, 
Fluorenyl-C2’/3’/6’/7’-H & arom. CH Trt); 4.36 (d, 3J = 7.0, 2 H, C10’-H2); 4.28 – 4.09 (m, 
2 H, C2-H & C9’-H); 2.68 (d, 3J = 5.6, 2 H, C3H2). 
 
13C-NMR (100 MHz, CDCl3 + MeOD): 172.52 (s, 1 C, C1OOH); 156.03 (s, 1 C, 
OCONH); 144.39 (s, 3 arom. Trt-C); 143.88; 143.74; 141.29; 141.27 (4 s, 4 arom. 
Fluorenyl-C); 129.54; 127.99; 127.74; 127.73; 127.12; 126.87; 125.14; 125.13; 
119.95 (9 d, 8 arom. Fluorenyl-CH & 15 arom. Trt-CH); 67.10 (t, 1 C, C10’H2); 66.96 
(s, 1 C, SCPh3); 52.84 (d, 1 C, NHCH); 47.09 (d, 1 C, C9’H); 33.91 (t, 1 C, SCH2).  
 
Analytical data for Fmoc-L-Cys(Trt)-18OH (product): 
 
[α]D20 (CHCl3): + 13.06  
IR (neat): 1700.9s; 1507.1m; 1443.5m; 1331.6w; 1221.7m; 1052.9m; 748.2s; 
702.9m; 622.9w. 
 
1H-NMR (400 MHz, CDCl3 + MeOD): 7.77 – 7.75 (m, 2 H, Fluorenyl-C4’/5’-H); 7.61 (br. 
s, 2 H, Fluorenyl-C1’/8’-H); 7.41 – 7.18 (m, 19 H, Fluorenyl-C2’/3’/6’/7’-H & arom. CH Trt); 
4.36 (d, 3J = 6.6, 2 H, C10’-H2); 4.26 – 4.15 (m, 2 H, C2-H & C9’-H); 2.68 (d, 3J = 5.2, 2 
H, C3H2). 
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13C-NMR (100 MHz, CDCl3 + MeOD): 172.37 (s, 1 C, C1-18O18OH); 156.05 (s, 1 C, 
OCONH); 144.38 (s, 3 arom. Trt-C); 143.86; 143.72; 141.26 (3 s, 4 arom. Fluorenyl-
C); 129.53; 127.96; 127.71; 127.10; 126.84; 125.11; 119.93 (7 d, 8 arom. Fluorenyl-
CH & 15 arom. Trt-CH); 67.07 (t, 1 C, C10’H2); 66.92 (s, 1 C, SCPh3); 52.81 (d, 1 C, 
NHCH); 47.07 (d, 1 C, C9’H); 33.91 (t, 1 C, SCH2). 
 
MS (- ESI-MS. MeOH + NaI): 1177.4 (9, [2 M2x - H]-); 588.1 (65, [M2x – H]-); 586.1 (7, 
[M1x – H]-); 392.1 (33, [M2x – H – C14H11O]-); 366.1 (60, [M2x – H – C15H10O2]-); 364.1 
(5, [M1x – H – C15H10O2]-); 275.0 (100, [Ph3CS]-); 243.0 (5, [Ph3C]-). 
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Part IV 
 
Appendix 
 
12.  Crystallographic data 
 
Table 12.1.  Crystallographic Data of 42 
 
Crystallised from dioxane / pentane  
Empirical formula C19H25N3O5  
Formula weight [g mol-1] 375.42  
Crystal colour, habit colourless, prism  
Crystal dimensions [mm] 0.12 × 0.25 × 0.30  
Temperature [K] 160(1)  
Crystal system monoclinic  
Space group P21/c  (#14)  
Z 4  
Reflections for cell determination 5672  
2θ range for cell determination [°] 4 – 60  
Unit cell parameters a [Å] 9.2486(2)  
 b [Å] 23.8477(8)  
 c [Å] 10.0247(3)  
 α [°] 90  
 β [°] 116.666(2)  
 γ  [°] 90  
 V [Å3] 1975.9(1)  
F(000) 800  
Dx [g cm-3] 1.262  
µ(Mo Kα) [mm-1] 0.0921  
Scan type φ and ω  
2θ(max) [°] 60  
Total reflections measured 39772  
Symmetry independent reflections 5719  
Rint 0.067  
Reflections with I > 2σ(I) 3851  
Reflections used in refinement 5718  
Parameters refined 256  
Final R(F) [I > 2σ(I) reflections] 0.0747  
 wR(F2) (all data) 0.2209  
Weights: w = [σ2(Fo2) + (0.0939P)2 + 1.7573P]-1 where P = (Fo2 + 
2Fc2)/3  
Goodness of fit 1.044  
Final ∆max/σ 0.001  
∆ρ (max; min) [e Å-3] 1.03; -0.35  
σ(d(C – C)) [Å] 0.003 – 0.005  
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Table 12.2.  Crystallographic Data of 89 
 
Crystallised from EtOAc / CH2Cl2  
Empirical formula C19H24N2O5S  
Formula weight [g mol-1] 392.47  
Crystal colour, habit colourless, prism  
Crystal dimensions [mm] 0.15 × 0.25 × 0.50  
Temperature [K] 160(1)  
Crystal system monoclinic  
Space group P21/c  (#14)  
Z 4  
Reflections for cell determination 30126  
2θ range for cell determination [°] 4 – 50  
Unit cell parameters a [Å] 13.9062(5)  
 b [Å] 9.7100(5)  
 c [Å] 15.3213(5)  
 α [°] 90  
 β [°] 103.880(3)  
 γ  [°] 90  
 V [Å3] 2008.4(1)  
F(000) 832  
Dx [g cm-3] 1.298  
µ(Mo Kα) [mm-1] 0.193  
Scan type ω  
2θ(max) [°] 50  
Transmission factors (min; max) 0.663; 0.981  
Total reflections measured 26977  
Symmetry independent reflections 3542  
Rint 0.109  
Reflections with I > 2σ(I) 2842  
Reflections used in refinement 3542  
Parameters refined 254  
Final R(F) [I > 2σ(I) reflections] 0.0551  
 wR(F2) (all data) 0.1244  
Weights: w = [σ2(Fo2) + (0.0375P)2 + 1.7222P]-1 where P = (Fo2 + 
2Fc2)/3  
Goodness of fit 1.125  
Secondary extinction coefficient 0.010(2)  
Final ∆max/σ 0.001  
∆ρ (max; min) [e Å-3] 0.28; -0.22  
σ(d(C – C)) [Å] 0.003 – 0.005  
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